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General Introduction
1.1 The ear
The ear converts the energy of pressure waves travelling through air into nerve impulses 
that the brain perceives as sound. The ear can be divided into three regions. The outer 
ear consists of the external pinna and the auditory canal, which collect sound waves and 
channel them to the tympanic membrane (eardrum) that marks the division between the 
outer and the middle ear (fig. 1). There, the vibrations are conducted through three small 
bones (the auditory ossicles), the malleus (hammer), incus (anvil), and stapes (stirrup), 
to the inner ear. These bones are attached to the wall of the middle ear chamber by 
ligaments and muscles. The “footplate” of the stapes is attached to the membrane 
covering the oval window. The middle ear also opens into the auditory (Eustachian) 
tube, which connects with the pharynx and equalizes pressure between the middle ear 
and the atmosphere. The inner ear consists of a labyrinth of channels, the membranous 
labyrinth, within the temporal bone, the hardest bone in the body, which is fused with 
the skull. These channels are lined by a membrane and contain fluid that moves in 
response to sound or movement of the head. The inner ear is divided into two separate 
sense organs; the organ of hearing, the cochlea, and that of equilibrium, or balance, 
consisting of the semicircular canals, the utricule, and the saccule (fig. 1). 
1.1.1 The inner ear
The sensory organs in the inner ear differ in their function, and in the fine details of their 
cellular architecture, but they all conform to the same basic plan. They are relatively simple 
epithelia composed of two basic cell types, the sensory hair cells and their surrounding, 
non-sensory supporting cells (fig. 2). These epithelia lie upon a sheet of extracellular 
matrix, a basal lamina. The lateral membranes of the supporting cells surround the hair 
cells that do not contact the basal lamina, and they are isolated from one another by the 
supporting cells. At the apical surface of the epithelium, the supporting cell processes 
form tight and adherens junctions with each other and with the hair cells. The hair 
cells have a highly specialized bundle of modified microvilli called stereocilia, on their 
apical surface and it is this feature that enables them to detect mechanical stimuli and 
transduce them into electrical signals.
The vestibular system
The utricular and saccular hair cells are arranged in clusters, and all hairs project 
into the otoconial membrane, a gelatinous material containing many small calcium 
carbonate particles called otoliths (“ear stones”). Because this material is heavier than 
the endolymph within the utricle and saccule, gravity is always pulling downward on 
the hairs of the receptor cells, sending a constant train of action potentials along the 
sensory neurons of the vestibular branch of the auditory nerve. When the position of the 
head changes with respect to gravity (as when the head bends forward), the force on 
the hair cells changes, and increases or decreases its output of neurotransmitter. The 
brain interprets the resulting change in impulse production by the sensory neurons to 
determine the position of the head. 
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Within the three semicircular canals the cristae harbour the sensory cells. The 
sensory cells contain about 50 stereocilia and one kinocilium, a primary cilium that 
protrudes into a gelatinous mass, the cupula. During movement of the head the fluid in 
the semicircular canals lags behind creating a relative fluid flow causing the hair bundles 
to bend. This results in a change in the output of neurotransmitters. The sensory input 
from the utricule, saccule and semicircular canals is integrated with the input from the 
eyes, from the receptors in the muscles, joints and skin, to initiate reflexes that maintain 
the normal orientation.
Figure 1. Schematic drawing of the outer, middle and inner ear 
The cochlea
The modiolus, a long cartilaginous process, forms the central axis of the cochlea. 
Spiralling around the modiolus from the base to the apex, the interior of the cochlea is 
partitioned into three tubes or spaces (scalae) (fig. 2). The upper space (scala vestibuli) 
is separated from the middle (scala media) by Reissner´s membrane (fig. 2). The scala 
media is separated from the lower space (scala tympani) by parts of the osseous spiral 
lamina and the basilar membrane. The scala tympani and scala vestibuli are actually 
continuous at the apical tip of the cochlea, connected by a narrow opening called the 
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helicotrema. The stapes is attached to the membrane covering the oval window of the 
cochlea at a hole in the otic capsule over the scala vestibuli. At the base of the cochlea, 
the scala tympani ends at the membrane-covered round window (fig. 2). 
Figure 2. The cochlea and the organ of Corti 
The organ of Corti, which harbours the sensory cells, spirals along the basilar 
membrane from the apex to the base of the cochlea (fig. 2). It is loosely structured to 
permit movement of the sensory epithelium in response to mechanical stimuli, yet it is 
rigid enough to transmit vibrations from the basilar membrane to the stereocilia. Along 
the spiral, the sensory epithelium contains approximately 20,000 sensory hair cells in 
humans (Dallos et al. 1996). In radial terms, sensory cells are either inner hair cells 
(IHCs), which form one row along the length of the sensory epithelium, or outer hair 
cells (OHCs), which form three rows. The hair cells each develop 10 to 50 stereocilia. 
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The stereocilia of the IHCs are arranged in a “U” shape, the stereocilia of the OHCs 
are arranged in a “W” shape. The tips of the stereocilia are embedded in the tectorial 
membrane, a fibrillar gelatinous substance that is carried by the spiral limbus whilst 
the bases of the hair cells make synaptic contact with dendritic endings of the cochlear 
nerve. Hair cells contact both afferent and efferent nerve fibres to permit transfer of 
information to the central nervous system and feedback to the periphery. The hair cells 
are separated from each other in a regular manner by various types of supporting cells 
that are specialised for mechanical and metabolic support. On the endolymphatic side of 
the spiral limbus, cells appear to have a secretory function and to be responsible for the 
formation of the tectorial membrane. Some cells separate the compartments containing 
the endolymph and perilymph, whereas others transport ions and may participate in the 
formation and maintenance of these two fluids.
The scala tympani and scala vestibuli are filled with perilymph, a high-sodium 
low-potassium solution resembling extracellular fluids and the scala media is filled with 
endolymph, a low-sodium high potassium solution resembling intracellular fluids. Tight 
junctions between the cells of Reissner´s membrane separate the endolymph from the 
perilymph of the scala vestibuli. Tight junctions at the apical surface of the sensory and 
supporting cells make up a second boundary. Thus, perilymph in the scala tympani can 
diffuse beyond the basilar membrane, and perilymph-like fluid bathes the cell bodies of 
the sensory and supporting cells of the organ of Corti. The stria vascularis, a complex 
vascularised epithelium located along the lateral wall of the cochlea is responsible for the 
production and maintenance of the endolymphatic potassium concentration. The stria 
vascularis is composed of three cell types; the marginal cells which line the endolymphatic 
compartment, the intermediate cells in a discontinuous layer enclosed entirely within 
the body of the epithelium, and the basal cells that separate the stria vascularis from 
the underlying spiral ligament. Tight junctions between adjacent marginal cells keep 
the endolymph from entering the stria vascularis. Within the lateral wall, adjacent cells 
coupled by tight junctions also form an intrastrial compartment. Thus, it appears that 
perilymph diffuses freely through the spiral ligament, but the stria vascularis is contained 
in a compartment that is formed and maintained by tight junctions among marginal cells 
on the endolymphatic side and among basal cells on the perilymphatic side.
1.1.2 The process of hearing
Vibrating objects, such as the reverberating strings of a guitar or the vocal cords of a 
speaking person, create percussion waves in the surrounding air. These waves cause 
the tympanic membrane to vibrate with the same frequency as the sound. The three 
bones of the middle ear transmit the mechanical movements to the cochlea. The stapes 
vibrating against the oval window creates a travelling pressure wave in the fluid of the 
cochlea that passes into the scala vestibuli. Reissner´s membrane is forced down and 
this increases pressure in the scala media until it is released by a downward movement 
of the basilar membrane. The resulting increase in pressure in the scala tympani is 
finally released by a bowing outward of the membrane covering the round window. 
The tectorial membrane, unlike Reissner´s membrane and the basilar membrane, floats 
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freely in the endolymph. In response to incoming sound the basilar membrane vibrates, 
but the tectorial membrane remains stationary. Therefore pressure changes will not 
cause it to move up and down in unison with the two other membranes. As the basilar 
membrane vibrates in response to the pressure waves, it alternatively presses the hair 
cells into and draws them away from the tectorial membrane. The stereocilia of the hair 
cells are thus subject to mechanical distortion. Movement of the hair cell stereocilia in 
the direction of the taller stereocilia opens transduction ion channels, allowing entry of 
potassium and calcium ions from the endolymph and generating a transduction current. 
This alters the hair cell resting electrical potential and leads to depolarisation of the hair 
cell. The depolarisation activates voltage sensitive calcium channels along the lateral 
wall and base of IHC as well as calcium-activated potassium channels. The end result 
is release of neurotransmitter at the hair cell base onto the auditory nerve endings. 
The signal is then transmitted to the brain where it is further processed. The apical 
influx of potassium ions in the stereocilia is coupled with a potassium efflux across the 
basolateral membrane. Potassium ions efflux to the supporting cells of the organ of 
Corti and through a mechanism of gap junctions and ion pumps, potassium is recycled 
back to the endolymph. This efflux is necessary to prevent cytotoxic accumulation of 
potassium in the hair cells and to maintain the correct potassium concentration in the 
endolymph. The efflux also serves to repolarise the cell by restoring the electronegativity 
of the cytoplasm. Movement of stereocilia in the opposite direction closes the stereocilia-
related channels and stops the release of neurotransmitter. In the “resting” position of 
stereocilia (upright) the transduction channels are partially open, leading to a small 
release of transmitter. This in turn generates spontaneous activity in the auditory nerve 
and the ascending auditory pathways, even in the absence of sound. The frequency 
of movement of stereocilia matches the frequency of the sound stimulus (Raphael and 
Altschuler 2003). Hair cells are thus mechanotransducers converting a mechanical 
stimulus into an electrical signal.
Two important aspects of sound are volume and pitch. Volume (loudness) is 
determined by the amplitude, or height, of the sound wave. The greater the amplitude 
of a sound wave, the more vigorous the vibrations of fluid in the cochlea, the greater 
the bending of the stereocilia, and the more action potentials generated in the sensory 
neurons. Pitch is a function of the frequency of sound waves and is usually expressed 
in hertz (Hz). Short, high-frequency waves produce high-pitched sound, while long, low-
frequency waves generate low-pitched sound. Healthy young humans can hear sounds 
in the range of 40 to 20,000 Hz, and a trained ear can discriminate between frequencies 
of 1000 Hz and 1002 Hz. Pitch can be distinguished by the cochlea because the basilar 
membrane is not uniform along its length. The proximal end near the oval window is 
relatively narrow and stiff, while the distal end near the tip is wider and more flexible. 
Each region of the basilar membrane is most affected by a particular frequency of 
vibrations, and the region vibrating most vigorously at any instant sends the most action 
potentials along the auditory nerve.
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1.2 Inner ear development
The inner ear is structurally complex. A molecular description of its architecture, 
development and homeostasis is now emerging from the use of contemporary methods 
of cell and molecular biology. In addition the application of clinical and molecular genetics 
is providing new insights into the pathogenesis of a range of inner ear disorders.
1.2.1 Embryology of the human inner ear
The vertebrate inner ear develops from the embryonic ectoderm. The first sign of the 
developing ear in humans can be found in embryos of approximately 22 days as a 
thickening of the surface ectoderm on each side of the rhombencephalon close to 
the hindbrain (O´Rahilly 1963) (fig. 3) (table 1). These thickenings, the otic placodes, 
invaginate rapidly and form the otic cup and otic vesicles (otocysts), an ellipsoid shaped 
structure lined by pseudo-stratified epithelium (fig. 3). Later in development, each vesicle 
divides into a ventral component, which gives rise to the saccule and the cochlea, and a 
dorsal component, which forms the utricule and the semicircular canals (fig. 4) (Sadler 
2004). 
Figure 3. Schematic transverse sections through the region of the rhombencephalon of a human 
embryo
In the sixth week of development, the saccule forms a tubular-shaped 
outpocketing at its lower pole (fig. 4). This outgrowth, the cochlear duct, penetrates the 
surrounding mesenchyme in a spiral fashion until, at the end of the eighth week, it has 
completed 2½ turns (fig. 4) (table 1). The mesenchyme surrounding the cochlear duct 
soon differentiates into cartilage. In the tenth week, this cartilaginous shell undergoes 
vacuolisation and the scala vestibuli and scala tympani, are formed. The cochlear duct 
(scala media) is then separated from the scala vestibuli by Reissner´s membrane, 
and from the scala tympani by the basilar membrane (Sadler 2004). The lateral wall of 
the scala media remains attached to the surrounding cartilage by the spiral ligament, 
whereas its median angle is connected to, and partly supported by the modiolus. The 
epithelial cells of the cochlear duct are initially all alike. With further development, 
however, they form two ridges: the inner ridge (the future spiral limbus) and the outer 
ridge. The latter forms one row of IHCs and three rows of OHCs (Sadler 2004). 
Chapter 1
17
Figure 4. Schematic representation of the development of the otocyst showing a dorsal utricular 
portion with the endolymphatic sac and duct, and a ventral saccular portion and the cochear duct 
at 6, 7, and 8 weeks, respectively. 
During the sixth week of development, the semicircular canals appear as 
flattened outpocketings of the utricular part of the otic vesicle (fig. 5) (Sadler 2004). The 
central portions of the walls of these outpocketings eventually disappear, thus giving 
rise to the three semicircular canals positioned in the three dimensions of space (fig. 5) 
containing the sensory cells that have evolved during the eighth week and detect angular 
accelerations of the head. At eight weeks the sensory areas have also developed in the 
walls of the utricule and the saccule (table 1) that respond to changes in head position 
with respect to gravity and movement in one direction.
The neurons that innervate the hair cells in each organ of the ear are derived 
from the otocyst, by a process of delamination, prior to the formation of the sensory 
organs (Rubel and Fritzsch 2002). Initially they form a single structure, the statoacoustic 
ganglion, which splits into the cochlear and vestibular ganglia as development proceeds 
(Politzer 1956).
Figure . Schematic representation of the development of the semicircular canals in humans
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Table 1. Timetable of inner ear development
Mouse Human Description
12-13 somites 
(9 days)
23 days Otic placode evident
24 days Otic pit present
17 somites Placode epithelium just starting to thicken, all ectoderm around 
placode thins
17-19 somites 26 days Otic placode transforms into otic vesicle; ventral wall of otocyst 
contributes to statoacoustic ganglion
22-24 somites Otocyst detached from the surface
27 somites 
(10 days)
4 weeks Otocyst is a closed sac; medial wall is pseudostratified 2-3 
layers of nuclei
12 days  weeks Otocyst elongates and endolymphatic duct buds off the medial 
wall; otic capsule represented by condensed mesenchyme
13 days 7 weeks ½ Coil of cochlear duct; otic capsule is cartilaginous and in 
direct contact with epithelial portions of the labyrinth; HCs 
differentiated in the utricle and saccule
14 days 7 weeks Cochlea at 1¼ turns; first definitive HCs
15 days 7 weeks Tectorial membrane has started to form (mouse)
16 days 8 weeks Cochlea has 1½ turns; perilymphatic spaces develop; many 
HCs differentiate in utricle, saccule, and semicircular canals
18 days 9 weeks 1¾ Turns (full number in mouse); 2½ turns (full number in 
human) but not full length in either; cochlear HCs identifiable 
in mouse; development of cuticular plate in mouse
9-10 weeks Tectorial membrane is starting to form; vestibular HCs 
11-12 weeks IHC visible throughout the cochlea; OHC indistinguishable; 
stereocilia present on OHC and IHC; some cuticular 
plates identifiable; synaptic specializations present on HC; 
perilymphatic spaces begin to develop in human
6 DAB 4 months 
(16 weeks)
Tunnel of Corti appears in the basal coil (mouse); membranous 
labyrinth has adult dimensions
10 DAB 4. months Tunnel of Corti formation complete (mouse)
16 DAB  months 
(20-22 weeks)
Adult stereocilia configuration on both OHC and IHC, but 
some kinocilia remain; tunnel of Corti appears in basal coil 
of human cochlea; periotic spaces fully formed; ossicles have 
adult configuration
20 DAB 8 months Cochlear structure essentially similar to adult, including 
formation of Nuel spaces
Adapted from: Sulik K.K. 1995, DAB: days after birth
1.2.2 Gene expression during early inner ear development 
The embryonic development of the inner ear is a very complex process and much 
research has been done to uncover all genes involved. It is impossible to include all 
these results here, however, the data presented below give a summary of what is known 
about the genes and signalling pathways involved in the most important developmental 
steps. 
Despite its complexity and multiple functions, the origin of the inner ear epithelium 
is simple. All cellular components of the otic epithelium, including the neurons of the 
cochlear and vestibular ganglia, derive from the embryonic otic vesicle. Therefore, the 
unravelling of the development of the inner ear is largely dependent on studying the 
development of the otic vesicle. The lateral edges of the hindbrain have long been 
considered a source of otic vesicle-inducing activity (Groves and Bronner-Fraser 2000). 
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However, studies by Jacobson (1966) indicate that signals from the hindbrain and 
mesoderm are both needed for optimal induction and normal development of the inner 
ear. In the otic vesicle cell-to-cell communication and cell exchange are restricted so 
that the otic vesicle is functionally isolated from the surrounding ectoderm (Vazquez et 
al. 1996). The first indication of regional and cell fate specification of the development 
of the inner ear coincides with the earliest stage of regional gene expression and to 
the first events of cell differentiation, respectively. Both events begin around the otic 
placode stage and extend through the whole embryonic development until the early 
post-natal stage. Genes expressed during early otic development encode transcription 
factors, diffusible molecules, receptors, and cell adhesion proteins. 
In the otic placode the earliest-expressed genes include several homeobox genes 
including those of the distal-less family, genes related to Drosophila muscle segment 
homeobox genes and NK-related homeobox genes, as well as LIM-homeodomain and 
paired-box transcription. Secreted factors like the BMP-family of TGFß-like polypeptides, 
and receptor molecules are also expressed at the placodal stage (reviewed by Torres 
and Giraldez 1998, Noramly and Grainger 2002). Most of the genes expressed at the 
otic placode stage maintain their expression in the otic vesicle, but typically restrict their 
expression domain, suggesting a role in the regional patterning of the otic vesicle. In 
the absence of available references to compartments or functional domains within the 
otic vesicle, genes expressed at this stage can be grouped as dorso-lateral on one side, 
and medial-ventral on the other (reviewed by Torres and Giraldez 1998, Represa et al. 
2000) (Appendix 1). 
As development progresses, groups of different genes are expressed in parallel 
to the generation of sensory and non-sensory patches in the auditory and vestibular 
sensory organs. Several classes of genes are expressed: (i) genes encoding transcription 
factors, (ii) genes encoding secreted factors, and (iii) genes encoding receptor tyrosine 
kinases. Some of these genes are specific for putative sensory epithelium while other 
genes are expressed in non-sensory areas. 
Because a highly conserved Pax-Six-Eya-Dach synergistic regulatory genetic 
network is involved in the development of a number of organs, it was suggested that a 
Pax-Six-Eya-Dach synergistic regulatory network may be involved in the formation of 
the ear and may be among the first genes activated in response to inducing signals. 
This is indeed the case and the interactions among the genes in this complex network 
have been worked out in most detail for Drosophila and vertebrate eye development (for 
a review see Wawersik and Maas 2000). Specificity is conferred by differences in which 
family members are expressed (Appendix 1). 
1.2.3 Differentiation of hair cells and supporting cells
Hair and supporting cells in the mammalian ear are born in a small developmental time 
window after the sensory patches have been specified (Sans and Chat 1982). In the 
cochlea of the mouse, the cyclin dependent kinase inhibitor, p27Kip1 is expressed by 
cells of the organ of Corti as soon as they withdraw from the cell cycle (Chen and Segil 
1999). The pattern of p27Kip1 expression precisely delineates the region of the cochlear 
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duct within which the hair and supporting cells will differentiate. The expression of 
p27Kip1 is down regulated in hair cells as they begin overt differentiation, but in supporting 
cells expression persists into adulthood (Chen and Segil 1999). In p27Kip1-/- mice, cell 
proliferation within the organ of Corti continues and an excess of hair and supporting 
cells is found (Chen and Segil 1999, Lowenheim et al. 1999). These data indicate that 
p27Kip1 negatively regulates cell proliferation in the organ of Corti. 
Hair and supporting cells are born simultaneously and there is evidence that 
hair- and supporting-cell lineages arise from a common progenitor and do not segregate 
until very late in development. It has been shown that the potential to become either a 
hair or supporting cell is retained by a progenitor cell until it has passed through its final 
mitotic division. In mature sensory organs, hair cells are isolated from one another by 
the processes of supporting cells. This arrangement implicates an inhibitory mechanism 
of cell fate determination for these two cell types, a process named lateral inhibition. 
A few scattered cells commit to the primary fate, the hair cell fate. A committed hair 
cell then prevents every cell in contact with it from becoming a hair cell; the inhibited 
neighbours commit to the secondary fate, the supporting cell fate. Other cells contacting 
these committed supporting cells can, in turn, assume a hair cell fate. Thus, a pattern is 
propagated in which hair cells alternate with supporting cells in all directions around the 
seeding site of a committed hair cell. 
Lateral inhibition is usually mediated by Notch signalling, and a number of 
studies have now shown that the Notch signalling pathway plays a key role in mediating 
the differentiation of hair and supporting cells in the inner ear (Adam et al. 1998, Haddon 
et al. 1998, Lanford et al. 1999, Eddison et al. 2000, Zine et al. 2000).
Notch1 and its ligands Delta1, Jagged1 and Jagged2 are expressed in the 
developing inner ear (Adam et al. 1998, Morrison et al. 1999). All progenitor cells 
initially express low levels of Delta1 and Notch1 and thereby mutually inhibit each 
other’s differentiation. Emerging hair cells strongly upregulate Delta1 expression, which 
elevates Notch activity in neighbouring cells. Notch1-/- mice are early embryonic lethals, 
but in heterozygotes with presumably reduced levels of Notch1, a significant increase is 
observed in the numbers of regions along the cochlea where there are four instead of 
three rows of OHCs (Zhang et al. 2000). In Jagged2-/- mice, there is an increase in the 
linear density of IHCs and OHCs in the cochlea, with a nearly complete duplication of 
the normal, single row of IHCs, and many stretches where there are four instead of three 
rows of OHCs (Lanford et al. 1999). Disruption of another gene, Lunatic fringe (Lfng), 
suppresses the Jagged2-/- phenotype (Zhang et al. 2000). Lfng in mouse is expressed 
throughout the region of the ear that gives rise to sensory epithelia. The expression 
of Delta1 and Jagged2 in hair cells, and the overproduction of hair cells seen in the 
corresponding mutants, indicates that the hair cells use Notch signalling to laterally 
inhibit their neighbouring cells. Jagged1 is expressed throughout the pro-sensory patch 
initially but becomes progressively restricted to the supporting cells as they differentiate 
(Morrison et al. 1999, Cole et al. 2000). The expression of Jagged1 by supporting cells 
may not appear to be consistent with the idea that hair cells inhibit their neighbours. 
However there is evidence from the chick inner ear that the expression of Jagged1 
in supporting cells is positively regulated by Notch signalling via lateral induction (fig. 
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6) (Eddison et al. 2000). This would ensure that they do not differentiate as hair cells. 
Hair cells are unresponsive to Jaggged1 because Notch expression is down-regulated 
during initial stages of hair cell differentiation (Lanford et al. 1999), and hair cells also 
express Numb, an intracellular antagonist of Notch activity (fig. 6) (Eddison et al. 2000). 
Homozygous loss of Jagged1 kills mouse embryos prior to the stage when hair cells 
differentiate, but Jagged1 heterozygotes show a modest increase in production of IHCs 
in the cochlea (Kiernan et al. 2001). In humans mutations in JAG1 are responsible for 
Alagille syndrome (Li et al. 1997, Oda et al. 1997). The overproduction of hair cells in 
the late embryonic rat cochlear cultures caused by Jagged1 antisense oligonucleotides 
(Zine et al. 2000) is consistent with this, as reduced Notch activation should lead to 
an excess of hair cells. Jagged1 appears to be signalling in the opposite direction as 
Jagged2. It has been proposed from gene reporter studies that Notch3 acts by interfering 
with Notch1 signalling, possibly by blocking Notch1-mediated Hes1 transcription in 
supporting cells (fig. 6) (Beatus et al. 1999). It is possible that Notch3 expression in hair 
cells may act as an antagonist of Notch1 expression in supporting cells, mediating an 
instructive signal for hair cells differentiation rather than inhibitory signal for supporting 
cell differentiation. Rivolta et al. (2002) propose that Jagged1 could have an inductive 
effect on hair cell differentiation mediated by Notch3.
Atoh1, a mouse homologue of the Drosophila proneural gene atonal, encodes 
a basic helix-loop-helix (bHLH) transcription factor. It is expressed in the primordium of 
the organ of Corti after the cells in this region have withdrawn from the cell cycle and 
have begun to express p27Kip1, but before hair cells have started to express myosin VIIA, 
a marker for overt differentiation (Chen et al. 2002). Initially, Atoh1 is expressed by a thin 
band of epithelial cells that span the entire thickness of the epithelium and expression 
becomes restricted to the hair cells as they differentiate (Lanford et al. 2000, Chen et 
al. 2002). Hair cells are absent from the inner ears of Atoh1-/- mice by birth; instead a 
uniform sheet of supporting cells is formed (Bermingham et al. 1999). Overexpression of 
Atoh1 results in the formation of supernumerary hair cells (Zheng and Gao 2000). Early 
markers of overt hair cell differentiation, myosin VI and calretinin, are never expressed 
during inner ear development in Atoh1-/- mice (Bermingham et al. 1999). These results 
indicate that Atoh1 is both necessary and sufficient for hair cell differentiation. Further 
research has shown that the hair cells may be produced, but fail to express any known 
markers of differentiation, and then die (Chen et al. 2002). Delta1 and Jagged2 are 
expressed by hair cells in the mouse cochlea approximately one day after the onset of 
Atoh1 expression (Morison et al. 1999, Lanford et al. 2000).
The transcription factors Hes1 and Hes5, mammalian homologues of the 
Drosophila hairy and enhancer of Split genes, are expressed in patterns that are 
both complementary and overlapping in the developing cochlea and act downstream 
of Notch (fig. 6) (Zheng et al. 2000a, Zine et al. 2001). Expression of Hes5 is first 
observed in the supporting cells of the organ of Corti after the expression of Atoh1 has 
begun in differentiating hair cells, and probably slightly after the onset of expression of 
Delta1 and Jagged2 (Lanford et al. 2000). The expression of Hes5 may be positively 
regulated by Notch activation as it is much reduced in the supporting cells of Jagged2-
/- mice (Lanford et al. 2000). Additional IHCs are observed in Hes1-/- mutant mice, and 
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additional OHCs are observed in Hes5-/- mutants (Zheng et al. 2000a, Zine et al. 2001) 
these phenotypes indicate that these genes are regulators of hair cell differentiation. 
Hes1 overexpression blocks the ability of Atoh1 to induce hair cell formation (Zheng et 
al. 2000a). This suggests that these genes act antagonistically such that Atoh1 promotes 
hair cell differentiation and Hes1 prevents it.
Figure 6. Diagram illustrating a model for lateral inhibition occurring between components of the 
Notch signalling pathway that lead to the differentiation of hair and supporting cells
Pou4f3 is a POU domain transcription factor that is expressed in all sensory 
areas of the otocyst and specifically by hair cells within the adult mouse inner ear (Erkman 
et al. 1996, Xiang et al. 1997). Pou4f3 is expressed by hair cells at approximately the 
same time as Jagged2 and Delta1, one day before the hair cell markers myosin VI and 
myosin VIIA (Xiang et al. 1997). Pou4f3-/- mice display a shaker/waltzer behavioural 
phenotype of circling and hyperactivity and are also completely deaf (Erkman et al. 
1996). Hair cells are generated and express myosin VI, myosin VIIA and calretinin, but 
they never develop sensory hair bundles and are lost from the inner ear by P14 due to 
apoptosis. This shows that Pou4f3 expression constitutes a requirement for the survival 
of the newly generated hair cells (Erkman et al. 1996, Xiang et al. 1997). Maturation 
of the supporting cells also appears to be impaired in the inner ears of these Pou4f3-
/- mice, suggesting that active hair cell-supporting cell interactions are required for the 
survival of the supporting cell lineage. The ectopic overexpression of Pou4f3 does not 
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lead to the production of supernumerary hair cells (Zheng and Gao 2000), indicating 
that Pou4f3 is only required for the later aspects of hair cell differentiation. In humans 
mutations in POU4F3 are associated with nonsyndromic hearing loss, DFNA15 (Vahava 
et al. 1998).
Gfi1 encodes a zinc finger transcription factor that controls slightly later stages 
of hair cell differentiation than Brn3C (Wallis et al. 2003). Gfi1 is related to Drosophila 
senseless, which is induced by proneural basic helix-loop-helix proteins and is required 
for development of the peripheral nervous system. In mice, Gfi1 is expressed in the early 
otic vesicle and is later restricted to differentiating hair cells. Hair cells are produced in 
Gfi1 mutants but show aberrant patterning and morphology. While mutant hair cells 
express most hair cell markers, including Brn3c, they also inappropriately express some 
neural markers. Hair cells in the cochlea die during early postnatal development, followed 
by death of cochlear neurons. Vestibular hair cells survive but are highly disorganised, 
and mutant mice exhibit ataxia and circling due to loss of vestibular function.
1.2.4 Roles of thyroid hormone and retinoic acid in hair cell differentiation
Nuclear receptors for thyroid hormone (TH) and retinoic acid (RA) are expressed in the 
developing sensory epithelia of the inner ear and their respective ligands are known to 
play a role in hair cell development. RA is produced by embryonic but not adult, organ 
of Corti. Treating cochlear cultures from early embryonic stages of development with 
RA leads to the production of extra rows of IHCs and OHCs (Kelley et al. 1993). The 
RARα/RXRα heterodimer is the most likely hair cell receptor for RA. The presence of RA 
has been documented in the developing inner ear (Kelley et al. 1993, Choo et al 1998). 
Embryos deficient in RA synthesis or reception show severe defects in morphogenesis 
and patterning of the otic vesicle, as do embryos treated with exogenous RA (Dupe et 
al. 1999, Romand et al. 2002) (appendix 1). 
Experimental hypothyroidism in rodents has revealed that the cochlea is a major 
site of TH action and has shown that cochlear maturation and the onset of auditory 
function around postnatal day 14 (P14) require TH during a critical period between the 
late embryonic stage and the second postnatal week (Deol 1973, Uziel et al. 1983). 
Chemically induced hypothyroidism results in a delay in the maturation of most elements 
in the organ of Corti such as the tectorial membrane, hair cells (Deol 1973), synapse 
formation (Uziel et al. 1983), and myelination (Knipper et al 1998). The temporal TH 
dependency may be delineated by several factors, including the expression of the thyroid 
hormone receptor (TR) genes in the cochlea (Bradley et al. 1994, Forrest et al. 1996) 
and the increasing serum levels of L-thyronine (T4) and L-triiodothyronine (T3) during 
development. The study performed by Campos-Barros et al. (2000) demonstrates that 
type 2 iodothyoninedeiodinase (DIO2), which converts T4 into T3, the ligand for TR, 
exhibits a marked activity peak in the cochlea around P7 and suggests that DIO2 is 
likely to play a key role as a temporal trigger of the TR pathway required for cochlear 
development. DIO2 mRNA was localized in the connective tissue that gives rise to the 
bony labyrinth and periodically along the spiral lamina. This pattern suggests that DIO2-
containing cells in the connective tissue take up T4 from the circulatory system, convert 
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T4 to T3, and then release T3 to responsive cells in the sensory epithelium and spiral 
ganglion. This invokes a local release of T3 to stimulate nearby TR-expressing cells, 
suggestive of a paracrine rather than endocrine mode of signalling in the cochlea. 
Two functional thyroid hormone receptors, TRα1 and TRß, and the non-ligand 
binding TRα2 are expressed in the sensory epithelia of the inner ear from early stages. 
TRα1 and TRß are expressed in the cochlea with TRß mRNA being prominent both in 
the embryonic otic vesicle and in the postnatal sensory epithelium and spiral ganglion 
(Bradley et al. 1994, Lauterman and Ten Cate 1997). The expression of TRß is restricted 
to the cochlear epithelium (Bradley et al. 1994). TRß-deficient mice and humans are 
severely deaf, as assessed by defective auditory-evoked brainstem responses (Refetoff 
1967, Forrest et al. 1996), whereas TRα1-deficient mice have a normal auditory-evoked 
brainstem response (Rüsch et al. 1998). Mice that lack all known thyroid receptors 
show the same deficiencies as those with hypothyroidism (Rüsch et al. 2001). A recent 
study has shown that the gene encoding prestin that is associated with hearing loss in 
humans (Liu et al. 2003) is regulated by thyroid hormone (Weber et al. 2002). 
1.2.5 Development of the sensory hair bundle
Following their specification hair cells undergo a series of morphological transformations 
leading to the development of a specialized cytoskeleton. At their apical surface, hair 
cells develop 10 to 0 actin-rich stereocilia, which are specialized derivatives of actin-
based microvilli. Microtubules project from the cytoplasm into the cuticular plate and 
serve as connectors to the hair cell cytoskeleton (Jaeger et al. 1994). The apical domain 
of the hair cell also contains the zonula adherens (adherens junction), a ring of mixed 
polarity actin fibres running in a circumferential belt parallel to the plasma membrane 
forming focal contacts, containing α-actinin and tropomyosin, with supporting cells 
(Tilney et al. 1992a). A coherent adherens junction might provide tension across the 
apical hair cell surface to stabilize the cuticular plate. 
Hair cell stereocilia cytoskeleton
The structure of the hair cell stereocilia cytoskeleton is mostly dominated by actin 
assemblies (fig. 7) (Tiley et al. 1992a). The extraordinary stability of a stereocilium was 
attributed long ago to the remarkable paracrystalline structure of its actin core (DeRosier 
et al. 1980, Tilney et al. 1980). The filaments are unidirectionally aligned with their barbed 
end — the site of high-affinity actin polymerisation — oriented away from the surface 
of the cell (Tilney et al. 1980). Growth of stereocilia therefore occurs by the addition of 
new actin monomers to their tips (Schneider et al. 2002). The main constituent of the 
stereocilia actin bundles is β-actin. Several dominant missense alleles of ACTG1 that 
encode γ-actin have been described that result in hearing loss in humans (DFNA20/26) 
(van Wijk et al. 2003, Zhu et al. 2003), suggesting there is also a requirement for γ-
actin in hair cell stereocilia. In auditory hair cells γ-actin is found in the stereocilia, the 
cuticular plate, and adherens junctions (Khaitlina 2001). The actin filaments are held 
together by actin-bundling proteins, such as espin and fimbrin/plastin (fig. 7) (Bartles 
2000). L-plastin, a homologue of the actin-bundling protein fimbrin, is transiently present 
Chapter 1
2
during mammalian stereocilia bundle formation, but not in mature bundles (Daudet and 
Lebart 2002). A characteristic property of espins is that they bind to and cross-link actin 
filaments with a 10-100 fold higher affinity than the other actin bundling proteins. Espins 
are believed to derive actin-bundling activity from two F-actin binding sites disposed 
roughly at opposite ends of the actin-bundling molecule (Bartles et al. 1998, Chen et 
al. 1999). Results from Loomis et al. (2003) suggest that espins increase parallel actin 
bundle length by causing a net barbed-end elongation of the treadmilling actin filaments. 
In both the cochlea and the vestibule of the mouse inner ear, espin is localized mostly 
to the stereocilia of hair cells (Zheng et al. 2000b). A recessive mutation of the espin 
gene in the deaf jerker mouse results in failure to accumulate detectable amounts of this 
protein in the hair bundle, which leads to shortening, loss of mechanical stiffness and 
eventual disintegration of stereocilia. Abnormalities in the deaf jerker mouse coincided 
with onset of auditory function (Zheng et al. 2000b). In humans, recessive mutations 
of ESPN at the DFNB36 locus cause profound prelingual hearing loss and peripheral 
vestibular areflexia (Naz et al. 2004). 
Figure 7: Schematic illustration of proteins that constitute adhesion complexes on the plasma 
membrane of the stereocilia.
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Several other proteins have been implicated in the actin cytoskeleton dynamics 
of stereocilia. Stereocilia develop in close apposition to extracellular matrix receptors of 
the integrin family. Integrins are cell surface receptors for extracellular matrix molecules 
that activate pathways that regulate actin cytoskeletal dynamics and cell motility, 
proliferation and survival (Giancotti and Ruoslahti 1999). Therefore, they could affect 
many aspects of hair cell differentiation, including stereocilia formation. One integrin, 
α8β1, is localized to the apical surface during formation of the stereocilia. In α8β1-/- mice, 
stereocilia start to develop, but they deteriorate in a subpopulation of hair cells. Focal 
adhesion kinase, a key component of integrin-activated signalling pathways, is recruited 
to the apical cell surface during stereocilia formation. This recruitment is defective in 
the integrin α8β1 mutants (Littlewood-Evans and Müller 2000), which suggests that 
α8β1 integrin and focal adhesion kinase are in a molecular pathway that regulates the 
assembly or maintenance of the stereocilia cytoskeleton. Key downstream targets for 
integrins and other cell-surface receptors include small GTPases of the Rho family 
such as RHO, RAC and CDC42 (Hall and Nobes 2000). Rho GTPases regulate many 
aspects of cytoskeleton dynamics in different cell types. Control of actin polymerisation 
in the hair bundle by Rho GTPases is suggested to be mediated by profilins and formin 
homology proteins. Profilins are localized at sites of actin polymerisation in vivo, bind 
stoichiometrically to actin monomers, and greatly increase the polymerisation rate at 
the barbed end of actin filaments (Schluter et al. 1997). Studies of the Diaphanous 
gene, which was originally isolated from the fruit-fly, have established a link between 
profilin, Rho GTPases, and the inner ear (Lynch et al. 1997, Watanabe et al. 1997). 
Diaphanous belongs to the family of formin homology proteins which appear to function 
as platforms directing actin polymerisation to local sites within the cell (Wasserman 
1998) and accelerate actin nucleation while interacting with the barbed end of actin 
filament (Higashida et al. 2004). The murine diaphanous protein binds to profilin as well 
as activated RhoA (Watanabe et al. 1997). A mutation in a human homologue of the 
D. melanogaster gene diaphanous is responsible for hearing loss at the DFNA1 locus 
(Lynch et al. 1997). In mammalian cells, DIAPH1 cooperates with the RHO-activated 
kinase ROCK in the assembly of actin stress fibres that terminate at the cell membrane 
in local attachment points containing integrins and focal adhesion kinase (Nakano et 
al. 1999, Watanabe et al. 1999, Tominaga et al. 2000). DIAPH1 apparently helps to 
determine nucleation sites for actin filaments, whereas ROCK activates the actin-based 
molecular motor myosin II to exert tension force on actin filaments during stress fibre 
formation (Schoenwaelder and Burridge 1999). Taken together this suggests that a 
RHO-DIAPH1-activated signalling pathway regulates the assembly or maintenance of 
the hair cell cytoskeleton. 
The tips of stereocilia might also contain an actin-binding protein, kaptin, which 
is recruited to the leading edge of lamellipodia of motile fibroblasts (Bearer and Abraham 
1999). Another actin-binding protein, radixin, was detected at the taper of the hair cell 
stereocilium in chick, frog, mouse and zebrafish (fig. 7) (Pataky et al. 2004). Proteins of 
the ezrin/radixin/moesin (ERM) family crosslink actin filaments to plasma membranes 
and are involved in organising the cortical cytoskeleton, especially in the formation 
of microvilli (Tsukita and Yonemura 1999). So far, there are no reports of hair-bundle 
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abnormalities associated with mutations of genes that encode ERM proteins. However, 
these proteins might interact with unconventional myosins VIIa or XV which have 
FERM (band4.1, ezrin, radixin, moesin) binding domains (Oliver 1999), are specifically 
expressed in hair cells (Hasson et al. 1997, Belyantseva et al. 2003a), and have mutant 
allele products that are known to disrupt formation of the hair bundle (Probst et al. 
1998, Self et al. 1998). Another unconventional myosin, myosin VI, is also involved 
in stereocilium formation. Myosin VI is a ‘backward-stepping’ actin-based motor that 
moves towards the pointed (minus) end of actin filaments (Wells et al. 1999, Nishikawa 
et al. 2002). In humans, dominant and recessive mutations in the MYO6 gene can cause 
hearing loss (DFNA22 and DFNB37) (Melchionda et al. 2001, Ahmed et al. 2003a). 
Myosin VI is involved in many processes, including membrane trafficking and recycling, 
cell movement, and endocytosis (Mermall et al. 1998, Buss et al. 2001). In mammalian 
hair cells myosin VI has not been observed in stereocilia, but instead, is localized at 
the base of the hair bundle (fig. 7) within the cuticular plate that is thought to provide 
mechanical stability to the apex of the hair cell  (Hasson et al. 1997). The Snell’s waltzer 
(sv) mouse is deaf and has no detectable myosin VI protein in any tissues (Avraham 
et al. 1995). Stereocilia of the Myo6sv/sv mouse are fused at their bases, indicating that 
myosin VI is required to link the apical plasma membrane to the base of stereocilia and/
or anchor stereocilia rootlets (Self et al. 1999, Altman et al. 2004).
Orientation and elongation of stereocilia 
The evolutionary conservation of a precise arrangement of stereocilia rows in a staircase-
like pattern indicates that this unique organization is required for mechanotransduction 
(Manley 2000). The orientation and overall arrangement of the stereocilia bundles 
indicates the presence of a mechanism that stabilizes the overall orientation of the 
cuticular plate and hair bundle as an integrated complex. This mechanism might involve 
myosin VIIa that is expressed in the stereocilia of the cochlea and vestibular epithelia as 
well as in the retina and several other tissues (El-Amraoui et al. 1996, Weil et al. 1996). 
Anchored by vezatin to a cadherin–catenin complex, myosin VIIa could link the cortical 
cytoskeleton to the adhesion junctions between hair cells and neighbouring supporting 
cells (fig. 7) (Kussel-Andermann et al. 2000). Consistent with this hypothesis mutations 
in myosin VIIa and cadherin 23 result in loss of the V/W configuration and disorientation 
of the bundle, respectively (Self et al. 1998, Di Palma et al. 2001). Mutations in several 
other genes are also known to cause hearing loss by disrupting bundle morphogenesis. 
Mutations in MYO15, which encodes myosin XV, cause non-syndromic sensorineural 
deafness (DFNB3) in humans as well as deafness and vestibular disorders in the shaker-
2 mouse (Probst et al. 1998, Wang et al. 1998b). Hair cell stereocilia in homozygous 
shaker-2 mice are present and properly positioned, but are much shorter than wild-type 
stereocilia and there is no staircase organization of the mature hair bundle (Probst 
et al. 1998). Myosin XV transcripts are observed within areas corresponding to the 
sensory epithelia of the cochlea and vestibular systems in the developing mouse inner 
ear. In the adult mouse organ of Corti the protein is concentrated within the cuticular 
plate and at the tip of every stereocilium in wild-type auditory and vestibular hair cells 
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(fig. 7). Myosin XV appears just before the staircase emerges, which indicates that it is 
required for the elongation and formation of the stereocilia-bundle staircase (Probst et al. 
1998, Belyantseva et al. 2003a). In a hair bundle, longer stereocilia have more myosin 
XV at their tips compared with the adjacent row of shorter stereocilia (Belyantseva 
et al. 2003a). Localization of myosin XV to the extreme tips of stereocilia raises the 
possibility that it is tethered there by integral membrane proteins. Although the proteins 
that interact with myosin XV are not known, it has two predicted FERM domains that 
could mediate interactions with ERM proteins. Perhaps more interestingly, myosin XV 
has a PDZ ligand sequence that could interact with PDZ domain-containing proteins to 
coordinate a macromolecular complex at the tips of stereocilia. PDZ scaffold proteins 
serve as organizing centres of macromolecular functional complexes (Harris and Lim 
2001). Recessive mutations in one such PDZ domain-containing gene, WHRN (which 
encodes whirlin) cause deafness in humans (DFNB31) and in whirler mice (Mburu et 
al. 2003). Stereocilia of whirler mice are arrayed in a near-normal configuration on the 
apical hair cell surface but are abnormally short (Mburu et al. 2003). IHCs and OHCs 
of whirler mice eventually degenerate. The overall inner ear phenotype of whirler mice 
is strikingly similar to that of shaker-2 mice. Whirlin also has a C-terminal PDZ ligand 
sequence that could interact with one of the PDZ domains of another whirlin protein to 
organize their multimerisation into a higher-order structure (Belyantseva et al. 2003b). 
Indeed, Delprat et al. (2005) have recently shown that myosin XVa and whirlin are both 
located at the tips of the stereocilia and interact directly. In addition, Belyantseva et al. 
(2005) have shown that myosin XVa is the motor protein that delivers whirlin to the tips 
of the stereocilia.
Links between stereocilia
Ultrastructural studies have revealed four different types of links between stereocilia that 
provide cohesiveness to the stereocilia bundle and might mediate signalling events during 
morphogenesis. From the top to the base of the stereocilia, these links are designated: 
tip-links, top-links, shaft connections or side-links, and ankle-links (fig. 7). Tip-links are 
present in mature hair cells and are believed to be crucial in mechanotransduction 
(Assad et al. 1991). They might serve as a gating spring that regulates the opening and 
closing of mechanically gated ion channels (Gillespie and Corey 1997). One component 
of the side links is a receptor protein tyrosine phosphatase (Müller and Littlewood-
Evans 2001), suggesting that linkages might fulfil not only adhesive but also regulatory 
functions during bundle development. Ankle-links are located at the beginning of the 
steoreocilia taper and might determine the precise positioning and concomitant growth 
of individual stereocilia within a bundle (Tilney et al. 1992b).
Intercellular adhesion is a key signalling process that initiates cytoskeleton 
rearrangement during morphogenesis (McNeill 2000, Jamora and Fuchs 2002). 
The genetic investigations in type 1 Usher syndrome (USH1) in humans that is 
characterized by inherited hearing loss in combination with retinitis pigmentosa, and the 
characterization of corresponding mouse models has revealed that hair cells might use 
analogous adhesion mechanisms to control the morphogenesis of the hair bundle. On 
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the basis of similar mutant phenotypes, as well as in vitro protein-interaction studies, 
it was suggested that the protein products of genes that are involved in USH1 might 
form a macromolecular complex that provides cohesiveness to the stereocilia bundles 
(Boëda et al. 2002, Siemens et al. 2002, Weil et al. 2003) (table 2). 
Table 2. Human Usher syndrome type 1 loci, genes, proteins and mouse models
Usher syndrome locus Gene Protein Mouse model
USH1A - - -
USH1B MYO7A myosin VIIa shaker-1
USH1C USH1C harmonin -
USH1D CDH23 cadherin 23 waltzer
USH1E - - -
USH1F PCDH15 protocadherin 1 ames waltzer
USH1G USH1G SANS jackson shaker
The protein encoded by USH1C, harmonin, has many tissue-specific isoforms 
in human (Scanlan et al. 1999). The predicted isoforms have two or three PDZ domains, 
one or two coiled-coil regions, and a PST (proline, serine, threonine) domain (Verpy 
et al. 2000). The harmonin b isoforms are found only in the inner ear and the eye, 
whereas the other isoforms are broader expressed (Verpy et al. 2000). In the inner 
ear, harmonin is found in the organ of Corti as well as in the five sensory areas of 
the vestibule (Verpy et al. 2000); in the eye harmonin b is found in the light sensitive 
rod outer segment (Reiners et al. 2003). An interaction has been shown between the 
first PDZ domain of harmonin and the second FERM and MyTh4 domain of myosin 
VIIa, while the second PDZ domain binds the cytoplasmic domain of cadherin 23, and 
the third PDZ domain along with the PST domain might interact with F-actin (fig. 7) 
(Boëda et al. 2002, Siemens et al. 2002). The three proteins form a transmembrane 
complex essential for the organisation and stabilisation of the stereocilia. SANS has 
also been implicated in an interaction with harmonin (fig. 7) (Weil et al. 2003). SANS 
and harmonin might act as cytoplasmic scaffold organizers of proteins. Cadherin 23 
and protocadherin 15 are members of the cadherin superfamily of integral membrane 
proteins that are responsible for intercellular adhesion as well as signalling (Nelson and 
Nusse 2004). Interaction of these proteins might form links that interconnect stereocilia 
within a bundle. Protocadherins represent a large family of non-classical cadherins that 
are structurally and functionally divergent from the classic cadherins (Angst et al. 2001). 
Expression of Pcdh15 is found in the developing sensory epithelia of the inner ear, 
the developing eye, the central nervous system, and epithelia of the kidney, lung and 
gastrointestinal tract (Murcia and Woychik 2001). Ahmed et al. (2003b) further localized 
the protein to the inner ear hair cell stereocilia, and to retinal photoreceptors. Both 
the IHC and OHC stereocilia of Pcdh15-/- mice were disorganised and associated with 
degeneration of the inner ear neuroepithelia (Alagramam et al. 2001). The OHCs did not 
display the characteristic “U” configuration found in wild-type mice. Protocadherin 15 
appears in the stereocilia of developing mammalian hair cells and persists in adult hair 
cells along the length of stereocilia, indicating that it might be important for the long-term 
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maintenance of lateral connections (side-links) between stereocilia (fig. 7) (Ahmed et al. 
2003b). In mice, cadherin23 is found specifically in the stereocilia of the IHCs and OHCs 
(Boëda et al. 2002, Siemens et al. 2002). During development in mammals, cadherin23 
and harmonin transiently appear together in stereocilia, and have been reported to 
diminish to undetectable amounts in adult stereocilia (Boëda et al. 2002). Söllner et al. 
(2004) show that the defects in zebrafish sputnik mutants are caused by mutations in 
Cdh23. In sputnik mutants, stereociliary bundles are splayed to various degrees, with 
mutants displaying reduced or absent mechanotransduction (Nicolson et al. 1998). In 
zebrafish Cdh23 protein is concentrated near the tips of stereocilia bundles and tip links 
are absent in homozygous Cdh23 mutant sputnik (Söllner et al. 2004). Cdh23 is large 
enough to be the tip link and has biochemical properties similar to those of the tip link. 
Although Cdh23 has been shown to have a role in the development of hair bundles (Di 
Palma et al. 2001), the findings of Siemens et al. (2004) suggest that its role in adult 
hair cells is to form tip links, which transmit force to mechanically gated ion channels. 
Moreover, Cdh23 forms a complex with myosin 1c, the only known component of the 
mechanotransduction apparatus (Holt et al. 2002), suggesting that Cdh23 and myosin 
1c cooperate to regulate the activity of mechanically gated ion channels in hair cells 
(fig. 7). 
At least some hair-bundle adhesion complexes seem to be linked by 
unconventional myosin VIIa to the actin core at sites of links between stereocilia (fig. 
7). At the lateral surface, myosin VIIa probably links USH1 macromolecular complexes 
(harmonin–cadherin23–SANS-protocadherin15) to the actin filaments during hair-bundle 
maturation (Boëda et al. 2002, Siemens et al. 2002, Weil et al. 2003). At the base of the 
stereocilium, myosin VIIa interacts with a novel transmembrane protein, vezatin, and 
could comprise part of an adhesion complex that is associated with ankle-links (fig. 7) 
(Kussel-Andermann et al. 2000). The unique location and putative composition of ankle-
links are consistent with an additional role: an adhesion complex that regulates actin–
myosin-based trafficking through the taper of a stereocilium (Frolenkov et al. 2004). 
Hair cell maintenance
Barhl1 is a mammalian homolog of the Drosophila BarH1 and BarH2 genes, which 
encode homeodomain proteins that are required for determination of sensory organs 
and for normal eye morphogenesis (Higashijima et al. 1992a, Higashijima et al. 
1992b, Bulfone et al. 2000). In the developing nervous system, Barhl1 is primarily 
expressed in migrating neurons that settle in specific domains within the diencephalon, 
rhombencephalon and spinal cord (Bulfone et al. 2000). In the inner ear, Barhl1 is 
expressed in all hair cells during inner ear development but it is more abundant in the 
adult cochlear OHCs. Targeted deletion of Barhl1 causes degeneration of cochlear hair 
cells that is progressive and severe to profound hearing loss (Li et al. 2002). The onset 
of degeneration of cochlear IHCs was delayed for more than half a year relative to that 
of the OHCs, suggesting that IHCs and OHCs are differentially maintained. In fact, these 
two hair cell types appear to require different levels of Barhl1 for their maintenance as 
a significantly higher level of Barhl1 expression is seen in the OHCs. Data from Li et 
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al. (2002) indicate that Barhl1 not only plays an essential role in the maintenance of 
cochlear hair cells but also in terminal differentiation of cochlear hair cells.
Caspase-3 has also been shown to play a role in inner ear hair cell maintenance 
(Takahashi et al. 2001). Caspases are cystein proteases that normally mediate apoptotic 
cell death. In developing Caspase 3-/- mice sensory epithelia initially appear normal, 
although maturation of the organ of Corti is slightly delayed. By five weeks, mutants 
show hyperplasia of supporting cells and significant loss of inner and outer hair cells 
(Takahashi et al. 2001). The few hair cells that survive show morphological abnormalities 
including loss of ciliary bundles or fusion of bundles between adjacent hair cells. 
Cochlear neurons also undergo significant degredation during this time (Takahashi et al. 
2001). While production of supernumary supporting cells could result from inhibition of 
apoptosis, the cause of hair cell degeneration is not clear. Loss of hair cells could be an 
indirect effect of altering the balance of signals from supporting cells. Another possibility 
is that Caspase 3 plays a direct role in the differentiation or maintenance of hair cells.
1.3 Hearing loss
Hearing loss is the most common sensory disorder in the human population. One in 1000 
children is born deaf and a similar number of children develop a hearing impairment 
during early childhood (Morton 1991, Gorlin et al. 1995, Fortnum et al. 2001). As age 
increases so does the prevalence of hearing impairment; by the age of 40-50 years, 
2.3% of the population experience a hearing loss of greater than 40 dB, which increases 
to nearly 30% after the age of 70 years (Davis 1995). 
1.3.1 Nonsyndromic hearing loss
Approximately equal numbers of cases of prelingual early childhood hearing loss are 
attributed to environmental and genetic factors. Of the cases attributed to genetic factors, 
about 70% are classified as nonsyndromic, i.e. hearing loss without other obvious clinical 
features, and 30% are classified as syndromic. Nonsyndromic hearing impairment 
can be further subdivided based on the mode of inheritance: ~77% of the cases are 
autosomal recessive, ~22% are autosomal dominant and ~1% are X-linked. Autosomal 
dominant loci are designated DFNA, autosomal recessive loci are designated DFNB 
and X-linked loci, DFN. The loci are numbered according to the order in which they 
were identified. Up to now, 39 autosomal dominant loci (DFNA), 37 autosomal recessive 
loci (DFNB) and 4 X-linked loci (DFN) have been described and 38 genes underlying 
nonsyndromic hearing impairment have been identified (table 3) (Van Camp G. and 
Smith R.J.H. Hereditary hearing loss homepage [http://www.uia.ac.be/DNAlab/hhh/]). In 
addition to nuclear genes some mitochondrial genes have been associated with hearing 
loss. As mitochondria have a crucial function in nearly every cell, it is not unexpected 
that mitochondrial DNA mutations mainly cause systemic diseases, including hearing 
impairment. Surprisingly, some mitochondrial mutations cause nonsyndromic hearing 
impairment in less than 1% of the cases (reviewed by Fischel-Ghodsian 2003).
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Table 3. Genes involved in nonsyndromic hearing impairment
Gene Locus Reference
CRYM Abe et al. 2002
GJA1 (Cx43) Liu et al. 2001
PRES (Prestin) Liu et al. 2003
ACTG1 DFNA20/26 van Wijk et al. 2003, Zhu et al. 2003
CDH23 DFNB12 Bork et al. 2001
CLDN14 DFNB29 Wilcox et al. 2001
COCH DFNA9 Robertson et al. 1998, de Kok et al. 1999
COL11A2 DFNA13 McGuirt et al. 1999
DFNA5 DFNA5 Van Laer et al. 1998
DIAPH1 DFNA1 Lynch et al. 1997
ESPN DFNB36 Naz et al. 2004
EYA4 DFNA10 Wayne et al. 2001
GJB2 (Cx26) DFNA3/DFNB1 Kelsell et al. 1997
GJB3 (Cx31) DFNA2 Xia et al. 1998
GJB6 (Cx30) DFNA3/DFNB1 Grifa et al. 1999, Del Castillo et al. 2002
KCNQ4 DFNA2 Kubisch et al. 1999
MYH9 DFNA17 Lalwani et al. 2000
MYH14 DFNA4 Donaudy et al. 2004 
MYO1A DFNA48 Donaudy et al. 2003
MYO3A DFNB30 Walsh et al. 2002
MYO6 DFNA22/DFNB37 Melchionda et al. 2001, Ahmed et al. 2003a
MYO7A DFNA11/DFNB2 Liu et al. 1997a, b, Weil et al. 1997
MYO15 DFNB3 Wang et al. 1998b
OTOA DFNB22 Zwaenepoel et al. 2002
OTOF DFNB9 Yasunaga et al. 1999
PCDH15 DFNB23 Ahmed et al. 2003b
POU3F4 DFN3 De Kok et al. 1995
POU4F3 DFNA15 Vahava et al. 1998
SLC26A4 DFNB4 Li et al. 1998a
STRC DFNB16 Verpy et al. 2001
TECTA DFNA8/DFNA12/DFNB21 Verhoeven et al. 1998, Mustapha et al. 1999
TFCP2L3 DFNA28 Peters et al. 2002
TMC1 DFNA36/DFNB7/DFNB11 Kurima et al. 2002
TMIE DFNB6 Naz et al. 2002
TMPRSS3 DFNB8/DFNB10 Scott et al. 2001
USHC1 DFNB18 Ahmed et al. 2002, Ouyang et al. 2002
WFS1 DFNA6/DFNA14 Bespalova et al. 2001, Young et al. 2001
WHRN DFNB31 Mburu et al. 2003
Recessive nonsyndromic hearing loss
Most of the recessively inherited forms of hearing impairment cause a phenotypically 
identical bilateral severe to profound, prelingual hearing loss that is stable and affects 
all frequencies. However, mutations at a few loci, DFNB2 (MYO7A) (Liu et al. 1997b), 
DFNB8/10 (TMPRSS3) (Veske et al. 1996), and DFNB16 (STRC) (Verpy et al. 2001), 
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cause delayed, childhood-onset hearing impairment. Also of note is that hearing loss 
caused by mutations at DFNB4 (SLC6A4) may be associated with dilated vestibular 
aquaducts and endolymphatic sacs (Phelps et al. 1998), and there may be an associated 
auditory neuropathy with mutations in OTOF (DFNB9) (Varga et al. 2003). In addition, 
vestibular symptoms have been noted in DFNB2 (MYO7A), DFNB4 (SLC6A4) and 
DFNB12 (CDH23).
Although recessive nonsyndromic hearing impairment shows a very high degree 
of genetic heterogeneity mutations in the GJB2 gene were shown to account for 0% 
of this type of hearing impairment in Caucasian populations (Denoyelle et al. 1997, 
Zelante et al. 1997, Morell et al. 1998). In European, North American and Mediterranean 
populations the most common mutation is a deletion of a single guanine nucleotide in a 
series of six guanines known as 35delG (Gasparini et al. 1997, Green et al. 1999). This 
mutation may account for 70% of mutant alleles of GJB2 and the carrier frequency of 
this mutation alone on average is estimated 1 in 51 in Europe, but is considerably higher 
in Mediterranean populations (Zelante et al. 1997, Gasparini et al. 2000). At present it 
is not known whether this high carrier frequency is to be explained by genetic drift or by 
increased reproductive fitness.
Dominant nonsyndromic hearing loss
Autosomal dominant nonsyndromic hearing impairment is generally less severe than 
the autosomal recessive types. Most forms of autosomal dominant nonsyndromic 
hearing impairment are difficult to distinguish phenotypically. The majority of autosomal 
dominantly inherited types of hearing loss are associated with hearing impairment 
that is postlingual in onset, often beginning before the age of 20 years, and mostly 
affecting the high frequencies. Some forms, however, notably DFNA4 (Chen et al. 
1995), DFNA9 (Manolis et al. 1996) and DFNA10 (O’ Neil et al. 1996), are associated 
with hearing impairment starting somewhat later, during the third and fourth decades. 
Mutations at the DFNA6/14/38 locus (Lesperance et al. 1995, Van Camp et al. 1999) 
as well as those associated with the DFNA9 (Manolis et al. 1996) locus tend to have 
distinguishable clinical phenotypes, because they are associated with low frequency 
hearing loss and vestibular symptoms respectively. DFNA8/12 (Verhoeven et al. 1997, 
Kischhofer et al. 1998), DFNA13 (Brown et al. 1997) and DFNA21 (Kunst et al. 2000) 
can be discriminated by mid-frequency hearing impairment. All DFNA types of hearing 
impairment are sensorineural, except in a single family linked to DFNA23 in which a 
conductive component is present in approximately 50% of the affected persons (Salam 
et al. 2000). 
In general, if more than one family has been linked to the same locus, the 
phenotypic characteristics of the hearing loss segregating in these families are 
comparable. Statistical analysis of audiometric data of large families can be used to 
construct age-related typical audiograms (ARTA) (Huygen et al. 2003), which often clearly 
characterize the hearing loss associated with the locus or gene. This type of analysis 
was recently performed for several autosomal dominant forms of nonsyndromic hearing 
impairment associated with mutations in the following genes: COCH (Kemperman et al. 
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2002), COL11A2 (De Leenheer et al. 2002a), DFNA5 (De Leenheer et al. 2002b), EYA4 
(De Leenheer et al. 2002c), KCNQ4 (De Leenheer et al. 2000d), POU4F3 (Gottfried et 
al. 2002) and loci for which causative genes not yet have been cloned (Huygen et al. 
2002). The use of ARTAs can greatly facilitate the identification of deafness causing 
genetic defects, as described in this thesis in chapters three and four.  
1.3.2 Syndromic hearing loss
There are many different syndromes that include an auditory phenotype as a prominent 
feature. Approximately 30% of individuals with prelingual hereditary hearing loss also 
have abnormalities of other organ systems. The accompanying abnormalities range 
from subtle to severe and may be congenital or delayed in appearance. The majority of 
these syndromes are inherited as monogenic disorders. Some of the genes involved in 
these syndromes have been mapped to chromosomal regions and a subset of these has 
been identified. A number of genes are involved in syndromic as well as nonsyndromic 
forms of hearing loss.
Table 4. Usher syndrome loci
Usher locus Chromosomal location Gene Overlapping NSHL locus
USH1A 14q32
USH1B 11q13.5 MYO7A DFNB2, DFNA11
USH1C 11p1.1 USH1C DFNB18
USH1D 10q22.1 CDH23 DFNB12
USH1E 21q21
USH1F 10q21.1 PCDH15 DFNB23
USH1G 17q25.1 SANS
USH2A 1q41 USH2A
USH2B 3p23-p24.2
USH2C 5q14.3-q21.3 VLGR1
USH3A 3q25.1 USH3A
USH3B 20q
 Adapted from Ahmed et al. 2003c Clin Genet 63: 431-444
Usher syndrome
Usher syndrome is characterized by various degrees of hearing loss and a progressive 
retinal dystrophy (retinitis pigmentosa [RP]) and is the most common form of deaf-
blindness (50%[Boughman et al. 1983]). Its prevalence is currently estimated between 
2-6.3 per 100,000 live births based on studies in Scandanavia (Hallgren 1959, Nuutila 
197, Grondahl 1987, Rosenberg et al. 1997), Colombia (Tamayo et al. 1991), the United 
Kingdom (Hope et al. 1997), and the United States (Boughman et al. 1983). Three 
distinct phenotypes have been described. Usher syndrome type 1 is the most severe, 
patients have congenital severe to profound hearing loss and absence of vestibular 
function, whereas patients with Usher syndrome type 2 have congenital moderate-to-
severe hearing loss and normal vestibular function. The onset of RP is prepuberal in 
patients with Usher syndrome type 1 and occurs during the second decade of life in 
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patients with Usher syndrome type 2 (Smith et al. 1994). Patients with Usher syndrome 
type 3 have postlingual, progressive hearing loss, and the onset of RP symptoms 
usually occurs by the second decade of life (Pakarinen et al. 1996). Some patients 
cannot be easily categorized into one of three subtypes and are designated atypical 
(Otterstedde et al. 2001). Usher syndrome is a genetically heterogeneous disorder, at 
least twelve loci account for subtypes of Usher syndrome, and eight genes have so far 
been identified (table 4). 
1.3.3. Molecular genetics of hearing loss in humans
The great clinical heterogeneity seen in heritable deafness suggests the involvement of 
many genes in hearing. The identification of genes involved in hearing loss has enabled 
geneticists to offer DNA diagnostic tests for many types of nonsyndromic hearing loss. 
Moreover, it holds the promise to significantly improve the molecular knowledge on the 
auditory and vestibular organs and on the pathological mechanisms leading to hearing 
loss. This opens perspectives for future therapeutic and/or preventive measures for 
hearing loss. Genes that have been found to be responsible for nonsyndromic hearing 
loss can be classified by their function.
Components of the extracellular matrix
To date four genes encoding extracellular matrix components have been identified as 
being involved in nonsyndromic hearing impairment: COCH, COL11A2, TECTA, and 
OTOA. 
The extracellular matrix protein COCH (Coagulation factor C Homologue) was 
isolated from a human fetal cochlea cDNA library by Robertson et al. (1994, 1997). 
Mutations in COCH are responsible for DFNA9, a form of autosomal dominant hearing 
loss that is associated with vestibular dysfunction (Robertson et al. 1998, de Kok et 
al. 1999). The COCH protein is ubiquitously present in the inner ear, and might even 
be the most abundant inner ear protein (Ikezono et al. 2000). Robertson et al. (2001) 
performed inmmunohistochemistry with an antibody raised against COCH and showed 
staining predominantly in the regions of the fibrocytes of the spiral limbus and of the 
spiral ligament in mouse and in human fetal ad adult tissue sections. High expression 
of COCH is unique to the cochlea, but the exact function of the protein is unknown. 
Grabski et al. (2003) showed that wild-type Coch accumulates in extracellular deposits 
that closely parallel the matrix component fibronectin, whereas mutant Coch varies in 
the amount and pattern of extracellular material. Whereas some mutants exhibited an 
almost normal deposition pattern, some showed a complete lack of deposition. These 
data suggest that DFNA9 results from gene products that fail to integrate correctly into 
the extracellular matrix. As symptoms of Menière’s disease (including vertigo, tinnitus 
and a pressure feeling in the ear) were found in about 25% of patients with a COCH 
mutation, a putative role for COCH in Menière’s disease was suggested (Fransen et al. 
1999, Usami et al. 2003) but never confirmed.
One of the most prominent structures of the organ of Corti, the tectorial 
membrane, is composed of extracellular matrix molecules. It consists of collagen fibres 
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and a non-collagenous matrix. The major collagen in the tectorial membrane is collagen 
type II. Human type XI collagen is a quantitatively minor collagen that is composed of 3 
α-chain polypeptide subunits: type XI collagen α1, α2, and α3. Mutations in COL11A2 
cause DFNA13, a mid-frequency hearing loss with no significant progression (McGuirt 
et al. 1999, De Leenheer et al. 2001), as well as two syndromic forms of hearing loss 
(Stickler syndrome type III and OSMED, Vikkula et al. 1995). In hearing impaired 
Col11a2-/- mice the tectorial membrane appeared to be thicker and less compacted than 
normal, due to disorganization of the type 2 collagen fibrils, which were not arranged 
in their usual parallel, evenly spaced manner (McGuirt et al. 1999). It was therefore 
hypothesized that the type XI collagen is needed in the tectorial membrane for even 
spacing of the type II collagen fibrils.
Three noncollagenous glycoproteins have been identified thus far that are 
components of the tectorial membrane (Cohen-Salmon et al. 1997, Legan et al. 1997). 
These are α-tectorin, β-tectorin, and otogelin. Up to 50% of the total protein content of 
the tectorial membrane consists of α- and β-tectorin (Goodyear and Richardson 2002). 
Mutation analysis of the gene encoding α-tectorin, TECTA, has revealed mutations 
associated with DFNA8/12 (Verhoeven et al. 1998) and DFNB21 (Mustapha et al. 1999). 
Dominantly inherited DFNA8/12 is a prelingual, moderate to severe, progressive type 
of hearing loss, whereas recessively inherited DFNB21 is characterized by prelingual, 
severe to profound hearing loss. The normal auditory function in carriers of recessive 
mutations implies that half the normal amount of α-tectorin is sufficient to maintain 
mechanical properties of the tectorial membrane. This implies that dominant mutations 
have a dominant negative effect, probably by interaction of mutant α-tectorin with wild 
type α-tectorin, β-tectorin, or collagen. In mice with a targeted deletion in the entactin 
G1-like domain of α-tectorin, the tectorial membrane lacks all noncollagenous matrix 
and is completely detached from the cochlear epithelium, but the architecture of the 
organ of Corti is otherwise normal (Legan et al. 2000).
The third component of the tectorial membrane, otogelin, is encoded by 
the gene OTOG. In Otog-/- mice, both the vestibular and the auditory functions were 
impaired (Simmler et al. 2000). Histological analysis of these mutants demonstrated 
that in the vestibule, otogelin is required for the anchoring of the otoconial membrane 
and cupulae to the neuroepithelia. No gross morphological anomalies were found in the 
tectorial membrane, however, ultrastructural analysis indicated that otogelin is involved 
in the organization of its fibrillar network. Otogelin could, therefore, be involved in the 
interaction or stabilization of this network, thus contributing to the mechanical stability, 
ductile capacity and tensile strength of the tectorial membrane. 
The inner ear-specific protein otoancorin is defective in nonsyndromic 
recessive deafness DFNB22 (Zwaenepoel et al. 2002). In the cochlea otoancorin is 
located along the interface between the apical surface of the hair cells and the tectorial 
plama membrane and remains attached to the apical plasma membrane of epithelial 
cells in the absence of a tectorial membrane. In the vestibule, otoancorin is present on 
the apical surface of sensory cells, where they contact the otoconial membranes and 
cupulae.  Sequence data have shown that otoancorin is probably a membrane-bound 
protein that is predicted to be a glycosyl-phosphatidylinositol-anchored protein, shares 
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weak homology with megakaryocyte potentiating factor/mesothelin precursor. 
That mutations in COL11A2 (collagen type XI polypeptide subunit 2), OTOA 
(otoancorin), and TECTA (alpha-tectorin) lead to either recessive or dominant 
nonsyndromic or syndromic hearing loss in humans emphasizes the importance of a 
structurally intact and firmly attached tectorial membrane. 
Cytoskeletal proteins
Mutations in many cytoskeletal components result in nonsyndromic hearing loss. To date 
15 such genes have been described. Several of these have been extensively discussed 
in the previous paragraph: ACTG1, CDH23, DIAPH1, ESPN, PCDH15, USH1C, and 
WHRN (table 3).
When analysing expression profiles of human inner ear tissues on a cDNA 
microarray, Abe et al. (2002) identified a gene, which was especially abundant in the inner 
ear, CRYM. Mutations in CRYM have been found to be responsible for nonsyndromic 
hearing loss (Abe et al. 2002). CRYM is one of the taxon-specific crystallins, also 
called “µ-crystallin” (Kim et al. 1992). CRYM transcription in fetal cochlea has been 
demonstrated in the Morton cochlear EST database. CRYM is thought to be a cytosolic 
NADP-regulated thyroid hormone-binding protein, a member of a group of molecular 
entities responsible for most of the intracellular high affinity binding of T3 and T4 (Vie et 
al. 1997). Thyroid hormone binding proteins are involved in sequestration and release 
of intracellular thyroid hormones. Whereas the cytosolic binding sites for T3 and T4 are 
similar to those of thyroid hormone receptors, the binding affinity of thyroid hormone 
binding proteins is 100 times greater than that of thyroid hormone receptors (Vie et al 
1997). It is therefore speculated that the mutant CRYM could abrogate the affinity for 
thyroid hormone, which is essential for developmental periods as described in paragraph 
2.2.6. Such deficiency results in defective morphological differentiation and maturation 
in the organ of Corti (Uziel 1986). Crym mRNA is localized in two distinct regions of 
the mouse cochlea, the lateral fibrocytes of the spiral ligament and the spiral limbus 
fibrocytes. The postulated role for these cells is potassium recycling (Spicer and Schülte 
1996), suggesting that CRYM dysfunction interferes with potassium ion recycling and 
thus disturbs the maintenance of potassium-rich endolymph and a positive electrical 
potential. 
Using a candidate gene approach Yasunaga et al. (1999) identified OTOF, the 
second member of a mammalian gene family related to C. elegans fer-1. It encodes 
otoferlin, a predicted cytosolic protein with six C2 domains and a single carboxy-
terminal transmembrane domain (Yasunaga et al. 1999). C2 domain proteins are known 
to interact with phospholipids and proteins (Rizo and Südhof 1998). In mice, Otof is 
mainly expressed in cochlear inner hair cells and vestibular sensory cells (Yasunaga 
et al. 1999) and it has been suggested that OTOF plays a role in Ca2+ triggered fusion 
of synapse vesicles with the plasma membrane or generation of the lipid secondary 
messengers involved in transduction pathways (Yasanuaga et al. 2000). Mutations in 
otoferlin cause autosomal recessive, nonsyndromic, severe to profound, prelingual 
hearing impairment (DFNB9) (Yasunaga et al. 1999, Yasunaga et al. 2000, Houseman 
General Introduction
38
et al. 2001). Varga et al. (2003) have also identified mutations in the OTOF gene in 
patients suffering from nonsyndromic recessive auditory neuropathy, in which patients 
have a hearing loss based on pure tone audiometry and auditory brain stem response, 
but with normal otoacoustic emissions. 
   
Myosins
Myosins are molecular motor proteins that bind to actin and hydrolyse ATP to generate 
the force to move across actin filaments. Myosins consist of a head and a tail connected 
by a flexible neck region. The myosin superfamily consists of 15 branches, 14 of which 
are composed of unconventional myosins and one of conventional myosins. Two 
heavy chain myosins of the class II conventional nonmuscle myosins have so far been 
implicated in nonsyndromic hearing loss. MYH9 is involved in DFNA17 (Lalwani et al. 
1999, Lalwani et al. 2000). Within the rat cochlea, MYH9 was localised throughout the 
outer hair cells, the subcentral region of the spiral ligament, and Reissner´s membrane 
(Lalwani et al. 2000). MYH14 is localised within the DFNA4 critical region (Chen et 
al. 1995a, Mirghomizadeh et al. 2002) and in 2004 Donaudy et al. found mutations in 
MYH14 two large pedigrees linked to DFNA4 and in one sporadic case among 300 
hearing-impaired individuals.. In human and mouse the gene is ubiquitously expressed 
at higher levels in adults than during development (Leal et al. 2003, Golomb et al. 2004). 
In the mouse cochlea (P0), with the exception of Reissner´s membrane, the protein is 
localised in all cells of the scala media wall, with relatively higher levels in the organ of 
Corti and the stria vascularis (Donaudy et al. 2004). 
Five unconventional myosin genes have been described to be involved in 
nonsyndromic hearing loss (MYO1A, MYO3A, MYO6, MYO7A, and MYO15). Mutations 
in shaker-1 mutant mice and human Usher syndrome type 1B patients were identified in 
the myosin VIIA gene simultaneously (Gibson et al. 1995, Weil et al. 1995). Subsequently, 
dominant and recessive human hearing loss were found to be associated with myosin 
VIIA mutations (Liu et al 1997a, 1997b). Mutations in MYO15 are responsible for 
congenital profound deafness DFNB3 in humans (Wang et al. 1998b). Shaker-2 mice 
show deafness and vestibular defects and carry a spontaneous mutation in the Myo15 
gene (Probst et al. 1998). Mutations in the myosin VI gene, Myo6, are associated 
with deafness and vestibular dysfunction in the Snell´s waltzer mouse (Avraham et al. 
1995) and mutations in the human ortholog, MYO6, are associated with dominantly 
inherited DFNA22 (Melchionda et al. 2001) and rcessively inherited DFNB37 (Ahmed 
et al. 2003a). The function of myosin VIIa, myosin XV and myosin VI in the inner ear is 
extensively discussed in paragraph 2 of the introduction.
Walsh et al. (2002) have shown that normal hearing in humans requires 
myosin IIIA, the human homolog of D. Melanogaster NINAC. Progressive hearing loss 
DFNB30 is caused by mutations in myosin IIIA. In Drosophila rhabdomeres, NINAC 
interacts with actin filaments and with a PDZ scaffolding protein INAD to organize the 
phototransduction machinery into a signalling complex. Mutations in Drosophila NINAC 
lead to retinal degeneration (Li et al. 1998b, Wes et al. 1999). Expression of mammalian 
myosin IIIA is highly restricted, with the strongest expression in retina and cochlea 
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(Walsh et al. 2002).
Donaudy et al. (2003) identified a nonsense mutation and six missense mutations 
in MYO1A, in DFNA48 patients suffering from sensorineural bilateral hearing loss of 
variable degree, usually ranging from moderate to severe hearing loss. Myosin I has 
been implicated in various processes involving motility, including organelle translocation, 
ion-channel gating and cytoskeleton reorganization. Besides in the cochlea (Donaudy 
et al. 2003) myosin 1a is present in the large and small instestine where it is a major 
component of the actin rich cytoskeleton of the brush border surface in intestinal 
epithelial cells (Skowron et al. 1998). 
Molecules involved in ion homeostasis
Maintaining ion homeostasis within the cochlear duct, and in particular K+ recycling, 
is of great importance for signal transduction involved in the hearing process. This is 
demonstrated by the number of genes involved in nonsyndromic hearing loss that are 
believed to play a role in ion homeostasis.
Mutations in the gene CLDN14, encoding tight junction claudin 14, cause 
autosomal recessive deafness DFNB29 (Wilcox et al. 2001). CLDN14 is a member of the 
claudin gene family, which comprises the components of tight junctions. Tight junctions 
in the cochlear duct are thought to compartmentalize the endolymph and provide 
structural support for the auditory neuroepithelium. In mice Cldn14 is expressed in the 
sensory epithelium of the organ of Corti and expression coincides with the development 
of the endocochlear potential during the first postnatal week, suggesting that Cldn14 
expression may be required for the development and maintenance of this latter process 
(Anniko and Bagger-Sjoback 1982, Souter and Forge 1998, Wilcox et al. 2001). 
KCNQ4 is a member of the voltage-gated potassium channel gene family. 
The potassium channels are tetramers of identical or homologous subunits. Kubisch 
et al. (1999) found mutations in KCNQ4 to be associated with DFNA2. Interestingly, 
otherpotassium channels have previously been associated with syndromic hearing loss. 
Mutations in KCNQ1 or KCNE1 cause the recessive Jervell/Lange-Nielsen syndrome 
characterized by hearing loss and cardiac rythm disturbances including a prolonged 
QT-interval (Neyroud et al. 1997, Schulze-Bahr et al. 1997). IN the mouse cochlea 
Kcnq4 is found in large amounts in the basal cell membrane of the OHCs (Kharkovets et 
al. 2000). In the mouse vestibular organs, Kcnq4 expression is restricted to the hair cells 
and the afferent nerve endings ensheating these sensory cells. Kcnq4 is also expressed 
in neurons of many, but not all, nuclei of the central auditory pathway (Kharkovets et al. 
2000 ). 
Liu et al. (2003) found that a mutation in the prestin gene, PRES, is responsible 
for recessive non-syndromic deafness in two families. Prestin is a member of the solute 
carrier (SLC) family 26 (SLC26A5), which constitute anion-transporter-related proteins. 
Like other members of this family, prestin has a highly hydrophobic core of 12 predicted 
transmembrane domains with the N- and C-termini located cytoplasmically (Dallos 
and Fakler 2002). Although prestin has not been shown to have any anion transport 
capability, it does appear to share the overall structure and specific protein domains 
General Introduction
40
of the anion transporter family SLC26. The prestin gene (Pres) is highly expressed in 
outer hair cells and prestin lines the lateral wall of these cells in a close-packed array 
(Dallos and Fakler 2002). Prestin is necessary for fast electromotility and is likely to 
be the electromotility motor of cochlear OHCs (Zheng et al. 2000c, Dallos and Fakler 
2002). Prestin is hypothesized to mediate the active amplification that boosts cochlear 
sensitivity by 100-1000 fold. A study of prestin knockout mice revealed hearing sensitivity 
that was reduced by 45-60 dB (Liberman et al. 2002). A recent study has shown that 
PRES expression is regulated by thyroid hormone (Weber et al. 2002).
SLC26A4 encodes pendrin, a chloride-iodide transporter (Scott et al. 1999). 
Yoshida et al. (2004) have shown that pendrin is important for chloride uptake and 
iodide efflux and that iodide and chloride activate the exchange activity of pendrin while 
they are transported. SLC26A4 is expressed in the endolymphatic sac and duct and 
in limited cell types including the marginal cells of the stria vascularis from embryonic 
day 13 onwards and in non-sensory parts of the utricle, saccule and cochlea where it 
may be involved in regulation and resorption of endolymph (Everett et al. 1999, Everett 
et al. 2001). Yoshino et al. (2004) confirmed the expression pattern of pendrin in the 
mouse inner ear with immunohistochemical analysis. In addition pendrin was found 
in the apical membrane of the endolymphatic sac and duct, in the spiral ligament, the 
supporting cells, and the spiral ganglion of the cochlea. Individuals with mutations in 
SLC26A4 have a variable clinical presentation ranging from full blown classical Pendred 
syndrome presenting with goitre and prelingual profound sensorineural hearing loss, to 
those without goitre in whom the hearing loss presents as nonsyndromic (Coyle et al. 
1998, Campbell et al. 2001). 
TMPRSS3 (transmembrane protease, serine 3) encodes a type II transmembrane 
serine protease that is mutated in both familial and sporadic cases of nonsyndromic 
autosomal recessive hearing loss (DFNB8/10) (Ben-Yosef et al. 2001, Masmoudi et al. 
2001, Scott et al. 2001, Wattenhofer et al. 2002). The mouse and rat cochlea Tmprss3 
gene is expressed in the spiral ganglion, the supporting cells of the organ of Corti and 
the stria vascularis (Guipponi et al. 2002). TMPRSS3 is anchored in the endoplasmatic 
reticulum membranes and may play a role in the processing of epithelial amiloride-
sensitive sodium channel, which is present in many sodium-reabsorbing tissues including 
the inner ear (Vallet et al. 1997, Vuagniaux et al. 2000). Recently, it has been suggested 
that EnaC plays a role in the establishment and maintenance of the remarkably low 
sodium concentration of the endolymph (Couloigner et al. 2001, Grunder et al. 2001). 
Guipponi et al. (2002) show that Tmprss3 co-localizes with EnaC in the spiral ganglion, 
the stria vascularis and in the supporting cells of the organ of Corti. 
Connexins
Connexins connect adjacent cells and facilitate the exchange of ions, secondary 
messengers and other small molecules in the cochlea (Kikuchi et al 1995). The 
numbers assigned to the various connexins refer to their approximate molecular weight. 
Connexins form a family of more than 13 membrane proteins that can be classified into 
subgroups: α, β, and γ, based on similarities at the nucleotide and amino acid level. Six 
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connexin molecules assemble to form a half-channel or connexon, which docks with its 
counterpart in an adjacent cell to form a complete intercellular channel or gap junction. 
In the rodent auditory organ, gap junction channels contribute to two independent 
intercellular networks (Lautermann et al 1999, Xia et al. 1999). The epithelial gap 
junction system forms around embryonic day 16 and connects all supporting cells of the 
cochlear neurosensory epithelium as well as adjacent epithelial cells. No gap junctional 
communication has been found between the hair cells and the adjacent supporting 
cells. The gap junction system between connective tissue cells starts to develop around 
birth; this gap junction system is composed of fibrocytes in the spiral ligament and spiral 
limbus, and also includes basal, intermediate and marginal cells of the stria vascularis. 
It is thought that these gap junctions facilitate the recycling of K+ from the hair cells back 
into the cochlear endolymph during auditory transduction, the K+-recycling pathway 
(Kikuchi et al. 1995). To date, expression of at least four different connexins has been 
reported in the inner ear, connexin 26 (GJB2), connexin 30 (GJB6), connexin 31 (GJB3), 
and connexin 43 (GJA1). The fact that mutations in these four genes can cause hearing 
loss shows the functional importance of these gap junction networks in man (Kelsell et 
al. 1997, Grifa et al. 1999, Lerer et al. 2001, Liu et al. 2001, Del Castillo et al. 2002).
As described in paragraph 3.1.1, mutations in GJB2 are responsible for DFNA3. 
Mutations in GJB3 have been pathogenically linked to erythrokeratodermia variabilis 
(Richard et al. 1998), nonsyndromic autosomal dominant (DFNA2) (Xia et al. 1998) and 
recessive hereditary hearing impairment (Liu et al. 2000). 
GJB6 mutations lead to a middle/high-frequency hearing loss (DFNA3/DFNB1) 
(Grifa et al. 1999, Lerer et al. 2001, Del Castillo et al. 2002, Pallares-Ruiz et al. 2002), 
hidrotic ectodermal dysplasia (Lamartine et al. 2000) and Clouston syndrome (Smith et 
al. 2002). Homozygous mouse mutants exhibit a severe constitutive hearing impairment 
(Teubner et al. 2003). A 342-kb deletion encompassing part of GJB6 is the second most 
frequent mutation causing prelingual hearing loss, DFNB1, in the Spanisch population 
(Del Castillo et al. 2002). This deletion also causes hearing loss when present 
heterozygously in combination with a heterozygous mutation in GJB2, which suggests 
a digenic pattern of inheritance (Lerer et al. 2001).
Liu et al. (2001) have found that alterations in GJA1 (Cx43) cause nonsyndromic 
autosomal recessive deafness. They show that connexin 43 is expressed in the cochlea 
in the non-sensory epithelial cells and in fibrocytes of the spiral ligament and the spiral 
limbus. 
Transcription factors
So far four transcription factors have been implicated in nonsyndromic hearing loss. 
Interestingly, three of these are involved in autosomal dominant progressive hearing 
loss, while, given their expression during embryogenesis, one intuitively would expect a 
congenital hearing loss. Two of the transcription factors, POU4F3 and POU3F4, belong 
to the POU-domain containing family of transcription factors. These transcription factors 
play an important role in tissue-specific gene expression. 
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Mutations in POU3F4 are responsible for X-linked mixed hearing loss that is 
characterized by temporal bone abnormalities, conductive hearing loss resulting from 
stapes fixation and progressive sensorineural hearing loss (DFN3) (de Kok et al. 1995, 
Cremers et al. 2000). DFN3 patients suffer from an increased perilymphatic pressure 
causing the typical “gusher” that appears during stapes footplate surgery. Throughout the 
inner ear, POU3F4 is expressed in the mesenchyme of both the cochlear and vestibular 
aspects but not in tissues derived from neuroepithelial or neuronal cells, including the 
organ of Corti (McEvilly et al. 1996). Minowa et al. (1999) found expression of Pou3f4 to 
be highest in the spiral ligament. In a study by Phippard et al. (1996) Pou3f4 was localized 
in the nucleus of ventral mesenchymal cells in the earliest developmental stages of the 
otic capsule. Pou3f4 remains nuclear in those regions of the otic capsule that give 
rise to the cellular regions of the mature bony labyrinth, while it shifts to perinuclear/
cytoplasmic localisation in those regions of the otic capsule that will cavitate to form 
acellular regions in the temporal bone such as the scala tympani, scala vestibuli and 
the inner auditory canal. Pou3f4-deficient mice were found to exhibit profound deafness 
but normal vestibular function (Minowa et al. 1999). The flexibility of auditory ossicle 
junctions and the mobility of stapes footplates of the mutant mice were indistinguishable 
from those of wild-type mice, but there was a dramatic reduction in endocochlear 
potential. Electron microscopy revealed severe ultrastructural alterations in cochlear 
spiral ligament fibrocytes. Because the number of fibrocytes in Pou3f4-deficient mice 
is similar to that in wild-type mice, Pou3f4 may be essential for the differentiation or 
function of fibrocytes but not for their survival.
A mutation in POU4F3 is responsible for DFNA15 (Vahava et al. 1998). Mutant 
POU4F3 loses most of its transcriptional activity and most of its ability to bind DNA 
(Weiss et al. 2003). Pou4f3 is uniquely and strongly expressed in cochlear and vestibular 
hair cells. Whereas wild-type POU4F3 is found exclusively in the nucleus, the mutant 
protein is localized both to the nucleus and the cytoplasm (Weiss et al. 2003). Targeted 
deletion of Pou4f3 in mice results in profound deafness and impaired balance due to 
complete loss of auditory and vestibular hair cells that is followed by a partial secondary 
loss of spiral and vestibular ganglion neurons (Xiang et al. 1995, Erkman et al. 1996, 
Xiang et al. 1997). Pou4f3 is required for the final differentiation and survival of hair cells 
(Xiang et al. 1998).  
Borsani et al. (1999) characterized EYA4 that is homologous to Drosophila ‘eyes 
absent’ (eya). In Drosophila, eya is known to be a key regulator of ocular development 
and to mediate developmentally important protein-protein interactions. The Eya family 
members are transcriptional activators and in the developing mouse embryo, Eya4 
is expressed primarily in the cranofacial mesenchyme, the dermamyotome, and the 
limb. Wayne et al. (2001) identified mutations in EYA4 that were responsible for the 
postlingual, progressive hearing loss, DFNA10. Just as EYA proteins interact with 
members of the SIX and DACH protein families during early embryonic development, 
the authors hypothesize that EYA4 is also important post-developmentally for continued 
function of the mature organ of Corti. Mutations in another member of this family, 
EYA1, are associated witht two forms of syndromic hearing loss, BOR (branchio-oto-
renal) syndrome (Abdelhak et al. 1997a, Abdelhak et al. 1997b) and BO (branchio-oto) 
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syndrome (Vincent et al. 1997).
In 2000 Peters et al. studied a family with progressive sensorineural hearing 
loss, DFNA28 and found a mutation in the gene TFCP2L3 (transcription factor cellular 
promoter 2-like gene 3). TFCP2L3 is a member of the family of transcription factors 
that are homologous to the Drosophila gene grainyhead. The TFCP2 protein family 
shares a novel DNA-binding domain that is distinct from previously described DNA-
binding domains (Johnson and McKnight 1989). The mouse gene Tfcp2l3 is expressed 
in many epithelial tissues, including cells lining the cochlear duct. Expression is most 
abundant during embryonic development, and less so during early postnatal stages. 
In the cochlea, Tfcp2l3 expression appears to be restricted to the epithelial cells of 
placodal origin, which line the endolymph-containing scala media (Peters et al. 2000).
Genes with an unknown function
For several genes involved in nonsyndromic hearing loss the function remains unknown 
and one of these genes is DFNA5. To date three families have been described with 
DFNA5 that have mutations in the DFNA5 gene (Van Laer et al. 1998, Yu et al. 2003, 
Bischoff et al. 2004 [chapter 3]). As there is no indication for the function of this gene and 
no significant homology with any other protein could be detected it was called DFNA5 
by default (Van Laer et al. 1998). Yu et al. (2003) used yeast as a model organism 
for studying the function of DFNA5. Yeast cells tolerated the expression of wild-type 
DFNA5, while expression of the mutant DFNA5 led to cell cycle arrest. There are some 
other clues that DFNA5 might be involved in the regulation of apoptosis. Lage et al. 
(2001) reported that decreased DFNA5 mRNA levels in cultured melanoma cells are 
associated with a decrease in apoptotic events after exposure to the drug etoposide. 
It appears that increased DFNA5 mRNA levels are associated with increased cellular 
disposition to programmed cell death mediated by activation of caspase 3.
In 2001 Verpy et al. reported the isolation of a mouse transcript that is almost 
exclusively expressed in the inner ear. The gene Strc, encoding stereocilin was isolated 
from a mouse inner ear cDNA library (Cohen-Salmon et al. 1997) created by using 
subtractive amplification based on representational difference analysis (RDA) (Hubank 
and Schatz 1994). Genetic analysis shows that mutations in the human ortholog STRC 
are associated with the DFNB16 locus in two families. Stereocilin shows no significant 
homology to any other known protein. In the mouse inner ear Strc is only expressed in 
the sensory hair cells and the protein is associated with the stereocilia. In the developing 
cochlea, stereocilin appears in the hair bundle of the inner hair cells before it appears 
in the hair budle of the outer hair cells. The precise function of stereocilin however, is 
unknown.
Kurima et al. (2002) identified eight mutations in a new gene, transmembrane 
cochlear expressed gene 1, TMC1, associated with DFNA36 and DFNB7/11. In addition, 
a deletion was detected in Tmc1 in a mouse model with recessive deafness, which lacks 
auditory responses and has hair cell degeneration (Bock and Steel 1983). The dominant 
mouse phenotype Beethoven is caused by a missense mutation in Tmc1 indicating that 
dominant and recessive mutations in TMC1 can cause progressive postlingual hearing 
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loss and profound prelingual deafness, in humans and mice respectively (Vreugde et 
al. 2002). TMC1 is a member of a gene family predicted to encode transmembrane 
proteins with an unknown function. A model of six to ten membrane-spanning regions 
and cytoplasmic N- and C-termini is predicted for TMC1. This model is similar to those 
observed in ion channels or transporters, especially the superfamily cation channels 
with six transmembrane segments (Clapham et al. 2001). Tmc1 mRNA is present in 
hair cells of the postnatal mouse cochlea and vestibular organs and inner and outer hair 
cells degenerate during the postnatal period in mice with a deletion in Tmc1 (Bock and 
Steel 1983). 
Naz et al. (2002) have identified five homozygous recessive mutations in a 
novel gene TMIE (transmembrane inner ear expressed gene), in patients suffering 
from DFNB6. TMIE encodes a protein that exhibits no significant nucleotide or deduced 
amino acid sequence similarity to any other protein. TMIE has a predicted intracellular 
amino terminus, two transmembrane regions separated by an extracellular loop, and 
an intracellular carboxy terminus and shares 92% identity with mouse Tmie. TMIE 
is expressed in many human tissues. Two independent recessive mutations were 
demonstrated to be responsible for hearing loss and vestibular dysfunction in the 
spinner mouse due to neuroepithelial defects in the inner ear (Mitchem et al. 2002). 
Loss of function of Tmie results in postnatal alterations of sensory hair cells in the 
cochlea, including severely shorter stereocilia. No obvious defects in gross inner ear 
morphogenesis or neuroepithelial cell patterning were noted. Later defects that were 
found included degeneration of the sensory cells in the cochlea and auditory nerve 
cells. The inner ear pathology in spinner mice suggests that Tmie is required for normal 
postnatal maturation of sensory hair cells in the cochlea (Mitchem et al. 2002).
Dominantly inherited progressive hearing loss DFNA6/14/38 is caused by a 
mutation in WFS1, the gene for recessively inherited Wolfram syndrome (Bespalova 
et al. 2001, Young et al. 2001,). Hearing loss in the DFNA6/14/38 families affects the 
low frequencies first and worsens over time without progressing to profound deafness. 
WFS1, encoding wolframin, is a member of a novel gene family with orthologs in 
several other organisms. Results from Osman et al. (2003) indicate that wolframin is 
an endoglycosidase H-sensitive multispanning membrane glycoprotein confined to the 
endoplasmic reticulum, where the protein is also predominantly localised (Takeda et 
al. 2001, Cryns et al. 2003). Wolframin appears to be important in the regulation of 
intracellular calcium homeostasis and may serve directly as an endoplasmic reticulum 
calcium channel or, alternatively, as a regulator of endoplasmic reticulum calcium 
channel activity. Given that regulation of the calcium concentration in the cytoplasm by 
the endoplasmic reticulum is prominent in cellular apoptosis, these data suggest that 
wolframin may be indirectly involved in the regulation of endoplasmic reticulum-mediated 
cellular mortality. Wolframin is N-glycosylated during maturation, which appears to be 
essential for the biogenesis and stability of the protein (Hofmann et al. 2003). Structural 
analysis by Hofmann et al. (2003) indicates that wolframin is organised in higher 
molecular weight complexes in which the protein is suggested to homo-oligomerise to 
a tetramer. WFS1 was found to be ubiquitously expressed (Hofmann et al. 2003, Cryns 
et al. 2003) and the inner ear wolframin was found in the vestibular hair cells, inner and 
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outer hair cells, Dieters cells, Hensen cells, Claudius cells, interdental cells, pillar cells, 
external and internal sulcus cells, marginal cells of the stria vascularis and Reissners 
membrane (Cryns et al. 2003). Ishihara et al. (2004) generated mice with a disrupted 
Wfs1 gene that develop glucose intolerance or overt diabetes due to insufficient 
insulin secretion. The defective insulin secretion was accompanied by reduced cellular 
calcium responses. Results from Ishihara et al. (2004) indicate that wolframin plays an 
important role in both stimulus-secretion coupling for insulin exocytosis, and regulation 
of calcium homeostasis, deterioration of which leads to impaired glucose homeostasis 
and diabetes. The progressive nature of the hearing loss suggests a role for wolframin 
in maintenance of sound transduction, but the function in hearing is still unknown. 
Mitochondrial hearing loss
In addition to nuclear genes two mitochondrial genes have been associated with 
nonsyndromic hearing loss. Mutations in the 12S rRNA gene lead to nonsyndromic 
hearing loss and aminoglycoside-induced hearing loss (Prezant et al. 1993). The second 
gene is the tRNASer (UNC) gene, in which four different mutations are known to cause 
nonsyndromic hearing loss (reviewed by Fishel-Ghodsian 2003). It is not unexpected 
that mitochondrial DNA mutations mainly cause multisystemic disease, but it is difficult 
to understand why these mutations only affect the inner ear, while a mutation in a 
mitochondrial tRNA gene would be expected to lead to aberrant mitochondrial protein 
synthesis and general dysfunction.
1.4 Strategies to identify hearing loss genes 
Characterisation of genes and proteins that are important for proper development and 
homeostasis of the inner ear is central to understanding the molecular basis of hearing. 
The identification of these genes and their corresponding proteins largely depends on 
the identification of genes involved in hearing loss. The general approach for identifying 
these genes involves genetic linkage studies in families with hereditary hearing loss 
and subsequent positional cloning. However, a candidate gene approach, based on 
the identification of genes uniquely or preferentially expressed in the inner ear has 
produced additional human hearing loss genes (Robertson et al. 1998, Yasunaga et 
al. 1999, Verpy et al. 2001, Zwaenepoel et al. 2002). In addition to studying the genetic 
causes for hearing loss in humans, many model organisms are used to find the origins 
of genetic hearing and balance disorders. The most important model organism used for 
this purpose is the mouse. In most cases however, the combination of more than one 
strategy is the most successful in identifying genes involved in the processes of hearing. 
Table 5 summarises the methods used to identify nonsyndromic hearing loss genes. 
Below, the different approaches are outlined in further detail. 
1.4.1. Positional cloning
Positional cloning of hearing impairment genes first involves localisation of the genetic 
defect(s) by linkage analysis or the fine mapping of structural rearrangements (e.g. 
deletions, duplications, translocations). The candidate region resulting from linkage 
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analysis can vary greatly in size depending on the number of individuals included in 
the study. The identification of disease associated chromosomal rearrangements, can 
rapidly result in the localisation of the causal gene. 
Up to a couple of years ago, when a good candidate region was identified, 
a physical map of the region was constructed with overlapping genomic DNA clones 
spanning the critical region. Subsequently, a cDNA expression map was created. With 
the completion of the sequence of the human genome, defining a candidate region and 
identifying expressed sequences within that candidate region has become much easier. 
By using internet tools for instance the genome browser (http://genome.cse.ucsc.edu), 
all genes, expressed sequence tags (ESTs) and predicted genes in a candidate region 
can be found. 
After the identification of expressed sequences in the candidate region, mutation 
analysis can be initiated. Depending on the number of genes present in the candidate 
region, and the size of genes, mutation analysis can be very laborious and expensive. 
An educated guess based on the predicted functional characteristics and available 
expression data of the most promising candidates, can limit the number of genes. 
Table 5. Nonsyndromic hearing loss genes and the method with which they were identified.
Strategy Gene
Positional cloning ACTG1, CLDN14, COL11A2, DFNA5, DIAPH1, 
EYA4, GJB2, GJB6, MYH9, MYO1A, MYO3A, 
OTOF, POU3F4, POU4F3, SLC26A4, TECTA, 
TFCP2L3, TMPRSS3, WFS1, WHRN 
Positional cloning/cDNA library USH1C
Mouse model/positional cloning CDH23, MYO15, MYO6, MYO7A, PCDH15, TMC1, 
TMIE
Mouse model/candidate gene approach ESPN
Candidate gene approach GJA1, GJB3, KCNQ4, MYH14, PRES
cDNA library analysis COCH, OTOA, STRC
DNA microarray CRYM
1.4.2 cDNA libraries
One of the most valuable tools to identify inner ear genes is a collection of cDNA libraries. 
High-quality inner ear cDNA libraries are the foundation of successful identification 
and cloning of inner ear-specific transcripts. cDNA libraries have been successfully 
constructed from the inner ears of a variety of species, including zebrafish (Coimbra et 
al. 2002), bullfrog (Chen et al. 1995b), chicken (Killick and Richardson 1997, Heller et 
al. 1998), guinea pig (Wilcox and Fex 1994), gerbil (Zheng et al. 2000c), mouse (Cohen-
Salmon et al. 1997, Crozet et al. 1997), rat (Ryan et al. 1993, Soto-Prior et al. 1997, 
Harter et al. 1999) and human (Robertson et al. 1994, Jacob et al. 1998, Luijendijk et 
al. 2003). In order to create an inner ear specific cDNA library a widely used technique 
is cDNA subtraction. Subtraction techniques are based on the comparison of two 
cDNA preparations isolated from different tissues or cell types, called driver and tester. 
Sequences present in both populations are selectively removed, and the remaining 
cDNAs, enriched for transcripts specific to the tester population, are retained (Luijendijk 
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et al. 2003). This strategy led to the identification of the outer hair cell protein prestin in 
a library constructed with cDNA that was enriched by subtracting an inner hair cell cDNA 
driver from an outer hair cell tester cDNA (Zheng et al. 2000c).
 The techniques that can be used to select inner ear-specific clones from cDNA 
libraries are manifold. Two approaches that are commonly used for this selection are 
EST analysis and serial analysis of gene expression (SAGE). Comparison of ESTs 
derived from an inner ear cDNA library with ESTs from libraries of other organs can 
indicate whether individual ESTs are expressed only in inner ear tissues. The use of this 
method has led to the identification of several novel inner ear genes (Jacob et al. 1998, 
Cohen-Salmon et al. 2000, Robertson et al. 2000). SAGE is a high-throughput method 
for assessing gene expression (Velculescu et al. 1995). It is based on creating double-
stranded cDNA that is biotin labelled at its polyA tail from mRNA of the experimental tissue. 
Digestion with the frequent cutting restriction enzyme NlaIII and affinity-purification using 
the biotin label results in enrichment of 3´-parts of cDNAs. High-throughput analysis is 
achieved by ligation of these short cDNA fragments to form long concatemers that are 
subcloned into plasmids to create a SAGE library. Sequencing of the library concatemers 
results in a collection of SAGE tags. These short tags are sufficient to identify specific 
transcripts because of their defined positions within known mRNA sequences. SAGE 
libraries can be analysed for multiple occurrences of individual tags, resulting in semi-
quantitative information of specific transcripts. Comparison of SAGE tags from different 
libraries can reveal organ specific tags. 
Although the discussed techniques are valid for the identification of genes that 
are restrictively expressed in the inner ear, they do not provide definite proof that an 
individual gene is specifically expressed in the inner ear. This requires other methods 
such as Northern blot analysis and reverse transcription PCR (RT-PCR) and in addition 
in situ hybridisation and immunocytochemistry allow visualization of mRNA or protein 
abundance, respectively, in individual cell types within the inner ear.
1.4.3 Mouse models
In the field of hearing research, recent advances using the mouse as a model for human 
hearing loss have brought insights into the molecular pathways involved in normal 
hearing and the mechanisms that are disrupted once a mutation occurs in one of the 
critical genes. The mouse, with its advantages of short gestation time, ease of selective 
matings, and similarity of the genome and the anatomy of the inner ear to humans, is a 
remarkable resource for knowledge on the human inner ear. 
There is already an impressive collection of mouse mutants with hearing and/
or vestibular dysfunction available. Defects in the vestibular system, often associated 
with hearing loss, are more severe in mice. The defects cause a phenotype of head 
bobbing or circling making deaf mice easily recognizable. There are three major ways in 
which mouse mutants are obtained; spontaneous, radiation or chemically induced, and 
transgenic or gene-targeted knockouts. Approximately 60 spontaneous mouse mutants 
have arisen in mouse facilities throughout the world over many years. Some of the 
mouse mutants suffering from hearing and/or vestibular dysfunction were by-products 
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of large-scale mutagenesis experiments designed to study the effects of radiation on 
the germline (Russel 1971). Mouse spermatogenesis cells are particularly susceptible 
to mutagenesis by chemicals such as N-ethyl-N-nitrosoura (ENU) and chlorambucil. 
Recently, several large ENU-mutagenesis screens have been initiated (Justice et al. 
1999) leading to a large number of mouse models for hearing and balance disorders 
(Kiernan et al. 2001, Tsai et al. 2001, Vreugde et al. 2002). In 1980 the first transgenic 
mouse was made by microinjection of a foreign gene directly into a mouse embryo 
(Gordon et al. 1980). Since then, the advances in this area have been spectacular, 
culminating in the ability to conditionally knock-out a gene in a specific tissue (Kuhn et 
al. 1995). 
One of the advantages of the use of mice in inner ear research is the ability 
to study the expression of a gene or protein during embryonic development and hair 
cell differentiation, as well as morphology. Visualization of the morphology of hair cells 
can provide valuable information about hair cell structure and loss. The morphology 
and physiology of the mouse inner ear can be studied using techniques such as 
scanning electron microscopy, patch clamping on individual hair cells (Kros et al. 
1992), immunohistochemistry, in situ hybridisation, and culturing of the organ of Corti 
(Sobkowicz et al. 1993).
1.4.3. Gene expression arrays
Gene expression microarrays contain either large numbers of cDNA sequences 
representing known genes or uncharacterised sequences or oligonucleotides that 
represent specific genes. This allows fast simultaneous assessment of expression 
of multiple genes using very little material. Commercial high-throughput cDNA or 
oligonucleotide arrays representing up to 30.000 known human genes and EST 
clusters, a large fraction of the human genome, can reveal gene expression in a 
specific tissue, differential gene expression between tissues as well as changes 
in gene expression under changing experimental conditions or due to a particular 
disease.
Analysis of gene expression data from the inner ear obtained with cDNA arrays 
can reveal transcripts that appear or disappear during development, damage, recovery 
from damage, or ageing of the inner ear. This type of analysis has already proven 
to be successful. Chen and Corey (2001) have used oligonucleotide arrays to profile 
gene expression in the mouse cochlea (http://www.mgh.harvard.edu/depts/coreylab/
index.html) and Cho et al. (2001) used a cDNA array to characterize and compare 
normal gene expression patterns in several regions of the auditory pathway of the rat. 
In 2003, Hawkins et al. used a set of custom microarrays to investigate differences 
in gene expression between constantly regenerating chick utricle and the mitotically 
quiescent cochlea. In addition, Abe et al. (2003) identified CRYM, a gene involved in 
nonsyndromic hearing loss through cDNA microarray analysis of human cochlear and 
vestibular tissues
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1.5 Outline of this thesis
Identification of genes and proteins that are crucial for proper development and 
homeostasis of the inner ear is essential to understanding the molecular basis of hearing. 
The characterisation of these genes and their corresponding proteins largely depends 
on the identification of genes involved in hearing loss. A candidate gene approach, 
based on the identification of genes uniquely or preferentially expressed in the inner ear 
has been successful in characterising human hearing loss genes. Chapter 2 describes 
the construction and characterisation of a human foetal cochlear cDNA library. Novel 
cochlea cDNA clones expressed preferentially in the cochlea may represent genes 
important for the development and homeostasis of the cochlea. These genes are also 
good candidate genes for hereditary hearing loss. 
Hearing loss is the most common sensory defect in the human population. 
Children can be born deaf or acquire hearing loss during their lifetime and as age 
increases so does the prevalence of hearing impairment. Approximately equal numbers 
of cases of prelingual early childhood hearing loss are attributed to environmental and 
genetic factors. Of the cases attributed to genetic factors, about 70% are classified 
as nonsyndromic, i.e. hearing loss without other obvious clinical features, and 30% 
are classified as syndromic. Up to now for nonsyndromic hearing loss, 39 autosomal 
dominant loci (DFNA), 37 autosomal recessive loci (DFNB) and 4 X-linked loci (DFN) 
have been described and 38 genes underlying nonsyndromic hearing impairment have 
been identified. Chapter 3 and 4 describe the identification of mutations in nonsyndromic 
hearing loss genes in two Dutch families. The identification of a novel mutation in the 
DFNA5 gene in a five-generation family is described in chapter 3. A nucleotide substitution 
in the splice acceptor site of intron 7, leads to skipping of exon 8 and the formation of 
an aberrant protein in part of the transcripts. Chapter 4 describes the identification and 
molecular modelling of a novel mutation in the motor head domain of myosin VIIA in 
a family with autosomal dominant hearing impairment. The amino acid substitution is 
predicted to lead to disruption of the ATP/ADP binding and impair the myosin power-
stroke, which would have a severe effect on the function of the myosin VIIA protein.
There are many different syndromes that include an auditory phenotype as a 
prominent feature. Approximately 30% of individuals with prelingual hereditary hearing 
loss also have abnormalities of other organ systems. The accompanying abnormalities 
range from subtle to severe and may be congenital or delayed in appearance. Some 
of the genes involved in these syndromes have been mapped to chromosomal regions 
and a subset of these has been identified. Usher syndrome is characterized by various 
degrees of hearing loss and of loss of eyesight and is the most common form of deaf-
blindness (50%). Three distinct Usher syndrome phenotypes have been described. 
Usher syndrome type II patients have a moderate-to-severe sensorineural hearing loss 
that is stable in most cases, normal vestibular function, and retinitis pigmentosa. In 
chapter  mutations in VLGR1 are shown to be involved Usher syndrome type IIc. This 
implicates G-protein signalling in the pathogenesis of Usher syndrome type II.
General Introduction
0
1.6 Electronic database information 
URLs for data presented herein are as follows:
Genome browser: http://genome.cse.ucsc.edu
Gene expression profile of mouse cochlea generated with oligonucleotide arrays: http://
www.mgh.harvard.edu/depts/coreylab/index.html 
Hereditary hearing loss homepage: http://www.uia.ac.be/DNAlab/hhh/
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2.1 Abstract
To identify novel genes that are expressed specifically or preferentially in the cochlea, 
we constructed a cDNA library enriched for human cochlear cDNAs using a suppression 
subtractive hybridisation technique. We analysed 2640 clones by sequencing and BLAST 
similarity searches. One hundred and fifty-five different cDNA fragments mapped in 
nonsyndromic hearing impairment loci for which the causative gene has not been cloned 
yet. Approximately 30% of the clones show no similarity to any known human gene or 
expressed sequence tag (EST). Clones mapping in nonsyndromic deafness loci and a 
selection of clones that represent novel ESTs were analysed by reverse transcriptase-
polymerase chain reaction (RT-PCR) of RNA derived from 12 human fetal tissues. Our 
data suggest that a quarter of the novel genes in our library are preferentially expressed 
in fetal cochlea. These may play a physiologically important role in the hearing process 
and represent candidate genes for hereditary hearing impairment. 
Keywords: Cochlea; cDNA subtraction; Hearing impairment; mRNA expression 
profiling
2.2 Introduction
Hearing is a complex process requiring highly specialized structures and mechanisms. 
The most intricate structure involved in hearing is the cochlea, which processes 
mechanical sound waves into a signal that can be perceived by the brain. Over the past 
years, many discoveries have been made regarding the structure and function of the 
cochlea by studying the molecular defects underlying hearing impairment and deafness 
(Morton 2002). Still, many gaps remain in our understanding of the molecular processes 
involved in hearing. 
Hearing loss is the most common sensory disorder in the human population. 
One in 1000 children is born deaf and approximately equal numbers of cases are 
attributed to environmental and genetic factors (Morton 1991, Gorlin et al. 1995). Of 
the cases attributed to genetic factors, about 70% are classified as nonsyndromic, i.e., 
deafness without other obvious clinical features. Nonsyndromic hearing impairment 
can be further subdivided based on the mode of inheritance: ~77% of the cases are 
autosomal recessive, ~22% are autosomal dominant, ~1% are X-linked, and ~1% are 
due to mitochondrial inheritance. Up to now, 39 autosomal dominant loci (DFNA), 33 
autosomal recessive loci (DFNB), and 5 X-linked loci (DFN) have been described and 31 
genes underlying nonsyndromic hearing impairment have been identified (http://www.
uia.ac.be/DNAlab/hhh/) (Morton 2002). Very few of these genes show expression that is 
restricted to the cochlea (Verpy et al. 2001, Zwaenepoel et al. 2002). It is possible that 
cochlea-specific genes have been refractory to cloning because their mRNA is present 
at very low levels, present only in specific cell types of the inner ear, e.g., inner or outer 
hair cells, or present in very small developmental time windows. In view of the complex 
nature of the process of hearing, it can be expected that the identification of novel 
genes expressed exclusively or predominantly in the cochlea will contribute greatly to 
the understanding of cochlear development and homeostasis and the pathogenesis of 
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hearing impairment. 
To identify genes underlying hereditary hearing impairment, the most common 
approach involves genetic linkage studies in families with hearing impairment and 
subsequent positional cloning of the mutated gene. However, the candidate gene 
approach could facilitate this kind of research greatly. This is especially true for small 
families and sporadic patients in which linkage analysis cannot be performed. 
To isolate novel cochlear-expressed genes, we constructed a cochlea-enriched 
complementary DNA (cDNA) library. We used a polymerase chain reaction (PCR)-
based suppression subtractive hybridisation technique (Diatchenko et al. 1996). This 
normalizes sequence abundance and achieves enrichment for differentially expressed 
cDNAs by a single round of suppression subtractive hybridisation. Subtraction was 
performed against a mixture of cDNAs from several tissues. This method has already 
proven its strength in research of retinal disorders (den Hollander et al. 1999). Here we 
describe the sequence analysis and mapping of 2640 cDNAs. In addition, we performed 
semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) to evaluate 
mRNA expression levels of selected clones in a panel of human fetal tissues.
2.3 Results
2.3.1. Subtraction efficiency analysis
Successful suppression subtractive hybridisation decreases the prevalence of 
ubiquitously expressed (housekeeping) genes and increases the prevalence of tissue-
specific genes in a cDNA library. The effectiveness of the technique was tested by 
RT-PCR of GAPDH, TECTA, and C1B10 on subtracted and unsubtracted cDNA, taking 
samples after 23, 28, and 33 cycles of PCR. The housekeeping gene GAPDH displays 
a significant decrease in the amount of transcript present after subtraction compared 
to before subtraction (fig. 1). In contrast, the amount of transcript of TECTA, a gene 
previously described to be expressed specifically in the cochlea (Legan et al. 1997), 
increased after subtraction. After subtraction, a TECTA cDNA product is clearly visible 
after 28 and 33 cycles of PCR, whereas before subtraction, no band is visible even 
after 33 cycles of PCR. As a control, we also used clone C1B10, which was isolated 
during this study and showed preferential expression in the cochlea. Before subtraction, 
C1B10 cDNA product is only detectable after 33 cycles of PCR. After subtraction a 
product is clearly visible after 28 and 33 cycles. 
2.3.2 Sequence analysis of cDNAs 
The sequences of 2640 clones from the cochlea-enriched cDNA library were determined 
and the clones were shown to be represented by 1944 unique sequences. Clones were 
sequenced in one direction. Some clones contained a stretch of A’s or T’s that disturbed 
the sequencing process. In these cases the clones were sequenced in both directions. 
Often the full insert sequence could be determined by sequencing in one direction, but 
several insert sequences are not complete. The length of the sequences ranged from 
59 to 699 bases with an average of 324 bases. These sequences were analysed by 
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comparing them to GenBank, EMBL, and human EST databases and nonhuman EST 
databases, using BLAST-analysis. The results of this analysis enabled localization of 
the majority of the clones in the human genome. 
Figure 1. PCR of the subtracted and unsubtracted cochlea cDNA as a control for the suppression 
subtractive hybridisation technique. Control PCR products of TECTA and C1B10, a clone showing 
preferential expression in cochlea isolated from the human fetal cochlea cDNA library, as positive 
controls for enrichment, and GAPDH, as a positive control for subtraction, are shown. The control 
PCRs were performed on cDNA samples of human fetal cochlea. The left panel shows samples 
taken before cDNA subtraction; the right panel shows samples taken after subtraction. Samples 
were taken after the indicated number of PCR cycles.
Table 1. Results of BLAST-analysis of 2640 sequences derived from the cDNA library
Sequence analysisa Number 
of 
clones
Percentage 
of clones
Number 
of unique 
sequences
Percentage 
of unique 
sequences 
Similarity to known gene 784 29.7 424 21.8
Similarity to predicted gene 106 4.0 82 4.2
Similarity to EST(s) Unigene cluster 1 20.9 386 19.9
Similarity to other EST(s) 31 1.2 26 1.3
Similarity to sequence non-human organism 309 11.7 269 13.8
Novel ESTsb 788 29.8 691 3.
Novel sequencesc 71 2.7 66 3.4
Total 2640 1944
aClones were subdivided into seven categories as indicated.
bClones have similarity to genomic DNA sequences but not to any other sequence.
cClones have no similarity to any sequence.
BLAST-analysis showed that 29.7% of the clones (table 1) had significant 
similarity to a total of 330 different known human genes. Of these known genes, 92 
were found in the library more than once and 46 were found more than twice (table 
2). The gene most highly represented in the cDNA library is osteoglycin (OGN; also 
named osteoinductive factor (OIF)) (table 2). Eighty-nine clones from the cDNA library 
are derived from OGN, the protein product of which is known to induce ectopic bone 
formation in conjunction with the transforming growth factor TGFB1 or TGFB2. The 
next most frequently found genes are COL1A2 (46 clones), COL2A1 (39 clones), DIO2 
(31 clones), and COL9A1 (26 clones). Among the 22 most highly represented genes, 
2 are known to be involved in hereditary nonsyndromic hearing impairment. COCH 
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is involved in DFNA9 (Robertson et al. 1998) and POU3F4 is involved in DFN3 (de 
Kok et al. 1995). OTOR (Robertson et al. 2000), a gene that was recently identified 
because of its presence in a human fetal cochlear cDNA library, was also among the 
22 most prevalent genes. Other deafness-associated genes represented in our library 
are COL1A1 (15 clones), COL11A1 (13 clones), COL3A1 (9 clones), SOX9 (3 clones), 
KCNQ1 (potassium voltage-gated channel, KQT-like subfamily member 1, NM_000218) 
(2 clones), and MANBA (mannosidase, βA, lysosomal, NM_005908) (1 clone). 
Table 2. Known human genes represented more than twice in the human fetal cochlear cDNA 
library
GenBank ID Gene Protein description Frequency
AF202167 OGN/OIF osteoglycin / osteo inductive factor / mimecan 89
NM000089 COL1A2 collagen 1A2 46
NM001844 COL2A1 collagen 2A1 39
AF093774 DIO2 deiodinase iodothyronine type 2 31
NM00181 COL9A1 collagen 9A1 26
AF193855 ZIC2 zinc finger protein of cerebellum 22
NM00307 POU3F4 POU domain transcription factor 3F4 16
NM000088 COL1A1 collagen 1A1 1
NM00184 COL11A1 collagen 11A1 13
NM000090 COL3A1 collagen 3A1 9
NM000618 IGF1 insulin-like growth factor 1 8
NM012431 SEMA3E sema domain immunoglobulin domain secreted 3E 7
NM003107 SOX4 SRY (sex determining region 4) box 4 7
NM00182 COL9A2 collagen 9A2 6
NM004967 IBSP integrin-binding sialoprotein, bone sialoprotein II 6
NM00236 MARCKS myristoylated alanine-rich protein kinase C substrate 6
AF217500 MORF histone acetyltransferase  6
NM02017 OTOR Otoraplin 6
NM004086 COCH coagulation factor C, cochlin 
NM014483 RBMS3 RNA binding motif single stranded interacting protein 3 
NM00498 SPARC/
SPOCK
secreted protein, acidic, cysteine-rich (osteonectin) 
NM003380 VIM vimentin, cytoskeletal element 
NM000484 APP amyloid beta protein 4
U8962 CREBBP cAMP responsive element binding protein binding 
protein
4
NM00697 HSPA8 heat shock 70kD protein 4
NM000304 PMP22 peripheral myelin protein 22 4
NM007168 ABCA8 ATP-binding cassette, subfamily 1 member 8 3
NM001614 ACTG1 actin gamma 1 3
NM01928 AS3 androgen-induced prostate proliferative shutoff 
associated protein
3
AB018321 ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 3
NM02284 CBFB core binding factor beta 3
NM001892 CSNK1A1 casein kinase 1 alpha 1 3
Chapter 2
67
AF042345 EVI5 ecotropic viral integration site  3
NM000146 FTL ferritin L chain  3
NM00348 HSPCA heat shock 90kD protein 1 alpha 3
NM014333 IGSF4 immunoglobulin superfamily member 4 3
NM016269 LEF1 lymhoid enhancer binding factor-1 3
NM006791 MRG15 MORF related gene 1 3
NM0038 NKTR cyclophilin related protein, natural killer tumor 
recognition sequence
3
NM006206 PDGFRA platelet-derived growth factor receptor alpha 3
NM000021 PSEN1 presenilin 1 3
NM003017 SFRS3 splicing factor arginine/serine-rich 3
NM00034 SNCA alpha-synuclein; precursor of non-A beta component 
of Alzheimer’s disease amyloid
3
NM000346 SOX9 SRY (sex-determining region Y)-box 9 3
AB038518 SRCL scavenger receptor with C-type lectin type I 3
NM00327 TJP1 tight junction protein 1 (zona occludens 1) 3
The cDNA fragments resulting from the suppression subtractive hybridisation 
cloning procedure are RsaI restriction fragments. The first-strand cDNA was synthesized 
using an oligo(dT) primer, which could possibly result in an overrepresentation of 
cDNA fragments from the 3’ end of the cochlear genes. To obtain an impression of 
the distribution and size of RsaI cDNA fragments, we analysed the 22 most frequently 
found genes. Multiple RsaI cDNA fragments can be derived from one gene. The gene 
represented by the highest number of different RsaI fragments is OGN (fig. 2). All six 
OGN RsaI cDNA fragments longer than 100 bp were each found at least six times. The 
RsaI fragments shorter than 100 bp were not found (four fragments) or found only once 
(one fragment). This absence of RsaI fragments from the library is due to the purification 
protocol (Advantage cDNA Pure) used after cDNA digestion in which fragments shorter 
than 200 bp are lost.
The longest mRNA transcript that can be reconstructed by sequence comparison 
of the RsaI fragments was 27 bp long and derived from the OGN gene. The average 
length of the RsaI fragments in this study was 347 bp. The longest fragment measured 
1280 bp and was derived from COL1A2; the shortest fragment measured 9 bp and 
was derived from COL2A1. 
Figure 2. RsaI cDNA fragment representation of the OGN gene. The distribution of RsaI restriction 
sites (vertical bars) is shown along the sequence of OGN and the number of clones representing 
each RsaI fragment is shown above each fragment. The open reading frame (ORF) is shown as 
a black box.
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Table 3. The number of clones and unique sequences mapping in known nonsyndromic deafness 
loci for which the causative gene is not known
Deafness 
locus
Map 
locationa
Flanking markersa Interval 
sizea
Number of 
clones 
Number of unique 
sequences
DFNA4 19q13 D19S208-ApoC2 ~9.8 Mb 4 4
DFNA7 1q21-q23 D1S104-D1S466 ~18.6 Mb 17 1
DFNA16 2q24 D2S2380-D2S335 ~8.7 Mb 20 16
DFNA23 14q21-q22 D14S980-D14S1046 ~8.0 Mb 6 6
DFNA25 12q21-q22 D12S327-D12S84 ~13.8 Mb 13 
DFNA26 17q25 D17S784-D17S970 ~8. Mb 8 
DFNA27 4q12 D4S428-D4S392 ~14.6 Mb 10 7
DFNA30 15q26 D15S130-D15S127 ~3.6 Mb 4 4
DFNA34 1q44 D1S102-D1S3739 ~4.7 Mb 7 
DFNB5 14q12 D14S253-D14S79 ~.6 Mb 3 3
DFNB13 7q34-q36 D7S2468-D7S2439 ~12.1 Mb 6 6
DFNB14 7q31 D7S527-D7S3074 ~11.9 Mb 7 7
DFNB17 7q31 D7S486-D7S2529 ~6. Mb 3 2
DFNB19 18p11 D18S62-D18S378 ~.3 Mb 16 11
DFNB23 10p11.2-q21 D10S220-D10S1652 ~12.0 Mb 4 4
DFNB24 11q23 D11S2017-D11S1992 ~8.3 Mb 17 14
DFNB25 4p15.3-q12 D4S1632-D4S428 ~2.3 Mb 14 11
DFNB26 4q31 D4S424-D4S1604 ~1.8 Mb 6 4
DFNB27 2q23-q31 D2S2157-D2S2273 ~18. Mb 7 7
DFNB28 22q13 D22S1045-D22S282 ~3.8 Mb 6 
DFN4 Xp21.2 DXS992-DXS1068 ~7.8 Mb 10 7
DFN6 Xp22 DXS7108-DXS7105 ~12.1 Mb  4
DFNM1 1q24 D1S2658-D1S2790 ~4.7 Mb 4 3
Total 197 155
aBecause of sequence gaps and rearrangements in the human genome sequence the positions 
of markers and clones may vary.
2.3.3 Expression profile analysis of clones located in known 
nonsyndromic deafness loci using semiquantitative RT-PCR 
Clones were mapped in the human genome using the results of BLAST-analysis and 
several databases. We compared the map location of the clones with the location of known 
nonsyndromic deafness loci for which the gene responsible has not yet been identified 
(http://www.uia.ac.be/ dnalab/hhh/). In total, 197 clones from our library representing 
155 unique sequences were found to be located within known nonsyndromic deafness 
loci (table 3). Of the 155 unique sequences, 72 (46.5%) showed similarity to a genomic 
sequence but not to any other sequence and are therefore considered novel ESTs, 52 
(33.5%) showed similarity to a human EST and 30 (19.3%) showed similarity to a known 
or predicted gene (table 4). 
 Semiquantitative RT-PCR was used to investigate if a sequence was specifically 
or preferentially expressed in human fetal cochlea. All cDNA was tested for genomic DNA 
contamination with primers for the housekeeping genes GAPDH and GUSB spanning 
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one or more introns. No contamination was detected, and equal expression was found 
across all tissues tested. To test the effectiveness of the semiquantitative RT-PCR, we 
determined the expression pattern of three genes that are involved in nonsyndromic 
hearing impairment and/or known to show a distinctive expression pattern, POU3F4 (de 
Kok et al. 1995), TECTA (Verhoeven et al. 1998), and OTOR (Robertson et al. 2000). 
Table 4. Results of sequence analysis of clones located in nonsyndromic deafness loci
Sequence analysisa
Number 
of 
clones
% Number 
of unique 
sequences
% Number 
of clones 
preferentially 
expressed in 
cochlea 
Similarity to known gene 44 22.3 2 16.1 
Similarity to predicted gene  2.  3.2 -
Similarity to EST(s) from Unigene cluster 44 22.3 36 23.2 8
Similarity to other EST(s) 18 9.1 16 10.3 3
Similarity to sequence non-human organism 1 0. 1 0.6 -
Novel ESTs 8 43.1 72 46. 29
Total 197 155 45
aClones located in nonsyndromic deafness loci were subdivided into seven categories as 
indicated.
POU3F4 shows distinctive expression in fetal cochlea, fetal spinal cord, 
fetal brain, and fetal kidney after 25 and 30 cycles of PCR (fig. 3A). After 35 cycles, 
expression can also be detected in other tissues. This is in accordance with what has 
been found in the developing rat embryo by in situ hybridisation (Le Moine and Young 
1992). Expression was present in the brain, the central nervous system, and the otic 
vesicles. There is no evidence that in rat POU3F4 is expressed in the developing kidney. 
However, expression of POU3F4 in human fetal kidney and human fetal brain has been 
shown by Northern blot analysis (personal communication, Y.J.M. de Kok, and F.P.M.C., 
unpublished data). TECTA shows highest expression in fetal cochlea after 25, 30, and 
35 cycles of PCR, but expression can also be detected in fetal spinal cord and fetal 
tongue after 25 cycles (fig. 3A). These results can be compared to what has been 
found by Northern blot analysis of tissues from 2- to 3-dayold mice (Legan et al. 1997). 
Expression of the TECTA gene was shown to be restricted to cochlea; no transcripts 
could be detected in any of the other tissues tested, which did not include spinal cord or 
tongue. OTOR shows a very distinct expression pattern. The expression in fetal cochlea 
is clearly the highest after 30 and 35 cycles of PCR, however, a band can also be 
detected in fetal brain and fetal tongue after 30 cycles and in fetal colon, fetal stomach, 
fetal lung, and fetal skeletal muscle after 35 cycles of PCR (fig. 3A). The expression 
of OTOR, found with semiquantitative RT-PCR of human fetal tissues as described, is 
similar to what has been published. With Northern blot analysis of human fetal tissues, 
expression could clearly be seen in cochlea, however, expression could not be detected 
in brain or tongue (Robertson et al. 2000). Using 35 cycles of semiquantitative RT-
PCR on mouse tissues, expression of OTOR could also clearly be detected in cochlea 
(Cohen-Salmon et al. 2000). 
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Figure 3. Semiquantitative RT-PCR analysis of known genes and clones isolated from the 
cochlea-enriched cDNA library. Samples were taken after 25, 30, and 35 cycles of PCR, except 
for (D), in which samples were only taken after 25 cycles. The mRNA employed for RT-PCR 
analysis was isolated from the following human tissues: (A) (1) fetal eye, (2) fetal cochlea, (3) 
fetal spinal cord, (4) fetal brain, (5) fetal kidney, (6) fetal colon, (7) fetal stomach, (8) fetal heart, 
(9) fetal lung, (10) fetal liver, (11) fetal skeletal muscle, (12) fetal tongue, and (13) placenta. (B 
through F) (1) fetal eye, (2) fetal cochlea, (3) fetal brain, (4) fetal kidney, (5) fetal colon, (6) fetal 
stomach, (7) fetal heart, (8) fetal lung, (9) fetal liver, (10) fetal skeletal muscle, (11) fetal tongue, 
and (12) placenta. (A) Known genes POU3F4, TECTA, OTOR, and GAPDH. (B) Four clones 
localized in nonsyndromic deafness loci. (C) Exon 2 of the SIX1 gene and two colocalizing clones 
in the DFNA23 locus. (D) Six clones that form a cluster derived from chromosome 21q21.1. As a 
positive control RT-PCR analysis of GUSB was performed. (E) Four clones that have similarity to 
up to five ESTs preferentially derived from brain or cochlea. (F) Three novel clones. Clone C13A6 
has overlap with a predicted exon in the Human Genome Project Working Draft (June 2002 
freeze) and clones C18A6 and C27F8 are represented by more than two sequences. 
Expression could also be detected in brain and some other tissues that were not tested 
in our study. Interestingly, expression of OTOR in the eye cannot be detected with RT-
PCR in human, but could be detected with RT-PCR in mouse. In summary, our results 
show that the expression patterns of these genes in human fetal tissues determined by 
semiquantitative RT-PCR are comparable with previously published expression data for 
these genes.
Semiquantitative RT-PCR analysis was performed for the 155 unique sequences 
mapping in known nonsyndromic deafness loci. Forty-five of these sequences (29%) 
showed preferential expression as either their cDNA PCR product is more abundant in 
fetal cochlea than in other fetal tissues analysed or their cDNA PCR product is more 
abundant in fetal cochlea and a small subset of other tissues than in other fetal tissues 
analysed (table 4). Representative results are shown for four of these clones (fig. 3B). 
Clone C23B7 is localized in the DFNB5 locus (Fukushima et al. 1995) and shows weak 
expression in fetal cochlea, fetal lung, and fetal tongue after 30 cycles of PCR. After 35 
cycles of PCR, this clone is preferentially expressed in fetal cochlea, fetal lung, and fetal 
tongue. Clone C20A10, localized in the DFNB14 locus (Mustapha et al. 1998), shows 
preferential expression in fetal eye, fetal cochlea, and fetal brain after 30 cycles of PCR. 
After 30 cycles of PCR, clone C10B5, localized in the DFNB27 region (Pulleyn et al. 
2000), shows preferential expression in fetal cochlea and to a lesser degree in fetal 
eye and fetal colon. C3E7 is derived from the DFN6 interval (Del Castillo et al. 1996) 
on the X chromosome. After 25 cycles of PCR, a vague band can already be seen in 
fetal cochlea. After 30 cycles of PCR, the clone shows preferential expression in fetal 
cochlea, but bands are also clearly visible in fetal eye, fetal colon, fetal heart, fetal 
skeletal muscle, and fetal tongue. 
Expression profiling of two clones colocalizing in the DFNA23 region, C29A4 
and C35D6, yielded very similar patterns of expression (fig. 3C). After 25 cycles of PCR, 
expression is shown in fetal eye, fetal cochlea, fetal lung, fetal skeletal muscle, and fetal 
tongue, with most pronounced expression in fetal cochlea. After 30 cycles, both clones 
show expression in fetal eye, fetal cochlea, fetal kidney, fetal lung, fetal skeletal muscle, 
and fetal tongue. These clones were found to be located 3’ of the SIX1 gene at 70 bp 
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from the last coding exon. To investigate whether the clones are part of the SIX1 gene, a 
pattern of expression of exon 2 of the SIX1 gene was determined (fig. 3C). SIX1 shows 
expression in the same tissues as the cDNA clones, which strongly suggests that the 
clones indeed belong to the transcriptional unit of the SIX1 gene. These results render 
SIX1 a good candidate gene for DFNA23. 
2.3.4. Expression profile analysis of clones that form a cluster 
The cDNA cloning procedure used to construct the cDNA library yields nonoverlapping 
RsaI cDNA fragments. Therefore cluster-analysis could not be performed by analysing 
sequence overlap between clones. This complicates the assessment of whether 
clones belong to the same gene. 
To obtain more information about the relationship between the clones located 
near each other, we performed expression pattern analysis for several of these clusters. 
This is exemplified by the analysis of a cluster of RsaI fragments that was localized on 
chromosome 21q21.1 (fig. 3D). The cluster consists of 20 sequences from which six 
representative RsaI fragments were selected for semiquantitative RT-PCR. All selected 
clones clearly show preferential expression in fetal eye, fetal cochlea, fetal brain, and 
fetal tongue after 25 cycles of PCR, indicating that these clones are either derived from 
the same gene or from closely related neighbouring genes with coordinate expression. 
2.3.5 Expression profile analysis of clones that represent novel genes
The majority of clones that are not derived from a known gene (70.3%, 1856 clones) 
(table 1) are not located in a known locus for nonsyndromic deafness. These clones 
can be subdivided into two groups: (1) clones that show similarity to a coding sequence 
present in GenBank; predicted genes, ESTs, and nonhuman coding sequences, and 
(2) clones that do not show similarity to any coding sequence present in GenBank; 
novel ESTs and novel sequences. To obtain more insight in the expression of these 
clones that are likely to represent novel genes, we performed mRNA expression profile 
analysis. 
From the first group consisting of 763 unique sequences, we selected 60 
clones that show similarity to up to five ESTs preferably derived from brain, fetal brain, 
or fetal cochlea. Twenty clones showed preferential expression in fetal cochlea and 
six clones showed preferential expression in fetal brain (table 5). Three clones with 
preferential expression in fetal cochlea and one with preferential expression in fetal 
brain are shown in figure 3E. After 35 cycles of PCR, clone C6F8 shows expression in 
all tissues tested. However, after 25 and 30 cycles, the clone clearly exhibits a much 
higher level of expression in fetal cochlea compared to the other tissues. Clone C1B10 
shows highest expression in fetal cochlea after 30 and 35 cycles of PCR. After 35 cycles, 
expression is also seen in other tissues. The expression of clone C11F3 is highest in 
fetal cochlea and fetal brain after 25 cycles. After 30 and 35 cycles, the clone is most 
highly expressed in fetal eye, fetal cochlea, fetal brain, and fetal skeletal muscle. Clone 
C30D5 is preferentially expressed in fetal brain after 25, 30, and 35 cycles of PCR. After 
30 cycles, expression can also be detected in fetal eye, fetal cochlea, and fetal skeletal 
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muscle and expression can be seen in all other tissues except fetal liver and placenta 
after 35 cycles. 
From the second group consisting of 757 unique clones, we selected 20 clones 
that either are represented by more than two clones or have overlap with an exon 
predicted in the Human Genome Project Working Draft (June 2002 freeze). Five clones 
showed preferential expression in fetal cochlea and two clones showed preferential 
expression in brain (table 5). Clone C13A6 has overlap with a predicted exon in the 
Human Genome Working Draft sequence and after 25, 30, and 35 cycles shows 
preferential expression in fetal cochlea and fetal eye (fig. 3F). The sequences of clone 
C18A6 and C27F8 are represented three times in the library. Clone C18A6 clearly 
shows preferential expression in fetal cochlea after 30 and 35 cycles of PCR (fig. 3F). 
However, after 35 cycles, expression can also be detected in other tissues. After 25 and 
30 cycles, clone C27F8 is clearly preferentially expressed in fetal brain. After 30 cycles, 
expression can also be detected in fetal cochlea and fetal tongue and after 35 cycles, 
expression can be detected in almost all tissues (fig. 3F). 
Of the 80 sequences representing novel genes in total, 25 (31.3%) showed 
preferential expression in fetal cochlea and 8 (10%) showed preferential expression in 
fetal brain (table 5). 
Table 5. Results of expression profile analysis of clones that represent novel genes
Sequence analysisa
Number 
of 
clones
% Number 
of unique 
sequences
% Number 
of clones 
preferentially 
expressed in 
cochlea 
Similarity to known gene 44 22.3 2 16.1 
Similarity to predicted gene  2.  3.2 -
Similarity to EST(s) from Unigene cluster 44 22.3 36 23.2 8
Similarity to other EST(s) 18 9.1 16 10.3 3
Similarity to sequence non-human organism 1 0. 1 0.6 -
Novel ESTs 8 43.1 72 46. 29
Total 197 155 45
2.4 Discussion 
The aim of this study was to identify novel ESTs that are specifically or preferentially 
expressed in the human cochlea. Using fetal cochlear cDNA as tester and driver cDNAs 
derived from several other tissues, the suppression subtractive hybridisation technique 
resulted in a highly complex cDNA library, as evidenced by the fact that we isolated 1944 
different cDNA clones among 2640 analysed. Cochlear cDNA libraries were previously 
constructed for rat (Ryan et al. 1993, Soto-Prior et al. 1997, Harter et al. 1999) and 
guinea pig (Wilcox and Fex 1992) and using a subtraction protocol for mouse (Cohen-
Salmon et al. 1997), chicken (Killick et al. 1997, Heller et al. 1998), gerbil (Zheng et al. 
2000), and zebrafish (Coimbra et al. 2002). Human cochlear cDNA libraries have been 
generated only without suppression subtractive hybridisation (Robertson et al. 1994, 
Jacob et al. 1998). In contrast to conventional subtraction methods and differential 
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hybridisation techniques previously used to isolate cochlea-specific genes (Robertson 
et al. 1994, Skvorak et al. 1999), suppression subtractive hybridisation allows the 
isolation of tissue-specific transcripts expressed at moderate or low levels in the tissue 
of interest. This has been demonstrated by the isolation of PRES, the motor protein 
of the cochlear outer hair cells (Zheng et al. 2000), from gerbil outer hair cells using 
a cDNA library constructed using suppression subtractive hybridisation (Zheng et al. 
2000). Such transcripts are underrepresented in the collection of ESTs deposited in 
public databases. 
About one-third of the cDNA clones of our library were novel and therefore not 
present among 14,850 ESTs derived from the fetal cochlear cDNA library constructed 
by Robertson et al. (1994) (http://hearing.bwh.harvard.edu/estinfo. HTM). Some of the 
novel ESTs may be the result of genomic DNA contamination. We have found that 1 
of 13 novel ESTs selected for expression profile analysis was not expressed in any of 
the tissues in our panel. Since the absence of an RT-PCR product could be due to a 
very low transcript level in the tissues tested, our most pessimistic estimate is therefore 
that of the 691 unique novel EST sequences we have identified, 53 will be the result of 
genomic DNA contamination. However, according to semiquantitative RT-PCR analysis 
of a subset of clones representing novel genes, 31% are preferentially expressed in fetal 
cochlea. Hence, our library potentially contains a high number of novel cochlear cDNAs, 
a substantial fraction of which might have an important function in the cochlea. 
2.4.1 Subtraction efficiency and evaluation of the cDNA library 
The efficiency of cDNA suppression was clearly shown by the considerable decrease 
in the abundance of cDNA of the housekeeping gene GAPDH after subtraction. 
Enrichment for cochlea-specific genes is more difficult to evaluate because of the 
scarcity of cochlea-specific genes. Both TECTA, which by Northern blot analysis 
could be detected only in the inner ear (Legan et al. 1997), and C1B10, a cDNA clone 
isolated from the library showing preferential expression in cochlea, showed increased 
abundance of cDNA after the suppression subtraction procedure. Additional evidence 
for enrichment of cochlear clones is provided by the presence in our library of genes 
known to be involved in hearing impairment, e.g., COCH, POU3F4, and KCNQ1. Not 
unexpectedly, several other important deafness genes known to be expressed in many 
noncochlear tissues, such as CX26 (Zhang and Nicholson 1989), MYO7A (Gibson et 
al. 1995), and MYO15 (Wang et al. 1998), are not represented in the library. Collagen 
genes are highly represented in our library. Collagen molecules are synthesized in the 
developing cochlea and defects in, e.g., COL1A2 (Pentinnen et al. 1975), COL2A1 
(Ahmed et al. 1991), COL11A1 (Richards et al. 1996), and COL11A2 (McGuirt et al. 
1999), have been associated with deafness. The high abundance of collagen cDNA 
fragments in our library probably also is due to the absence of driver mRNAs derived 
from noncochlear bony tissues. 
2.4.2 Expression profile analysis 
To analyse the expression characteristics of a selected number of clones, we have used 
Chapter 2
7
a semiquantitative RT-PCR method, which is sensitive, fairly fast, and in our hands 
reproducible. Alternative high-throughput or more global analyses methods, such as 
cDNA microarray analysis, might not be sensitive enough to detect transcripts of genes 
expressed only in a subset of cochlear cells. 
The majority of the 31 known genes mutated in inherited deafness is expressed 
either ubiquitously or in several (fetal) human tissues. At the onset of this study we 
speculated that the scarcity of cochlea-specific genes might be due to their under 
representation in commonly used cDNA libraries. Our results suggest, but do not prove, 
that true cochlea-specific genes may be very rare. Due to illegitimate transcription with 
little functional meaning, it is possible that some cochlea-specific clones appear to 
be preferentially expressed only in fetal cochlea in our study. Given this limitation, we 
find that no cDNA clones are exclusively expressed in the (developing) inner ear. In 
contrast many clones show preferential expression in the cochlea. RT-PCR analysis of 
256 unique sequences selected based on their location in hereditary deafness linkage 
intervals (155 sequences), their location in a cluster of clones (21 sequences), their 
similarity to a maximum of five ESTs preferably from (fetal) brain or fetal cochlea (60 
sequences), or their novelty and overlap with a predicted exon (20 sequences) resulted 
in the identification of 70 clones with preferential expression in fetal cochlea. The 
expression of these clones will be analysed in more detail in the future by Northern blot 
analysis and mRNA in situ hybridisation. The semiquantitative nature of our expression 
analysis cautions us to draw definite conclusions. Nevertheless, our data suggest that 
at least a quarter of the novel genes in our library are preferentially expressed in fetal 
cochlea. Hence, over 250 such clones may be present in our collection. 
In conclusion, this study resulted in a valuable collection of novel cDNA fragments 
that will form the basis for more detailed spatial and temporal expression analysis (e.g., 
mRNA in situ hybridisation), characterization of the corresponding genes, and future 
investigations into their putative roles in hearing and/or hereditary deafness. 
2.5 Materials and methods
2.5.1 Suppression subtractive hybridisation
For suppression subtractive hybridisation, poly(A)+ RNA from five human adult 
tissues (brain, kidney, liver, heart, skeletal muscle) and total RNA from placenta were 
purchased from Clontech. Total RNA from fetal brain, tongue, kidney, adrenal gland, 
lung, and liver was isolated with RNAzol B (Campro Scientific). Total fetal cochlear 
RNA of 16- to 22-week-old fetuses was kindly provided by Dr. C.C. Morton. The RNA 
was isolated as described elsewhere (Robertson et al. 1994). Complementary DNA 
(cDNA) was synthesized using the SMART PCR cDNA Synthesis Kit (Clontech). First-
strand synthesis was performed with 1.0 μg total RNA using an oligo(dT) primer. Single-
stranded cDNA was amplified by long-distance PCR with the Advantage cDNA PCR Kit 
(Clontech). Prior to subtraction, cDNA was size fractionated with Chroma Spin-1000 
columns (Clontech), digested by RsaI, and purified with the Advantage PCRPure Kit 
(Clontech). 
Subtraction of the cochlear RNA was performed with the PCR-Select cDNA 
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Subtraction Kit (Clontech) according to the method described by Diatchenko et al. 
(Diatchenko et al. 1996). Tester cDNA consisted of cochlear cDNA. Driver cDNA 
consisted of a mixture of cDNAs from fetal tissues (brain, tongue, kidney, adrenal gland, 
lung, and liver) and adult tissues (brain, heart, skeletal muscle, kidney, and liver). Tester 
cDNA was divided into two portions and ligated to two different adaptors. In the first 
hybridisation step, an excess of denatured driver (450 ng) was added to each sample of 
denatured tester (12 ng). In the second hybridisation step, the two primary hybridisation 
samples were mixed, and freshly denatured cDNA (300 ng) was added. Differentially 
expressed cDNAs were amplified by two suppression PCR amplifications with the 
Advantage cDNA PCR Kit (Clontech). 
2.5.2 Cloning and analysis of the subtracted cDNA 
Subtracted PCR products were ligated into plasmid vector pCRII, using a T⁄A cloning 
kit (Invitrogen). The resulting constructs were transformed to TOP10F’ competent cells 
(Invitrogen) and selected by blue/white screening. Approximately 3000 clones from 
the cochlea-enriched library were picked manually and grown for 16 h in 100 μL LB 
containing ampicillin (50 μg/ml) in 96-well tissue culture plates. After the addition of 100 
μL 30% (w/v) glycerol, the plates were stored at -80°C. 
Inserts from cDNA clones were recovered by direct PCR amplification of the 
culture using the vector primers T7 and M13 Reverse. Insert PCR products were isolated 
from an agarose gel with the Qiaquick Gel Extraction Kit (Qiagen) and sequenced with 
the Thermo Sequenase Dye Terminator Cycle Sequencing Pre-mix Kit (Amersham), 
using an automated DNA sequencer (Applied Biosystems, Inc., Model 3700). The 
clones were sequenced using the vector primers. Nucleic acid similarity searches were 
performed using the BLAST program (Altschul et al. 1997) against the GenBank, EMBL, 
and EST databases at the Centre for Molecular Bioinformatics (http://www.cmbi.kun.nl/). 
Sequence data have been deposited with GenBank under Accession Nos. CB831773-
CB831790 and CB410624-CB410971. 
Subtraction efficiency was tested with PCR according to the protocol provided 
with the PCR-Select cDNA Subtraction Kit (Clontech). 
2.5.3 Mapping and analysis of clones 
In the early phase of the project, radiation hybrid mapping was performed with the 
Stanford G3 Radiation Hybrid Panel (Research Genetics) for a number of clones. PCRs 
were performed in a volume of 10 μL using 25 ng DNA of each hamster/human cell 
line, 4 pmol of each primer, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2 (for 
most primer sets), 5 mM DTT, 200 μM of each dNTP, and 0.4 U Taq DNA polymerase 
(Invitrogen). Amplification was performed for 35 cycles at 94°C for 1 min, 60°C for 1 min 
(for most primer sets), and 72°C for 1 min in a microtiter PCR machine (MG Research). 
The localization of the cDNA fragments with the Stanford G3 Radiation Hybrid Map 
was determined at the Stanford Human Genome Centre Web site (http://www-shgc.
stanford.edu). 
Most of the clones were mapped using the results of BLAST-analysis using 
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publicly available programs UCSC Human Genome Project Working Draft, http://
genome.cse.ucsc.edu; NCBI Mapviewer, http://www.ncbi.nlm. nih.gov/cgi-bin/Entrez/
hum_srch; and Unigene at the NCBI, http://www.ncbi.nlm.nih.gov/UniGene/). Other 
programs used to analyze the clones were the Celera database (http://cds.celera.com) 
and Vector NTI 7.1 (InforMax, http://www.informaxinc.com). 
2.5.4 Expression profile analysis by semiquantitative RT-PCR 
For semiquantitative RT-PCR, total RNA was isolated from nine human fetal tissues 
(eye, cochlea, spinal cord, heart, kidney, colon, stomach, lung, tongue, and skeletal 
muscle) (Chirgwin et al. 1979). Total RNA from three human tissues (fetal brain, 
fetal liver, and placenta) was purchased from Clontech. Total RNA was treated with 
DNase I (Invitrogen). Random-primed RNA was synthesized in a volume of 250 μL 
from 3.1 μg total RNA using 4 pmol random hexanucleotides (pd(N)6; Pharmacia), 
10 mM Tris-HCl, pH 8.3, 50 mM KCl, 0.01% (v/w) gelatin, 5 mM MgCl2, 1 mM DTT, 
95 U RNAguard (Pharmacia), and 2500 U MMLV reverse transcriptase (Invitrogen). 
All cDNA was tested for genomic DNA contamination by performing a PCR on 
the cDNA, using primers spanning an intron of the housekeeping genes GAPDH 
(5’-ACCACAGTCCATGCCATCAC-3’ and 5’-TCCACCACCCTGTTGCTGTA-3’, 
spanning intron 8) and GUSB (3’-ACTATCGCCATCAACAACACACTGACC-3’ and 5’-
GTGACGGTGATGTCATCGAT-5’, spanning introns 3 and 4). Primer sets were designed 
with the Primer 3 program (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.
cgi) (Rozen and Skaletsky 2000) to amplify products of 100 to 250 bp. The primer sets 
were first tested on genomic DNA for the optimal annealing temperature and MgCl2 
concentration of the PCR. Semiquantitative RTPCRs were performed in a volume of 
35 μL using 87 ng randomly primed cDNA, 11.2 pmol each primer, 10 mM Tris-HCl, 
pH 8.3, 50 mM KCl, 0.01% gelatin, the optimal concentration of MgCl2, 160 μM of each 
dNTP, and 1.75 U Taq DNA polymerase (Invitrogen). For the majority of the primer sets 
amplification was performed at 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min in a 
Peltier thermal cycler (PTC-200; MJ Research). Samples of 10 μL were taken from the 
PCRs after 25, 30, and 35 cycles. 
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3.1 Abstract
A novel DFNA5 mutation was found in a Dutch family, of which 37 members were 
examined. A nucleotide substitution was identified in the splice acceptor site of intron 
7, leading to skipping of exon 8 in part of the transcripts. The mutation was found in 
18 individuals. Sensorineural hearing impairment was non-syndromic and symmetric. 
In early life, presumably congenitally, hearing impairment amounted to 30 dB in the 
high frequencies. Progression was most pronounced at 1 kHz (1.8 dB/year). Speech 
recognition was relatively good with a phoneme score of about 50% at the age of 
70. Onset age was 37 years, and recognition deteriorated by 1.3% per year. The 
recognition score deteriorated by 1.0% per decibel threshold increase from a mean 
pure-tone average (PTA at 1, 2 and 4 kHz) of 63 dB onwards. Vestibular function was 
generally normal. The second mutation identified in the DFNA5 gene results in hearing 
impairment, similar to that in the original DFNA5 family in terms of pure-tone thresholds, 
but with more favourable speech recognition.
Keywords: DFNA5 gene; Hearing impairment, progressive; High frequency; Splicing 
defect
3.2 Introduction
Since the early nineties, gene linkage and mutation analysis have been applied to 
increase our knowledge of hereditary non-syndromic hearing impairment. At the 
moment about 75 genetically different types of non-syndromic hearing impairment have 
been identified (Van Camp G. and Smith R.J.H. Hereditary hearing loss homepage 
[http://www.uia.ac.be/DNAlab/hhh/]). Knowledge of hereditary hearing impairment at a 
molecular level is still limited but can be enhanced by studies on genotype-phenotype 
correlations in families with hearing impairment (Huygen et al. 2003). This is especially 
true for autosomal dominant types, which display the largest phenotypic variation. The 
results of such family studies are also of value for genetic counselling purposes. 
Up to now, only 1 DFNA5 family has been described (Huizing et al. 1965, 
Huizing et al. 1966a, Huizing et al. 1966b, Huizing et al. 1972, Huizing et al. 1983, van 
den Wijngaard et al. 1985a, van de Wijngaart et al. 1985b). In this family, non-syndromic 
symmetric hearing impairment was severest at the high frequencies, and progression 
was most distinct in the first three decades of life. In 1995, the responsible gene was 
localized to a region on chromosome 7p15. The locus was designated DFNA5 (Van 
Camp et al. 1995). After sequencing of the DFNA5 gene, a complex insertion/deletion 
mutation was found in intron 7, causing skipping of exon 8 and leading to premature 
termination of the encoded protein. As there was no indication for its function, the 
gene was called DFNA5 by default (Van Laer et al. 1998). The DFNA5 protein is not 
homologous to any other human protein described up to now. Also no information is 
available about the structure or the subcellular localization
of the protein. 
In this report we describe a second mutation in the DFNA5 gene, in a Dutch family 
with autosomal dominant sensorineural hearing impairment. A nucleotide substitution 
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was identified in the splice acceptor site of intron 7, which leads to alternative splicing. 
This results in skipping of exon 8 in part of the transcripts. Pure-tone and speech 
audiometric data were analysed and compared to the results in the previously described 
DFNA5 family (De Leenheer et al. 2002a). Although a larger part of the transcripts is 
normal in comparison to the original DFNA5 family, the severity of hearing impairment 
is fairly similar in terms of pure-tone hearing thresholds. 
 
Figure 1. Pedigree of family W00-212 and genotypic data for markers flanking the DFNA5 gene, 
listed in centromere-to-telomere order. The most likely haplotypes are shown. A bar indicates 
the haplotype that is associated with the affected status. The marker order is in agreement with 
the most recent freeze (June 2002) of the Human Genome Working Draft (http://genome.ucse.
edu). Men are indicated with a square, women are indicated with a circle and filled symbols 
indicate affected persons. The proband is indicated with an arrow. Haplotype reconstruction for 
the individuals III:2 and III:3  suggests the presence of 5 alleles. However, assuming one allele 
change for marker D7S2493 for either individual IV:3 or IV:6 can explain this.
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3.3 Results
The pedigree (fig. 1) comprised 27 affected family members, 18 of whom were still alive 
and participated in this study. The pattern of inheritance is clearly autosomal dominant. 
Affected persons showed no evidence of other causes of hearing impairment than otitis 
in the past, except for case V:21, who had a cholesteatoma in the right ear at 14 years 
of age that required surgery. The data for the right ear in this individual were therefore 
excluded from the present analysis. The first symptoms of hearing impairment were 
reported at ages ranging from 0 to 40 years. Vestibular symptoms were not reported. 
Otoscopy was generally normal. Pure-tone audiograms (fig. 2) showed a so-called Z 
shape curve; predominantly highfrequency hearing loss with a large drop for the mid 
frequencies and relatively sparing of the lower frequencies. The audiograms were fairly 
symmetric, except for cases V:21 and V:30.
3.3.1 Audiometric analysis
All available data, combining individual longitudinal (11 cases) and single snapshot (7 
cases) measurements are shown in figure 3. As analysis of covariance indicated that 
pooling of regression lines was not allowed for any frequency, the trend lines were 
derived. At each frequency, it was checked that fairly similar numbers of individuals 
were represented by threshold values - either pertaining to longitudinal or snapshot 
observations - above and below the trend line. The annual threshold of deterioration 
increased from 0.7 dB/year at 0.25 kHz to 1.8 dB/year at 1 kHz and then decreased to 
1.2 dB/year at 4-8 kHz.
The constructed ARTA (fig. 4) show a configuration with congenital high-
frequency hearing impairment of about 30 dB and progression that was most pronounced 
at 0.5 and 1 kHz. To check whether the constructed ARTA was reliable, we plotted the 
thresholds predicted for minimum and maximum age, derived from the ARTA, in the 
original audiograms (fig. 2, dotted lines). This highlighted threshold variability, especially 
in the younger individuals, who seemed to be more severely affected than was indicated 
by their expected audiograms. Attempts to improve prediction for the younger patients 
only succeeded at the cost of the quality of prediction in the remaining cases and were 
therefore abandoned. 
In figure 4, the ARTA published for the original DFNA5 family (De Leenheer et 
al. 2002a) is illustrated, in juxtaposition to the ARTA derived for the present family. For 
both families, we created a threshold features array as described elsewhere (Huygen et 
al. 2003). A χ2 test did not detect a significant difference between the families, although 
in the first four decades the ARTA of the present family exhibited better thresholds at the 
speech frequencies. 
We checked for the presence of phenotypic differences related to gender since the 
expression of DFNA5, also known as ICERE-1, is higher in oestrogen-receptor-negative 
than in oestrogen-receptor-positive breast carcinomas (Thompson and Weigel 1998); 
none were found.
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Figure 2. Audiograms of the 18 affected family members. Nl = Normal. The dotted lines represent 
the predicted thresholds at the ages specified, as derived from the ARTA. The results of the 6 
vestibulo-ocular function tests are also indicated.
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Figure 3. Longitudinal analysis (binaural air conduction threshold). Threshold data (in decibels 
hearing level) versus age (in years) for the frequencies from 0.25 to 8 kHz combining individual 
longitudinal data (open circles) with connecting hairlines and single snapshot measurements 
(filled circles) of the 18 mutation carriers. The regression lines fitted to the individual longitudinal 
measurements are included (a bold line indicates significant progression). The dotted line pertains 
to the trend line derived for the ensemble of these data points (see text). Slopes and intercepts 
are indicated in bold.
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Figure 4. ARTA of the original and the present DFNA5 family from birth to the 7th decade. Italics 
indicate age (years) in decade steps.
Figure 5. Cross-sectional binaural mean speech recognition scores at the last visit against age 
(A) and PTA at 1, 2 and 4 kHz (B). The continuous curve was fitted using a non-linear equation. A 
straight line (dashed) approximated the relevant part of this curve, see methods. The onset age 
and onset level were derived, using the non-linear curve.
3.3.2 Speech recognition
Speech recognition was relatively good, with scores still better than 50% at the age of 
70. The recognition score (fig. 5A) declined substantially from onset at the age of 37 
with a deterioration rate of 1.3% per year (table 1). The 90% recognition score was 
found at a PTA level of 63 dB HL and deteriorated by about 1.0% per decibel (fig. 5B). 
The present findings were compared to and tested against the previously 
reported results for the original DFNA5 family (De Leenheer et al. 2002b). It appeared 
that onset age, onset level and deterioration gradient were significantly higher in the 
Novel DFNA5 Mutation
90
present family (table 1, fig. 6). The deterioration rate of the present family, although 
substantially higher, did not differ significantly from the one derived for the original 
DFNA5 family. Figure 6 demonstrates that at an age of <65 years, our patients had 
better recognition scores than the patients from the original family, which could also be 
explained by their more favourable thresholds in the speech frequencies in the first four 
decades of life (fig. 4). Patients from the two DFNA5 families tended to develop similar 
poor phoneme scores at an advanced age (fig. 6A) and around a PTA level of about 
85 dB at a score of about 75% (fig. 6B). Remarkably, figure 6B suggests the scores to 
diverge at higher PTA levels, with a relatively better performance in the original DFNA5 
family (De Leenheer et al. 2002b). 
Figure 6. Comparison of performance versus age (A) and performance versus impairment level 
(B) plots pertaining to speech recognition scores of the present (A5new, dashed line) and the 
original (A5old, dotted line) DFNA5 patients. Linear plots (X>X90) for the scores of DFNA2 (A2) and 
DFNA9 (A9) patients are included for comparison (see text).
3.3.3 Vestibular Function Tests and Computerized Tomography
Although no vestibular problems appeared to be present in this family, vestibular 
function was tested in 6 cases. Electronystagmography was normal in 5 cases (IV:22, 
IV:25, IV:29, V:28 and V:47) and revealed a hyperactive vestibulo-ocular reflex in 1 
individual (V:41). Computerized tomography (case IV:22) showed a normal temporal 
bone configuration.
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Table 1. Speech recognition scores
Present DFNA5 Original DFNA5 DFNA2 DFNA9
Age, years
n 12 33 43 41
Onset age 38 (28-49)S 16 (10-22) 34 43
SE  3
Det. Rate 1.3 (0.5-2.0)NS 0.7 (0.4-0.9) 0.3 1.8
SE 0.3 0.1
PTA, dB
n 11 33 42 41
Onset level 66 (53-80) 41 (31-52) 6 46
SE 6 
Det. gradient 1.0 (0.5-1.6)S 0.4 (0.3-0.6) 0. 1.2
SE 0.3 0.1
Onset age (years), onset level (dB), deterioration (det.) rate (% per year) and deterioration gradient 
(% per dB) are shown for the original and the present DFNA5 families; figures in parentheses 
indicate 95% confidence intervals. n = Number of cases; SE = standard error; S = significantly 
different; NS = not significantly different. The data of the present family shown in the table were 
derived from the linear curve that approximates the most relevant part of the continuous curve. 
The two columns on the right show reference data of DFNA2 and DFNA9.
Figure 7. Restriction analysis. (A) Sequence of the boundary of intron 7 and exon 8 of the DFNA5 
gene, showing that the mutation creates an RsaI restriction site. (B) Restriction digestion with 
RsaI in 18 affected and 19 non-affected family members. The 265-bp fragment represents the 
wild-type allele, the 226-bp fragment the mutant allele.
3.3.4 Linkage analysis
Due to the similarity of the type of hearing loss in the present family as compared to that 
in the DFNA5 family described previously, linkage studies were initiated with markers 
flanking the DFNA5 gene. The markers D7S629 and D7S673 are located telomeric to 
the DFNA5 gene at 7p15.3, and D7S2493 and D7S529 are derived from the region 
centromeric to the gene. All markers are located within a distance of 2.5 cM from the 
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gene according to the Généthon genetic map (Dib et al. 1996). All affected individuals 
were included in the linkage analysis, as well as non-affected individuals from the age 
of 30 years onwards. As already suggested by the type of hearing loss, there was co-
segregation of the disorder and a specific haplotype in the DFNA5 interval (fig. 1). A 
maximum lod score of 6.82 was calculated for marker D7S673. The maximum lod scores 
for markers D7S629, D7S2493 and D7S529 were 3.85, 2.34 and 5.09, respectively.
Figure 8. (A) Aberrant splicing of exon 8 of the DFNA5 gene. Two affected persons from the 
original DFNA5 family (A5old), 2 affected persons from the present DFNA5 family (A5new) and 8 
control individuals (control) are shown. The wild-type splice product is 345 bp long; the aberrant 
splice product in which exon 8 is skipped is 152 bp long. (B) Ratios of mutant versus wild type (wt) 
cDNA of 2 patients of the present family (A5new), 2 patients of the original DFNA5 family (A5old) 
and 22 control individuals. The inset shows part of the data on a different scale.
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3.3.5 Mutation analysis
For 2 affected family members the coding region and the exon-intron boundaries of 
the DFNA5 gene were analysed for the presence of a mutation by DNA sequencing. 
When compared to the published sequence, 2 changes were found. The first change 
was a C-to-G transversion in the splice acceptor site of intron 7 at position -6, which 
was heterozygously present. The second change was a c.1200 G>A transition in exon 
9 (1257 G>A (Van Laer et al. 2002a)), which was homozygously present. This was a 
silent mutation that was also seen homozygously in patients from the original DFNA5 
family and the majority of the control individuals. The C-to-G transversion created an 
RsaI restriction site. The co-segregation of the mutation in the family could therefore be 
shown by restriction digestion of a 265-bp PCR fragment encompassing the mutated 
splice site, resulting in 2 fragments of 226 and 39 bp in length (fig. 7). The mutation was 
not present in 100 control individuals. 
No deletions in any part of the gene could be detected by probing a Southern 
blot containing genomic DNA of 2 patients (III:15 and IV:1) and 2 control individuals with 
cDNA representing the entire protein-coding region (data not shown).
3.3.6 Effect of the splice site utation on splicing efficiency
Although the detected mutation in the splice acceptor site of intron 7 was not predicted 
(Shapiro and Senapathy 1987) to lead to a reduced splicing efficiency (86.25 vs. 85.00), 
mRNA derived from cultured lymphoblastoid cells was analysed for the presence of 
alternative splicing products. RT-PCR with primers located in exon 7 and exon 9 resulted 
in a fragment of 152 bp, which indicates skipping of exon 8 (fig. 8A). The absence of exon 
8 in the fragment was confirmed by sequence analysis. Skipping of exon 8 causes a 
frame shift at amino acid 330. This leads to 41 aberrant codons followed by a premature 
stop codon. The amount of the short PCR product found in this study was lower than 
the amount found in patients from the original DFNA5 family, in which the mutation also 
affects splicing of intron 7 leading to skipping of exon 8 (Van Laer et al. 1998) (fig. 8A). 
A variable but low amount of the PCR fragment representing the alternatively spliced 
mRNA was also seen in some control individuals. Therefore, 22 control individuals, 2 
patients of the present family and 2 patients of the original DFNA5 family were compared 
with regard to the ratio between RT-PCR products with and without exon 8 by phospho-
imaging (fig. 8B). One control measurement was detected as an outlier because the 
background signal was higher than the signal from the alternatively spliced mRNA 
resulting in a negative measured ration. Therefore this measurement was excluded 
from the analysis. For the remaining control measurements, the mean was 0.034 and 
SD 0.024. Ninety-five percent tolerance limits, according to t statistics, ranged from -
0.017 to 0.084. All DFNA5 patients had values above the upper tolerance limit. Skipping 
of exon 8 was therefore statistically significantly more frequent in patients of the present 
and the original family as compared to control individuals. Student’s t test detected a 
significant difference (p = 0.003) between the original DFNA5 patients (mean 4.34) and 
the present DFNA5 patients (mean 0.365). Consequently, splicing in the patients of 
the present family was less severely disturbed than in the  original DFNA5 family. The 
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presence of the C-to-G transversion in the splice acceptor site of intron 7 at position -6 
was excluded in the 22 normal-hearing control individuals by restriction digestion with 
RsaI and DNA sequencing.
To exclude that the difference in the amount of the long and the short splice 
product was a result of preferential degradation of the short splice form by NMD, we used 
the chemical cycloheximide to inhibit NMD in lymphoblastoid cell cultures of 2 affected 
individuals from the present family. We found a 1.36-fold increase in the average ratio 
when cycloheximide was added (data not shown). Because the amounts of long as well 
as short splice product were increased after treatment, 1.33- and 1.80-fold respectively, 
the increased ratio could only be attributed to the presence of an increased amount of 
short splice product. 
To exclude additional intronic mutations that affect correct splicing of the DFNA5 
mRNA, RT-PCR was performed with mRNA derived from cultured lymphoblastoid 
cells of 2 patients and 2 control individuals. Six primer combinations were used, which 
amplify overlapping cDNA fragments, covering the entire coding region. There were no 
indications for additional alternative splicing (data not shown).
3.4 Discussion 
We report the second family with a mutation in the DFNA5 gene associated with hearing 
loss. Noticeable is the fact that the mutation in both families influences the splicing 
process resulting in skipping of exon 8, however to a different extent. The relatively fast 
elucidation of the molecular defect in this second DFNA5 family, based on a comparison 
of the type of hearing loss with that of a genetically elucidated type, illustrates the value 
of a detailed analysis of hearing loss in families. 
Sensorineural hearing impairment in the present family was non-syndromic and 
symmetric with progression of 0.7-1.8 dB/year, depending on the frequency. Progression 
was fairly constant, in contrast with the original family, in which there was more rapid 
progression in the first 4 decades than at more advanced ages, especially in the high 
frequencies (about 1 dB/year at 0.25-1 kHz and 1-4 dB/year at 2-8 kHz) (De Leenheer 
et al. 2002a). The ARTA, however, were not significantly different. A large variation in 
audiogram types was found, which was also reported in the original family. There was 
severer hearing loss in the younger individuals than was predicted following the present 
procedures. 
Speech recognition scores were relatively good with an onset age of 37 years 
and a deterioration rate of 1.3% per year. Recognition scores decreased by 1.0% 
per decibel threshold increase from a mean PTA (1, 2, 4 kHz) of 63 dB onwards. The 
difference in speech recognition between both families might be explained by the 
more favourable thresholds in the speech frequencies in the first four decades of life, 
demonstrated by the ARTA of the present family. 
Table 1 and figure 6 include data derived from previous reports on DFNA2 
and DFNA9 (Bom et al. 2001). Straight lines were fitted for X>X90 to approximate 
the regression curves. The original DFNA5 patients tended to show similar phoneme 
scores as the DFNA9 patients, only at a more advanced age. The present DFNA5 
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patients showed this similarity already from a younger age onwards. At a given level 
of hearing impairment, DFNA5 patients of both families generally showed recognition 
scores that were better than those of DFNA9 patients but worse than those of DFNA2 
patients. As previously described (Bom et al. 2001), the high-frequency sensorineural 
hearing impairment of DFNA2 may be attributed to lack of expression of potassium 
channels, especially in the inner hair cells of the lower turns in the cochlea. Relatively 
better speech recognition in DFNA2 was explained by relative sparing of outer hair cell 
function in this region preserving pre-amplification and fine-tuning mechanisms. The 
relatively goodspeech recognition performance in DFNA5 patients might be explained 
in a similar way. 
The similarities in the type of hearing loss and a comparable effect of the 
mutations, namely skipping of exon 8 in both the present and the original DFNA5 family, 
indicate that the mutation in the present family indeed is the disease-causing genetic 
defect. Also, despite one silent mutation, no other mutations were found in the DFNA5 
gene in the present family. Although the transcript without exon 8 was also seen in 
control individuals, the relative amount was statistically significantly higher in the two 
patients from the present family than in the control individuals. Also, we have to note 
that the effect of the mutation on splicing might be different in the inner ear compared 
to lymphoblastoid cell lines. The 1200 G>A polymorphism has no major influence on 
the splicing efficiency of exon 8, because the disease-causing mutation in the present 
and the original family co-segregates with an A at position 1200. Also, the majority of 
the controls were homozygous A. Even though our results show that the ratio between 
the long and short splice form increases after treatment with cycloheximide, the lower 
amount of short splice product as compared to the amount of long splice product in 
the present family remains, indicating that this difference is not a result of NMD. Also, 
the low amount of short mRNA in the present family as compared to the previously 
described family cannot be explained by a higher rate of NMD in the present family. 
The relatively low amount of the short transcript in the present family suggests 
that not haplo-insufficiency but a dominant negative effect of the mutant protein causes 
the hearing loss, which might be attributed to the relatively large stretch of 41 aberrant 
amino acids. Since the alternative splicing product is also seen in a variable but lower ratio 
to the normal mRNA in controls, there might be a critical threshold for the aberrant protein 
above which it becomes pathogenic. This is underlined by the fact that the mutations in 
the only two DFNA5 families known so far have the same effect on the mRNA and the 
putative protein but affect a different amount of the transcript. Unfortunately, nothing is 
known about either the wild type or the short protein. Both proteins have very different 
C termini and neither have similarity with any other protein or protein domain. Whether 
the differences in speech recognition between the two families are due to the different 
ratios of normal versus short protein remains to be elucidated. One might think about 
discrepancies in pathogenic thresholds in different parts of the cochlea. Alternatively, 
modifier genes might be involved. Findings in additional families with a mutation in the 
DFNA5 gene may elucidate whether other mutations in the gene also lead to a similar 
type of hearing impairment or whether only the putative short protein causes hearing 
loss. 
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The function of the DFNA5 protein is still unknown, although there are some 
clues indicating that DFNA5, also designated ICERE-1, might be involved in the 
regulation of apoptosis. Recently, Lage et al. (Lage et al. 2001) reported that decreased 
DFNA5 mRNA levels are associated with a decrease in apoptotic events after exposure 
to the drug etoposide. It appeared that increased DFNA5 mRNA levels are associated 
with increased cellular disposition to programmed cell death mediated by activation of 
caspase 3. However, it has not yet been proven that there is a direct effect of DFNA5 
on apoptosis. Interestingly, apoptosis is important in the development of the inner ear 
predominantly during the embryonic and early postnatal development of the cochlea 
(Jókay et al. 1998, Nishizaki et al. 1998, Nishikori et al. 1999, Nikolic et al. 2000). 
Two studies of caspase 3 knockout mice have shown that caspase 3 deficiency results 
in severe hearing loss (Morishita et al. 2001, Takahashi et al. 2001). Hyperplasia of 
supporting cells and degeneration of sensory hair cells and cochlear neurons are seen 
in the inner ear of these mice (Morishita et al. 2001, Takahashi et al. 2001). In 5-week-
old homozygous caspase 3 knockout mice extensive loss of hair cells was observed in 
the basal and middle turns of the cochlea but not in the apical turns. Degeneration of the 
hair cells begins early, progressively worsens with age and spreads from the basal turns 
towards the apical turns. These findings might explain why DFNA5 is a progressive form 
of hearing loss that affects the higher and middle frequencies earlier and more severely 
than the lower frequencies. The ongoing characterization of mice in which the mutation 
in the original DFNA5 family is mimicked will elucidate whether the cochlear defects are 
similar to those in the caspase 3-deficient mice and thus whether DFNA5 might have a 
function in apoptosis in the inner ear (Van Laer et al. 2002b).
3.5 Patients and methods
A 5-generation pedigree was established for the present family (W00-212). Thirty-seven 
family members participated in this study. The medical history was taken and otological 
examination was performed. Attention was paid to the presence of any syndromic features. 
Non-hereditary causes of hearing loss were excluded, and written informed consent 
was obtained. All individuals included in this study underwent pure-tone audiometry; 
speech audiometry was performed in affected persons only. Vestibular function was 
tested in 6 cases. One affected person underwent computerized tomography of the 
temporal bones. Blood samples were obtained for linkage analysis from 18 presumably 
affected family members and 19 presumably unaffected persons.
3.5.1 Audiometric Analysis
Pure-tone and speech audiometry were performed in a soundtreated room, conforming 
to the International Standards Organisation (ISO) standards (ISO 389: Acoustics. 
Standard reference zero for the calibration of pure tone air conduction audiometers. 
Geneva, International Organisation for Standardization, 198 and ISO 823-1: 
Acoustics. Audiometric test methods. I. Basic pure tone air and bone conduction 
threshold audiometry. Geneva, International Organisation for Standrdization, 1989). The 
individual 95th percentile threshold values of presbyacusis in relation to the patient’s 
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sex and age were derived for each frequency using the ISO 7029 method (ISO 7029: 
Acoustics. Threshold as hearing by air conduction as a function of age and sex for 
otologically normal persons. Geneva, International Organisation for Standardization, 
1984). Persons were considered affected if the best hearing ear showed thresholds 
beyond this 95th percentile threshold of presbyacusis. Mean binaural threshold levels 
were used to perform longitudinal regression analyses. Analysis of covariance (Prism PC 
version 3.02; GraphPad, San Diego, Calif., USA) was performed to compare between 
slopes and intercepts of the regression lines pertaining to individual measurements per 
frequency. Where pooled regression was inappropriate, the median slope (called annual 
threshold deterioration, expressed in decibels per year) and intercept were calculated, 
following inspection of the corresponding frequency distributions. Outlying values were 
excluded, if necessary. The lines defined by the combination of the slope and intercept 
values thus obtained were called trend lines. These lines were used to construct age-
related typical audiograms (ARTA). To compare the audiological data of the original 
(De Leenheer et al. 2002a) and the present DFNA5 family, we transformed the ARTA 
into a one dimensional threshold features array, which can be used for χ2  analysis, as 
previously described (Huygen et al. 2003).
3.5.2 Speech audiometry
Speech audiometry was performed, using standard monosyllabic Dutch word lists. The 
maximum monaural phoneme score (percent correct recognition) was derived from a 
performance versus intensity plot. Cross-sectional binaural mean phoneme recognition 
scores were plotted for all mutation carriers against age and binaural mean PTA at 1, 2 
and 4 kHz (pure-tone average in decibels hearing level). Non-linear regression analysis 
was used to fit sigmoidal doseresponse curves with variable slope, as previously 
described (Bom et al. 2001). Outlying values were excluded, if necessary. The age of 
onset and onset level were defined at a maximum phoneme recognition score of 90% 
in the performance versus age and performance versus impairment plots. The slope 
was called deterioration rate in the performance versus age plot, whereas it was called 
deterioration gradient in the performance versus impairment plot. To simplify the results 
and allow for additional testing, ‘local average’ slope (i.e. on a linear scale) for X>X90 (X 
is either age or PTA level) was obtained by fitting a straight line as previously described 
(Bom et al. 2003), using a non-linear method to estimate X90 (De Leenheer et al. 2002b). 
Student’s t test (with Welch correction if significantly unequal variance was detected 
by Bartlett’s test) was employed to test age of onset, deterioration rate, onset level or 
deterioration gradient between the present and the original DFNA5 family (De Leenheer 
et al. 2002b).
3.5.3 Linkage analysis
DNA was isolated from peripheral blood according to Miller et al. (1988). Analysis of 
the microsatellite markers was performed as described by Kremer et al. (1996). Two-
point lod scores were calculated with the MLINK subroutine of the LINKAGE package 
version 5.1 (Lathrop and Lalouel 1984, Lathrop et al. 1984, Lathrop et al. 1986). A 
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penetrance of 0.95, a disease allele frequency of 0.0001 and a phenocopy rate of 0.001 
were assumed for the calculations.
3.5.4 Mutation analysis
Amplification of the protein-coding region from chromosomal DNA was performed 
using standard PCR conditions. Primer sequences have been described by Van Laer 
et al. (Van Laer et al. 2002a), except for amplification of exon 9 for which we used 
5’-GGTCCCACCTGGGAGGTTGC-3’ and 5’-CTGTGACTGTGATTTTTCTCTCC-3’. 
Prior to sequencing, PCR fragments were purified with the QIAquick gel extraction 
kit (Qiagen). Sequence analysis was performed using the ABI PRISM Big Dye 
Terminator cycle sequencing V2.0 ready reaction kit and an ABI PRISM 3700 DNA 
analyser (Applied Biosystems). For testing the segregation of the mutation in the family, 
genomic DNA was amplified with the primers 5’-GTCTCCAGCTGTGTCATGACC-3’ 
and 5’-CCATTTCTTTCATTTTCTTTTCTCC-3’. PCR fragments were digested with RsaI 
(Invitrogen) and separated on an agarose gel (Seakem agarose, FMC).
3.5.5 Reverse transcriptase polymerase chain reaction
Messenger RNA of lymphoblastoid cells cultured under standard conditions was 
isolated according to the RNA-Bee (Campro Scientific) protocol. To establish the effect 
of nonsense mediated RNA decay (NMD), lymphoblastoid cells were treated with 
cycloheximide (100 μg/ml cell culture medium) for 4.5 h. For the initial testing of skipping 
of exon 8 and detection of other alternative splicing products, cDNA was synthesized 
by random priming with MMLV reverse transcriptase (Invitrogen). Subsequently PCR 
was performed with the primers 5’-CCTGAGCCACAACAGACAGC-3’ in exon 7 and 
5’-GGCACAGTGTGGGAATGATCTG-3’ in exon 9, and fragments were analysed 
on agarose gel. For the detection of alternative splicing in other parts of the mRNA, 
the following primers were used: 5’-AGAGGCCCCGACATCTCC-3’ in exon 1, 5’-
TCGACCTGCATGTGCTCAG-3’ in exon 4, 5’-GGTGCTGGAAGGAAGGAATG-3’ in 
exon 4, 5’-CAAATAGGACCGCCTGGAAG-3’ in exon 7, 5’-TCTGCTGGGCACTTGCTG-
3’ in exon 9 and 5’-TCATCATGCAAAATGTCACCAC-3’ in exon 10. For comparison 
of the ratio between the normal and the short DFNA5 mRNA, cDNA synthesis was 
performed with the one-step RT-PCR kit (Qiagen). The 32P-labelled primers given above 
for testing of exon 8 skipping were used, and 25 cycles of PCR were performed. After 
denaturation, fragments were separated on a denaturing acrylamide gel. Phospo-
imaging was performed using the Gs-363 molecular imaging system (Biorad). The data 
were analysed, and the ratios between normal and short mRNA were determined with 
the molecular analyst software, version 1.5 (Biorad). As control samples for RT-PCR, 
mRNA was isolated from lymphoblastoid cells of 22 normal-hearing individuals. One 
individual was 15 years old, all others were between 20 and 83 years old.
3.5.6 Southern blot analysis
Chromosomal DNA (about 8 μg per lane) was digested with MspI, EcoRI and TaqI and 
separated on a 0.8% agarose gel (Seakem agarose, FMC) and blotted onto GeneScreen 
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plus (NEN Life Science Products) by a standard dry blot transfer method. As probe, 40 
ng of a cDNA encompassing the complete coding region was labelled with α[32P]dCTP 
by random primer extension and hybridised under standard conditions.
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4.1 Abstract
Myosin VIIA is an unconventional myosin that has been implicated in Usher syndrome 
type 1B, atypical Usher syndrome, non-syndromic autosomal recessive hearing 
impairment (DFNB2) and autosomal dominant hearing impairment (DFNA11). Here, 
we present a family with non-syndromic autosomal dominant hearing impairment 
that clinically resembles the previously published DFNA11 family. The affected family 
members show a flat audiogram at young ages and only modest progression, most 
clearly at the high frequencies. In addition, they suffer from minor vestibular symptoms. 
Linkage analysis yielded a maximum two-point lodscore of 3.43 for marker D11S937 
located within 1 cM of the myosin VIIA gene. The myosin VIIA gene was sequenced and 
11 nucleotide variations were found. Ten nucleotide changes represent benign intronic 
variants, silent exon mutations or nonpathologic amino acid substitutions. One variant, 
a c.1373A>T transversion that is heterozygously present in all affected family members 
and absent in 300 healthy individuals, is predicted to result in an Asn458Ile amino acid 
substitution. Asn458 is located in a region of the myosin VIIA motor domain that is 
highly conserved in different classes of myosins and in myosins of different species. 
To evaluate whether the Asn458Ile mutation was indeed responsible for the hearing 
impairment, a molecular model of myosin VIIA was built based on the known structure of 
the myosin II heavy chain from Dictyostelium discoideum. In this model, conformational 
changes in the protein caused by the amino acid substitution Asn458Ile are predicted 
to disrupt ATP/ADP binding and impair the myosin power-stroke, which would have a 
severe effect on the function of the myosin VIIA protein.
4.2 Introduction
Myosin VIIA is an unconventional myosin that has been implicated in recessively 
inherited Usher syndrome type 1B (Weil et al. 1995, Weston et al. 1996), recessively 
inherited atypical Usher syndrome (Liu et al. 1998, Zina et al. 2001), non-syndromic 
autosomal recessive hearing impairment (DFNB2; Liu et al. 1997a, Liu 2002) and 
autosomal dominant hearing impairment (DFNA11; Liu et al. 1997b). The myosin VIIA 
(MYO7A) gene consists of 49 exons and encodes a polypeptide of 2,215 amino acids. 
MYO7A is expressed in the inner ear, retina, testis, lung and kidney (Hasson et al. 
1995). In the human retina MYO7A is expressed in the retinal pigment epithelium and 
in photoreceptor cells (El-Amraoui et al. 1996). In the inner ear, the gene is expressed 
in the inner and outer hair cells of the cochlea and in the type I and type II hair cells of 
the utricular and semicircular canal hair cells, in which it is found in the stereocilia, the 
cuticular plate and the cell body (Hasson et al. 1995, 1997).
Unconventional myosins are actin-based motor molecules that transduce 
chemical energy derived from ATP into a force enabling them to move along actin 
filaments, thereby transporting cargo along these filaments (see Hirokawa and Takemura 
2003, and references therein). The structure of type VII myosin proteins is highly 
conserved in vertebrates and invertebrates (Oliver et al. 1999). The human myosin VIIA 
consists of a motor head domain (amino acids 1-729) containing ATP- and actinbinding 
motifs, a neck region composed of five isoleucine/glutamine (IQ) motifs (amino acids 
Novel Myosin VIIA Mutation Responsible For DFNA11
104
730-855; expected to bind calmodulin) and a long tail (amino acids 856-2,215). The tail 
begins with a short coiled-coil domain (amino acids 848-1,095) shown to be involved in 
homodimer formation (Weil et al. 1997). This domain is followed by two large repeats of 
~460 amino acids each containing a myosin tail homology 4 (MyTH4) and a 4.1, ezrin, 
radixin, moesin (FERM)-like domain, separated by a poorly conserved src homology type 
3 (SH3) domain (fig. 4; Oliver et al. 1999). Previously, Liu et al. (1997b) have shown that 
an inframe 9-bp deletion in exon 22 of MYO7A causes DFNA11 in a Japanese family. The 
affected family members suffer from postlingual, bilateral, non-syndromic sensorineural 
hearing loss, with gradual progression at all frequencies and minor vestibular problems; 
no evidence has been found for retinitis pigmentosa (Tamagawa et al. 2002). The 9-bp 
deletion is predicted to result in a 3-amino-acid deletion in the coiled-coil region of the 
protein. The aberrant protein is thought to be able to interact with the wild-type protein, 
resulting in a dominant negative effect (Liu et al. 1997b).
Here, we present a second mutation in MYO7A found to be implicated in 
DFNA11. Affected family members suffer from bilateral non-syndromic hearing loss, 
which is most progressive at the higher frequencies, and minor vestibular problems. We 
have found a nucleotide change causal for the hearing impairment, viz. a transversion 
that is heterozygously present in all affected persons. This nucleotide change results 
in an Asn458Ile amino acid substitution. We present a molecular model of the motor 
head domain of the human myosin VIIA protein. In the model of the mutant protein, 
the isoleucine residue at position 458 probably disrupts ATP/ADP binding and impairs 
the myosin power-stroke. The c.1373A>T nucleotide change is therefore considered to 
underlie the hearing impairment in this family. 
4.3 Results
4.3.1 Linkage analysis
The cross-sectional age-related typical audiograms combined with the minor vestibular 
problems suggested DFNA11 as the type of hearing loss segregating in family W02-
011 (fig. 1). Therefore, a linkage study was initiated with the maker D11S937 located 
at 11q14.1 approximately 1 Mb telomeric of the causative gene for DFNA11, MYO7A. 
The distance between marker D11S937 and MYO7A is <1 cM according to the deCode 
genetic map (Kong et al. 2002). All affected and non-affected family members from the 
age of 30 years onwards were included in the linkage study. As suggested by the clinical 
data, the hearing loss completely co-segregated with one particular allele of D11S937 
(fig. 2), with a maximum two-point lodscore of 3.43. 
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Figure 1. Audiograms of the left ear (L) of affected family members III:22 and III:24. The frequency 
is indicated on the X-axis in kilohertz (kHz). The hearing threshold is indicated on the Y-axis in 
decibels (dB). The ages at which audiograms are taken are given in years (y).
Figure 2. Pedigree of family W02-011 and D11S937 marker analysis. Square Men, circle women, 
filled symbols affected persons, arrow proband. Allele 9 co-segregates with the disease. The 
hearing status of person II:5 was unclear; she was therefore given an unknown status (?).
4.3.2 Mutation analysis
Only one other DFNA11 family has been described so far (Liu et al. 1997b) in which 
a 9-bp deletion in exon 22 of the MYO7A gene results in a 3-amino acid deletion 
(Lys888-Lys890del) in the coiled-coil region of the protein. Therefore, exon 22 was first 
analysed by DNA sequencing in the present family but no mutation was found. The 
remaining 48 exons of the gene were subsequently analysed by direct DNA sequencing 
of DNA from person III:3. Eleven sequence variations were found that were all present 
heterozygously, except for the homozygous change IVS41-12T>C (table 1). A total of 
four intronic nucleotide changes previously described as polymorphisms reside in or 
near splice sites. According to the “splice efficiency” calculation proposed by Shapiro 
and Senapathy (1987), these nucleotide changes are not predicted to have a negative 
effect on splicing efficiency. 
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Table 1. Polymorphisms found in the MYO7A DNA sequence in the DFNA11 family.
Exon Nucleotide 
change
Amino acid change Reference
8 c.783T>C Gly261Gly Weston et al. 1996; Lévy et al. 1997; 
Bharadwaj et al. 2000
10 c.1007G>A Arg336His This study
13 c.1373A>T Asn458Ile This study
27 IVS27+10del22 no effect on splicinga Adato et al. 1997; Janecke et al. 1999)
30 IVS30+12C>T no effect on splicinga (Bharadwaj et al. 2000
3 c.4755C>T Ser18Ser Lévy et al. 1997; Adato et al. 1997; Janecke et 
al. 1999; Bharadwaj et al. 2000
36 c.4996T>A Cys1666Ser Lévy et al. 1997; Janecke et al. 1999; 
Bharadwaj et al. 2000
41 c.5715G>A Lys1905Lys Lévy et al. 1997; Adato et al. 1997; Janecke et 
al. 1999; Bharadwaj et al. 2000
42 IVS41-12T>Cb no effect on splicinga This study
43 c.5860A>C Ile194Leu Adato et al. 1997; Janecke et al. 1999; 
Bharadwaj et al. 2000
43 IVS42-7A>T no effect on splicinga Lévy et al. 1997; Janecke et al. 1999; 
Bharadwaj et al. 2000
aAccording to Shapiro and Senapathy (1987)
bHomozygous sequence variant
Three previously described variants reside in the MYO7A open reading frame 
but do not lead to amino acid substitutions. Three other exonic changes result in amino 
acid changes. Cys1666Ser and Ile1954Leu are previously described polymorphisms 
(Lévy et al. 1997, Adato et al. 1997). Arg336His is a novel sequence variant that 
has been shown not to co-segregate with the hearing impairment in our family. We 
therefore assume that this is a rare polymorphism. A c.1373A>T transversion was found 
heterozygously in exon 13 (fig. 3A, B) in all affected, but in none of the unaffected, 
family members, as confirmed by direct sequencing. Individual II:5 did not carry the 
mutation. The nucleotide change is predicted to result in an Asn458Ile amino acid 
substitution. ARMS analysis showed that the c.1373A>T change was absent in 300 
control individuals. In this analysis, we found one control individual with a c.1373A>G 
transversion, which leads to amino acid change Asn458Ser (data not shown). 
4.3.3 Molecular modelling
Asn458 is located in a region of the myosin VIIA motor domain, which is highly conserved 
in different classes of myosins and myosins of different species (fig. 4). To evaluate 
whether the Asn458Ile mutation is indeed responsible for the hearing impairment in 
this DFNA11 family, a molecular model of myosin VIIA was built based on the known 
structure of the myosin II heavy chain from D. discoideum (Kliche et al. 2001). With 
37% sequence identity and an alignment spanning 750 amino acid residues, both 
proteins are guaranteed to adopt the same fold (Rost 1999). In the model, Asn458 is a 
conserved residue that is part of the switch II α-helix and fulfils an important structural 
role by attaching the helix to the preceding switch II loop (fig. 3C). This is achieved via a 
strong hydrogen bond between its side-chain amino group and the backbone oxygen of 
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the Phe439 in the loop. The two conserved flanking residues, Ile438 and Gly440, have 
been shown to be of crucial importance for a conformational change of the myosin head. 
Depending on the ligand bound in the ATPase pocket, the two corresponding residues 
in D. discoideum, Ile455 and Gly457, undergo changes of the backbone torsion angles 
that are accompanied by a concerted rigid body movement of the Cterminal domain 
(Fisher et al. 1995). Whereas the precise mechanism of the myosin power-stroke is still 
a matter of debate, this domain movement clearly plays an important role. 
Figure 3. Identification of the Asn458Ile mutation and the predicted functional effect in the myosin 
VIIA model. (A) Sequence analysis of exon 13 of MYO7A reveals a heterozygous c.1373A>T 
(Asn458Ile) substitution. (B) Sequence analysis of exon 13 of MYO7A of an unaffected individual. 
(C) Molecular modelling of myosin VIIA. If isoleucine replaces asparagine at position 458, its 
larger side-chain collides with the backbone oxygen of phenylalanine 439 in the switch II loop 
(arrow), pushing the loop towards the ATPase pocket. This is assumed to negatively influence the 
sensing of the active site state (involving Asp437) and the reorientation in the switch II loop hinge 
region (Ile438 and Gly440, not shown).
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In the model, the Asn458Ile mutation is predicted to have severe effects (fig. 
3C). The differently shaped isoleucine side-chain collides with the backbone of Phe439 
and pushes the entire switch II loop towards the ATPase pocket (arrow in fig. 3C). The 
connecting hydrogen bond is lost and, at the same time, the hydrophobic side chain of 
Ile458 covers the backbone oxygen of Phe439, adding an unsaturated hydrogen-bond 
acceptor to the energetic cost of the mutation.
Figure 4. Myosin VIIA protein domain structure and amino-acid sequence alignment of myosin 
VIIA orthologues derived from six different species. Upper panel The various protein domains 
are indicated with different shades of grey. The motor head domain, 5 IQ regions, a coiled-coil 
domain (c-c), two MyTH4 domains, two FERM-like domains, and an SH3 domain are shown. The 
positions of two DFNA11 mutations and one DFNB2 mutation are also indicated. Lower panel 
Sequences of myosin VIIA protein orthologues from six species are compared: Homo sapiens 
(Hs.), Mus musculus (Mm.), Drosophila melanogaster (Dm.), Caenorhabditis elegans (Ce.), Sus 
scrofa (Ss.) and Dictyostelium discoideum (Dd.). Conserved residues are indicated in bold. The 
highly conserved switch II loop and switch II α-helix. The DFNA11 and USH1B mutations are 
indicated.
4.4 Discussion
Based on careful phenotypic analysis, we could identify a second family in which non-
syndromic autosomal dominant hearing impairment segregates with the DFNA11 locus 
at 11q14.1. Sequence analysis revealed 11 sequence variations in the MYO7A gene. 
Only one nucleotide change, c.1373A>T, leading to an Asn458Ile amino acid change, 
was inherited with the hearing loss. Asn458 is fully conserved in all known myosin 
VIIA homologues. Computer modelling based on the known structure of the myosin II 
heavy chain of D. discoideum revealed that Asn458 has an important structural role. 
In the model of the aberrant protein, the differently shaped side chain of isoleucine 
at position 48 is predicted to cause important structural changes in the motor head 
domain of the protein. This will probably disrupt ATP/ADP binding and/or impair the 
myosin power-stroke. A putative Asn458Ser amino acid change found heterozygously 
in one out of 300 control persons tested was predicted by modelling to have little or no 
effect on the function of the protein (data not shown). We assume that Asn458Ser is a 
rare polymorphism or a rare recessive mutation.
In a previously described Japanese family (Liu et al. 1997b), a 9-bp deletion 
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was found in exon 22 encoding the coiled-coil region that is predicted to allow myosin 
VIIA to dimerise (Weil et al. 1997). The 3-amino-acid deletion in the coiled-coil region 
is presumed to have a dominant negative effect, because of the improper dimerisation 
of wild-type and mutant proteins and thus the impairment of the function of the wild-
type protein. In contrast, in the family described here, the aberrant protein is expected 
to dimerise properly. However, since aberrant proteins can dimerise with wild-type 
proteins and thus also impair the function of wild-type proteins, this is presumed to give 
a dominant negative effect. The phenotypes in the Japanese and Dutch families are 
similar, suggesting similar disease mechanisms, despite the underlying mutations being 
different. 
The main phenotypic variation caused by mutations in the MYO7A gene 
is the presence or absence of impaired visual function. The function of the protein 
therefore probably differs in the processes of hearing and vision. The recent finding 
of a protein (MyRIP) that binds myosin VIIA and Rab27a, a melanosome-binding G-
protein, supports the idea that, in the eye, the myosin VIIA protein is involved in the 
short-range peripheral movement of melanosomes along the actin-rich microvilli of the 
retinal pigment epithelial cells (El-Amraoui et al. 2002). Wolfrum and Schmitt (2000) 
have demonstrated that myosin VIIA and rhodopsin are spatially co-localized at the 
membrane domain of the connecting cilium of the photoreceptor cells. Combined with 
the abnormally high amounts of opsin seen in the connecting cilia of shaker-1 mice (Liu 
et al. 1999), these results indicate the functional coupling of myosin VIIA motor function 
and the transport of opsin through the connecting cilium. In addition, Gibbs et al. (2003) 
have concluded that myosin VIIA is required for the normal processing of ingested disk 
membranes in the retinal pigment epithelium, primarily in the basal transport of the 
phagosomes into the cell body where they then fuse with lysosomes. From their recent 
studies, Kros et al. (2002) have suggested that, in the inner ear, myosin VIIA participates 
in the anchoring of membrane-bound elements to the actin core of the stereocilium and 
is required for the normal gating of transducer channels in the stereocilia. Boëda et al. 
(2002) have shown that myosin VIIA interacts directly with harmonin and may convey 
harmonin b along the actin core of the developing stereocilia where it anchors cadherin 
23 to the actin filament core. Boëda et al. (2002) have postulated that myosin VIIA 
indirectly modulates the gating properties of the transducer channels in the stereocilia 
during development, by translocating the proteins that regulate the transduction process 
along the developing stereocilium. These findings are supported by studies on a mouse 
model for myosin VIIA mutations, shaker-1 (sh1; Self et al. 1998), which have revealed 
that severe mutations result in the disorganization of the normal pattern of stereocilia 
on the surface of the hair cells in the cochlea. Milder mutations do not cause changes 
in hair cell morphology, but affected animals are nevertheless deaf (Self et al. 1998), 
suggesting that myosin VIIA performs other functions in the hair cells in addition to 
ensuring the proper organization of the stereocilia. Apparently, the transversion of 
asparagine into isoleucine in the aberrant protein causes impaired inner ear function, 
whereas the function of the retina is not affected. 
Alternatively, other complementary proteins might rescue the loss of function of 
myosin VIIA in the eye, whereas in the inner ear, the function of the protein is unique and 
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cannot be compensated for by other proteins. In addition, the residual wild-type dimers 
that can still be formed may suffice for proper visual function. 
There appears to be no obvious correlation between the location of a missense 
mutation in the myosin VIIA protein and the resulting phenotype. For example, Asn458Ile 
causes DFNA11, whereas a change in the flanking amino acid, Ala457Val combined 
with Arg90Pro, can cause Usher syndrome type 1B (Bharadwaj et al. 2000), as does 
Glu450Gln in the same highly conserved switch II α-helix (Weston et al. 1996). In order to 
understand the disease mechanisms underlying these different phenotypes and to gain 
more insights into the function of individual amino acids in the protein, in vivo functional 
studies are essential. Of late, many functional studies of various model organisms, such 
as mice and zebra fish, have been published (Self et al. 1998, Ernest et al. 2000). A 
model organism that is frequently used for these investigations is D. discoideum (Sasaki 
and Sutoh 1998, Furch et al. 1999, Tsiavaliaris et al. 2002). Unfortunately, none of the 
many studies of mutations in the motor domain that have been undertaken to investigate 
myosin VIIA properties have, to our knowledge, included the mutation that we describe 
here. Further functional studies of the myosin VIIA protein, e.g. in Dictyostelium, should 
be carried out to provide further evidence that the amino acid change Asn458Ile is 
causative of the hearing impairment inherited in this family. 
In conclusion, in this study, we have identified the first autosomal dominant 
hearing impairment mutation in the motor head domain of myosin VIIA and have 
provided a model for the functional consequences of the mutation. The phenotype in the 
first DFNA11 family is similar to that in the present family, although the mutation in the 
first DFNA11 family is in a different region of the protein and can be predicted to have 
a different effect. Our results also show that phenotypic characteristics in a family with 
hearing loss can lead to the rapid elucidation of the underlying genetic defect.
4.5 Patients and methods
4.5.1 Patients
A four-generation pedigree was established for a Dutch family (W02-011) with hearing 
impairment (fig. 2). Twenty-six family members from the youngest three generations 
participated in this study. The local ethics committee approved this study and written 
informed consent was obtained from all participating individuals. Blood samples were 
obtained for linkage and mutation analysis. 
The genetic defect segregating in this family shows autosomal dominant 
inheritance (fig. 2). Affected family members present with a flat audiogram at young 
ages and there is only modest progression, most clearly at high frequencies, with 
increasing age (A.M.L.C. Bischoff et al., unpublished data). Two audiograms are given 
in figure 1. Vestibular examination in six affected individuals showed a variation in 
vestibular function from normal vestibular responses to areflexia. Four out of six affected 
individuals in whom vestibular examination was performed presented with vestibular 
symptoms such as vertigo and unsteady walking, especially in the dark. Five affected 
individuals underwent extensive ophthalmological examination. Minor abnormalities in 
electro-oculograms and electro-retinograms were found in some affected individuals. 
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The hearing status of person II: in the pedigree was unclear; she was therefore given 
an unknown status in the linkage analysis. Clinical details will be presented in a separate 
paper (A.M.L.C. Bischoff et al., unpublished data).
4.5.2 Linkage analysis
DNA was isolated from peripheral blood according to Miller et al. (1988). Analysis of 
microsatellite markers was performed as described by Kremer et al. (1996). Two-point 
lod scores were calculated with the MLINK subroutine of the LINKAGE package version 
5.1 (Lathrop and Lalouel 1984, Lathrop et al. 1984, 1986). A penetrance of 0.95, a 
disease allele frequency of 0.0001 and a phenocopy rate of 0.001 were assumed for 
the calculations.
4.5.3 Mutation analysis
All 49 exons and exon-intron boundaries of the MYO7A gene were amplified by using 
standard polymerase chain reaction (PCR) conditions and were completely sequenced. 
The primer sequences are given in table 2 and the precise PCR conditions are 
available from the authors upon request. Prior to sequencing, PCR fragments were 
purified with the QIAquick gel extraction kit (Qiagen). Sequence analysis was performed 
with the ABI PRISM Big Dye Terminator cycle sequencing V2.0 ready reaction kit 
and an ABI PRISM 3700 DNA analyzer (Applied Bio systems). The sequences were 
compared with the known sequence (GenBank accession no. NM_000260). The 
presence of the mutation was tested in 300 ethnically matched control individuals 
with the amplificationrefractory mutation system (ARMS; Newton et al. 1989) and 
primers: 5′-TTGAGCAGCTCTGCATCAACTTCGCCGT-3′ (MYO7A mutant forward), 
5′-TTGAGCAGCTCTGCATCAACTTCGCCGA-3′ (MYO7A wild-type forward) and 5′-
acttgctctcctcatcgatgagggagat-3′ (MYO7A ARMS reverse). The ARMS reaction was 
performed with the standard protocol described by Newton et al. (1989), at an annealing 
temperature of 62°C and a final concentration of 2.5 mM MgCl2.
4.5.4 Molecular modelling of human myosin VIIA
The sequence of human myosin VIIA (Swissprot ID MY7A_HUMAN) was submitted 
to the 3D-PSSM-fold recognition server (Kelley et al. 2000), which identified four 
homologues of known structure with E-values below 0.1 (PDB IDs 1BR1, 1I84, 1B7T 
and 1G8X). Molecular models for all four alignments were built with WHAT IF (Vriend 
1990) and refined with YASARA (Krieger et al. 2002). Validation of the models with 
WHAT_CHECK (Hooft et al. 1996) identified template 1G8X, the myosin II heavy chain 
from Dictyostelium discoideum solved at a resolution of 2.8 Å (Kliche et al. 2001), as the 
best choice. The model covers the myosin head domain from residue Val2 to Gln752; a 
coordinate file is available from the authors upon request.
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Table 1 Oligonucleotides flanking MYO7A exons. Sequences (5’-3’) of forward and reverse 
primers.
Exon Forward 
primer
Code
Sequence
Reverse 
primer
Code
Sequence
1 6889 GAGAAGGCTCTGGAGTGAGG 6890 GCAGAGGCTCTAGAGGTAGC
2 6891 CAAGGAGGGTTCCCTTGAG 6892 CATATGGATGAGGGGATATGG
3 6893 ATATAGGGCTGCCTGGAAGG 6894 TTCGATCATCTCCCTGCATC
4 689 AGAGAGGTCGAGGCCCTTAC 6896 CACAGCGGACAAAGTCTCAG
 6897 GTCTCCCACATGGAATCAGC 6898 CGCACAGTTGGAGCTCTAGG
6-7 6899 GAGTCCCTGTGGGTTGTGAC 6900 AGCAATACGGGCAGCAATAC
8 6901 TAGTTCCTGATGGCCTCCTC 6902 TAGCCAGCTCCCTACAATCC
9 6903 GGTACACTGACGTCCTCTTGC 6904 AAACTGAGCTGCCAATACCAC
10 690 TCTTAGGACTGTCCCCTTGC 6906 CCCAGCAATGTGGTTCCTAC
11 6907 ATCCGGGTGTGGGTGGAG 6908 AACTTCCCAAGGGGTAGGG
12 6909 GTTCCACACAAGGGCTGGAG 6910 CTTATTTCCATATTGGGGAAGG
13 6911 CTTGCTAATGGCCATGCTG 6912 AAAGCAGGGAAGGAAGCTG
14 6913 GAGAGGGTGGGCTCACAG 6914 TATTCCTGGGCTGGAGCAG
1 691 CCAGAGCTGGTGAGAGGTG 6916 GCTGAAGCTGTTGGACAAGG
16 6917 TCCTGGGACACTGGATGG 6918 CTCCACGTCACCCTAGCC
17 6919 GTGGACTTGGCCTTTCTGAG 6920 AAGAAAATTGGGACCCTTGC
18 6921 GAAGAGCCCTGCCTCTCAG 6922 GCCCACATCATGGGAATTTAC
19 6923 TCCCAGTGAAGGAAGAGCAG 6924 CCAAACACCACACGTACACC
20 692 ATCCCAAACCCACCTGTACC 6926 AGCAAGGCTGGGTTCAAAG
21 6777 AGTCTGGAATGGGACAGCAG 6778 CTGTGGGTGCTATGGACTTG
22 6682 CCCTGCAACAACAGCTACAC 6683 ACCGGGTGACAGATGAGAAG
23 6779 GACCCCGTGTCTTCTGTGTC 6780 ACACAAGCGGTGTGTGTGG
24 6781 GATCCTCCCACCTGAGCTTC 6782 CCCACCACCCTCATCACTAC
2 6783 CGCCAGGTCATTTTGACAG 6784 GGGAGGGACATCATCCAGAG
26 6927 GCTTTCTGCTCAGCCACTTG 6928 AGTGTCCACTCCTGCTCCTG
27 6929 GGGAACACCCCTAACTTTACC 6930 TTGACAGAGGCACCACTCAG
28 6931 TTGGAGAGGACAGCTGTGTG 6932 ATGGGGCTCAGTAAGGAGTG
29 6933 GCTGCCCTCAAAATCCAC 6934 CACACACGCATTTACACACG
30 693 AGCAGAGAGCCAAAGTCCAG 6936 GTGCTCAAGGGTGAATAGCC
31 6937 GTCCTTCCCTGACTCTGTGC 6938 CTCACAGAGGAGCACTCAGC
32 6939 AGCCTTTGGTGGTGTGGAAG 6940 TCAGGTCCACATCCCTTCTC
33 6941 GCAGCAGCAGCTGATTTTTAG 6942 GCTGGAGCTACAGAGCAAGG
34 6943 GAAATCAGTGTATTGCCACCTG 6944 CTCTCCTTCCCCTCTGTCTG
3 694 ACTGGTTGGGGCATGACTG 6946 AGTCTGCATAACACCCTGACC
36 6947 TCCAACTCAGCCTGTCTCTG 6948 GGACAAAGAGGGGTCTAATGG
37 6949 TGGTGGCCACAGGTAGAGAG 690 GACCAGACAGTAGCGGAAGC
38 691 CACAACCTGGGGGTTTCTC 692 AGGCAGTGTGCAGACGAAG
39 693 CCAGTGCTCCCTCTATTCG 694 TCACAGCAGGTGAGGTCTG
40 69 AGGTCCTGTGACTCCCGATG 696 AAGGGGCTCATCCCACAAG
41 697 GGATCAGAACTGGGGTTGTC 698 GAGGCTTAAGGCCACCTTTG
42 699 ATAGGAGGCATAGCCAGAGG 6960 CCCCCAGTTCCTCTCTCTTC
43-44 6961 GGGAAGGTCAGAAAATGCAG 6962 TTTCAGGGCCAAAGTACAGC
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4 6963 GTCTTGGTGTGGTGGGAAAG 6964 GCGGCCTCATCAAGTACAAG
46 696 GGAGGTCGGGAGTCCATTAG 6966 TGCTTTATCAATGCCCTGTTC
47 6967 CCCAAATGCTTTTCTTGCTC 6968 TGTCTGTGGTTCAGGCAGAG
48 6969 CTTCTGTGAGGGCATGTGTG 6970 CGCACACTACTGTGTTTGTTCC
49 6971 CTGGGAGCTGTGCTATGGTC 6972 CAGTCCCTTCGGTTTCAGAG
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5.1 Abstract
Usher syndrome type II (USH2) is a genetically heterogeneous autosomal recessive 
disorder with at least three genetic subtypes (USH2A, USH2B, and USH2C) and is 
classified phenotypically as congenital hearing loss and progressive retinitis pigmentosa. 
The VLGR1 (MASS1) gene in the 5q14.3-q21.1 USH2C locus was considered a likely 
candidate on the basis of its protein motif structure and expressed-sequence-tag 
representation from both cochlear and retinal subtracted libraries. Denaturing high-
performance liquid chromatography and direct sequencing of polymerase-chain-reaction 
products amplified from 10 genetically independent patients with USH2C and 156 other 
patients with USH2 identified four isoform-specific VLGR1 mutations (Q2301X, I2906FS, 
M2931FS, and T6244X) from three families with USH2C, as well as two sporadic cases. 
All patients with VLGR1 mutations are female, a significant deviation from random 
expectations. The ligand(s) for the VLGR1 protein is unknown, but on the basis of its 
potential extracellular and intracellular protein-protein interaction domains and its wide 
mRNA expression profile, it is probable that VLGR1 serves diverse cellular and signalling 
processes. VLGR1 mutations have been previously identified in both humans and mice 
and are associated with a reflex-seizure phenotype in both species. The identification 
of additional VLGR1 mutations to test whether a phenotype/genotype correlation exists, 
akin to that shown for other Usher syndrome disease genes, is warranted.
5.2 Introduction, results, discussion, materials, and methods
Usher syndrome is a clinically and genetically heterogeneous recessive disease with 
three clinical subtypes. The subtypes are differentiated on the basis of the severity of 
hearing loss and presence or absence of vestibular abnormalities. Patients with Usher 
syndrome type I (USH1) present with profound congenital hearing loss, vestibular areflexia 
(in most cases), and a progressive retinal degeneration, with impaired night vision and 
decreased visual fields diagnosed as retinitis pigmentosa (RP). Usher syndrome type 
II (USH2 [MIM 276900]) have a moderate-to-severe sensorineural hearing loss that is 
stable in most cases, normal vestibular function, and RP, whereas patients with type 
III (USH3) present a moderate sensorineural hearing loss with progression to acquired 
deafness, progressive vestibular dysfunction, and RP. Currently, 11 loci have been 
identified for Usher syndrome (Kimberling et al. 1990, 1992, Kaplan et al. 1992, Smith 
et al. 1992, Sankila et al. 1995, Wayne et al. 1996, 1997, Chaib et al. 1997, Hmani et 
al. 1999, Pieke-Dahl et al. 2000, Mustapha et al. 2002); families that do not link to the 
known loci indicate additional genes exist. Of the 11 loci, 7 genes have been found with 
Usher syndrome mutations (Weil et al. 1995, 2003, Eudy et al. 1998, Bitner-Glindzicz et 
al. 2000, Verpy et al. 2000, Ahmed et al. 2001, Alagramam et al. 2001, Bolz et al. 2001, 
Bork et al. 2001, Joensuu et al. 2001). 
Previously, we had localized the USH2C gene to a 20-cM region on chromosome 
5q14.3-5q21.1 (Pieke-Dahl et al. 2000). Reference mRNAs in this linkage interval were 
obtained from the UCSC Genome BrowserWeb site and were prioritised for candidate-
gene mutation screening. The very large G-coupled receptor gene (VLGR1) was 
considered a likely USH2C candidate (Burgess 2001, Staub et al. 2002), with EST 
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representation in both human fetal retina and cochlea (obtained from the National 
Eye Institute Gene Bank Web site) subtracted libraries. Use of the conserved domain 
architecture retrieval (CDART) tool on VLGR1 (Geer et al. 2002) revealed a motif 
architecture similar to the cadherin superfamily of integral membrane proteins. This 
superfamily includes CDH23 and PCDH15, which are the genes mutated in USH1D (MIM 
601067) and USH1F (MIM 602083), respectively. In addition, VLGR1 and the USH2A 
gene product usherin exhibit a high degree of similarity in their respective pentraxin 
(PTX) homology domains. On the basis of this evidence, we sought to implicate the 
VLGR1 gene in the pathogenesis of USH2.
Denaturing high-performance liquid chromatography (DHPLC) and direct 
sequencing were used to detect mutations in PCR-amplified genomic DNA from 10 
probands with USH2C (MIM 605472) for 90 VLGR1 exons. The 10 affected probands 
were members of families consistent with genetic linkage to 5q14-21 (Pieke-Dahl et 
al. 2000). We had previously obtained informed consent and had extracted DNA from 
peripheral whole blood of the study subjects according to standard conditions (Puregene). 
Patients with a clinical diagnosis of USH2 were ascertained through physician referral 
and self-referral. The study was conducted with the approval of the Boys Town National 
Research Hospital (BTNRH) institutional review board and met all ethical requirements 
and Health Insurance Portability and Accountability Act (HIPAA) standards. DNAs from 
an additional 152 unrelated patients with USH2 without an identifiable USH2A mutation 
on chromosome 1q41 were used to screen for specific VLGR1 mutations identified 
from either the mutation screen of the 10 probands with USH2C or from those VLGR1 
mutations reported elsewhere (Nakayama et al. 2002).
Genomic VLGR1 PCR primer pairs were designed and synthesized commercially 
(sequences available upon request [Integrated DNA Technologies]). PCR used 20 ng 
genomic DNA, 0.2 μM primer, 2.5 mM MgCl2, 200 μM dNTP, in 1X PCR buffer with 
0.5 units AmpliTaqGold (PE Biosystems) in 25 μl total volume. The initial PCR cycle 
was 95ºC for 8 min and 30 sec, followed by 40 cycles of 95ºC for 30 sec, 55ºC for 30 
sec, and 72ºC for 1 min, with a final step of 70ºC for 10 min. BAC clones spanning the 
VLGR1 genomic interval (CTD-2034A10, exons 1-4; RP11-29K14, exons 2-42; RP11-
62E10, exons 18-73; RP11-3B6, exons 51-83; CTD-2001K4, exons 84 and 85; CTD-
2266L18, exons 86 and 87; RP11- 414H23, exons 88-90) were identified and used as 
a control template to evaluate PCR-product heteroduplexes that were separated by 
DHPLC; these clones were also used in direct PCR sequence analysis.
Table 2.  VLGR1 DNA variants including pathologic USH2C mutations (italicized).  
BTNRH Frequency
Exon Name Codon USH2C USH2Aa Controls SNP DB Reference
4 380T>G L127R 1/20
7 746G>A R249Kb 1/20 0/188
9 IVS9+54C>T 4/20
10 IVS10+53delA 4/20
12-13 IVS11-19G>T 4/20 1344030 Nakayama et al. 2002
12-13 IVS12+8C>T 3/20 2366773 Nakayama et al. 2002
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BTNRH Frequency
Exon Name Codon USH2C USH2Aa Controls SNP DB Reference
1 IVS14-34C>G 4/20 Nakayama et al. 2002
17 3141A>G A1047A 3/20 90692 Nakayama et al. 2002
17 3279G>T L1093F /20 2366777 Nakayama et al. 2002
22 IVS22+87T>A 6/20 1028191
Ac IVS22 +234A>G 6/20 1028192
Ac IVS22+244A>G 1/20
24 5304G>A E1768E 1/20 1/190
Bc IVS25+780C>T 3/20
28 IVS27-23T>C /20 Nakayama et al. 2002
28 5780C>T T1927M 1/20
28 5851A>G I191V /20 Nakayama et al. 2002
28 5953A>G N1985D 3/20 Nakayama et al. 2002
28 5960C>T P1987L /20 Nakayama et al. 2002
28 6012G>T L2004F 3/20 20/170 Nakayama et al. 2002
30 6695A>G Y2232C 6/20 36/144 Nakayama et al. 2002
31 6901C>T Q2301X 1/20 3/282 0/190
32 IVS31-10G>A 8/20 Nakayama et al. 2002
32 c.7034A>G N234S 8/20 2366926 Nakayama et al. 2002
33 7135G>A G2379A 0/20 1/190
33 7155G>T L238L 0/20 1/190
33 7176C>T S2392Sd 1/20 0/190
33 7179C>T D2393D 0/20 2/190
33 7206G>A E2402E /20 69/190 Nakayama et al. 2002
33 7751G>A S284N /20 1878878 Nakayama et al. 2002
33 IVS33+27A>C 7/20
34 IVS34+82T>C 6/20
36 IVS35-60G>A 0/20 1/190
36 8291C>T S2764L 1/20 6/190 Nakayama et al. 2002
37 8495C>A S2832X 0/20 0/276 Nakayama et al. 2002
37 8407G>A A2803T 1/20 1/190
37 8538T>G L2846L 4/20 21/190 Nakayama et al. 2002
38 IVS37-60G>T 6/20 1160121
38 IVS37-13C>T 0/20 1/28e Nakayama et al. 2002
38 8716-17insAACA I2906FS 1/20 0/276 0/190
38 IVS38+10insT 6/20
39 8790delC M2931FS 1/20 0/280 0/190
39 ISV39+50A>C 1/20 6/190
41 IVS41+57C>T 2/20
4 9650C>T A3217V 1/20 3/190
4 9743G>A G3248D 4/20 21/190
47 IVS46-35C>A 6/20
47 9927T>G P3309P 8/20
48 IVS48+26G>T 6/20
49 10411G>A E3471K 3/20 2366928
1 10577T>C M326T 1/20 3/182
1 IVS51+9A>G 0/20 2/182
6 IVS55-3insC 8/20 90/190
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BTNRH Frequency
Exon Name Codon USH2C USH2Aa Controls SNP DB Reference
6 11599G>A E3867K 8/20 7/190
6 11682C>T P3894P 8/20 92/190 2438349
9 12269C>A T4090Nf 1/20 0/166
64 IVS63-36A>T 2/20 19/190
64 IVS63-31C>T 2/20 6/190
67 13590C>T P430P 2/20 3/18
67 13599A>G T433T 3/20 29/18
74 15987C>T Y5329Yg 1/20 0/190
74 16031G>A G344E 0/20 4/190 2438374
76 IVS75-15G>Ah 1/20 0/190
76 16248C>T V416V 0/20 3/190
76 16312A>G T438G 0/20 1/190
82 17626A>G I876V /20 2247870
88 IVS87 complexi 3/20 34/190
Cc IVS24a+1G>A 6/20 0/192
89 IVS88-7T>C 3/20 12/192
89 18732-18750delj Y6244X 1/20 0/282 0/190
89 18741G>A G6247G 0/20 23/192
89 ISV89+44C>G 0/20 1/40e
a Cohort of 152 USH2 patients negative for identified mutations in the USH2A gene, 11 samples 
failed amplification consistently due to poor template quality.  
b Conservative missense mutation in cis (paternal) with Q2301X mutation in family 1848.  
c Alternative exons based on EST evidence.  
d Isocoding mutation in cis (maternal) with I2906FS mutation in family 1848.  
e Variant frequency identified from direct sequence of PCR products chosen to identify a distinct 
DHPLC positive variant.  
f Conservative missense mutation disrupts a potential N-glycosylation site within the 27th CalX-β 
motif. 
g Isocoding mutation in cis (paternal) with Q2301X mutation in family 1848.  
h IVS mutation increases the potential of a cryptic splice site donor cite.  Pathology unknown.  In 
cis (paternal) with an undetected USH2C mutation in family #964.  
i IVS87 33:(CTTTT)4(T)9GCAG>IVS87-31(CTTTT)3(T)12GCAG.  
j Deletion is TGGCCAGGGGTCACTGATA.  
Three human VLGR1 mRNA isoforms are expressed (VLGR1a, VLGR1b, 
and VLGR1c), of which only VLGR1b and VLGR1c isoforms are expressed in mouse 
(McMillan et al. 2002) (fig. 2). Of 72 nucleotide changes discovered in VLGR1 (table 1), 
4 mutations would prematurely terminate VLGR1a and VLGR1b protein translation (fig. 
1). The VLGR1 6901C>T (Q2301X) and 8716-17insAACA (I2906FS) mutations were 
found in repulsion exclusively in the members of family 1848 who were affected with 
USH2C (fig. 1a and 1c). Family 964 (with USH2C) was found to segregate a maternal 
VLGR1 8790delC (M2931FS) mutation (fig. 1b). A paternal 19-bp deletion (18732-
18750del19bp; T6244X) segregates appropriately with the phenotype in family 735 (fig. 
1d). Families 735 and 964 have been shown elsewhere to genetically link to the 5q14.3-
q21 region, with all affected siblings sharing family-specific 5q 14.3-q21 haplotypes 
Chapter 5
121
(Pieke-Dahl et al. 2000). No other potential VLGR1 variant was found associated with 
the maternal allele of family 735; however, a paternal IVS75-15G>A mutation absent 
in 190 control chromosomes was found segregating with the phenotype in family 
964 (data not shown). It remains to be determined whether and how IVS75-15G>A 
affects VLGR1 expression. Screening for USH2C mutations in 152 patients with USH2 
revealed the Q2301X mutation in two other unrelated patients with sporadic USH2. 
Table 2 presents a clinical summary of all patients with USH2C who harbour VLGR1 
mutations. A total of five independent probands with USH2 and eight affected siblings 
were found to bear pathological VLGR1 mutations. Two probands have pathological 
mutations identified in both alleles; three occult mutant alleles either have escaped 
detection by the methodology employed, lie in unscreened regions of the gene, or 
have been detected but not appreciated as disease alleles. None of the four VLGR1 
mutations was observed in 190 control chromosomes. These results establish VLGR1 
as the USH2C gene and implicate the protein, which is the largest cell surface receptor 
known (McMillan et al. 2002), in the pathogenesis of USH2.
Because the USH2 phenotype manifests cochlear and retinal defects, we 
wanted to determine if any of the three VLGR1 isoforms were tissue specific in these 
organs (fig. 3a and 3b). We performed semiquantitative RT-PCR by use of total RNA 
isolated from nine human fetal tissues. Primer pairs for the human isoforms VLGR1a, 
VLGR1b, and VLGR1c have been described elsewhere (McMillan et al. 2002). Total 
RNA from three human tissues (fetal brain, fetal liver, and placenta) was purchased 
from Clontech. For cDNA synthesis, total RNA was treated with DNase I (Invitrogen), 
according to the manufacturer’s conditions, and random-primed in a volume of 250 μl 
from 3.1 μg total RNA using 4 pmol random hexanucleotides, 10 mM Tris-HCl, pH 8.3, 
50 mM KCl, 0.01% (v/w) gelatin, 5 mM MgCl2, 1 mM DTT, 95 U RNAguard (Pharmacia), 
and 2,500 U MMLV reverse transcriptase (Invitrogen). Semiquantitative RT-PCRs were 
performed by sampling 50 μl RT-PCR reactions at the 25th, 30th, 35th, and 40th cycle. 
PCR reactions included 87 ng of randomly primed cDNA, 11.2 pmol of each primer, 
10 mM Tris-HCl, pH 8.3, 50 mM KCl, 0.01% gelatin, 2.5-3 mM MgCl2, 160 mM of each 
dNTP, and 1.7 U Taq DNA polymerase (Invitrogen) under the following conditions: 
92ºC for 4 min, followed by 40 cycles of 95ºC for 30 sec, 50ºC / 55ºC for 30 sec, and 
72ºC for 1 min, with a final step at 72ºC for 10 min. RT-PCR results show expression of 
all three VLGR1 isoforms from fetal retina and cochlea, confirming the EST expression 
profile of VLGR1. High relative expression in fetal brain and spinal cord confirms 
the neuronal expression of VLGR1 (McMillan et al. 2002) (fig. 3a and 3b). Although 
there appears to be a consistent difference in the amount of VLGR1a, VLGR1b, and 
VLGR1c RT-PCR products amplified from different tissues, no apparent tissue-specific 
differences in the relative abundance between the three isoforms was seen in any of 
the fetal tissues tested (fig. 3a and 3b). In addition, we find the relative amount of the 
VLGR1a and VLGR1b isoforms to be roughly equal as judged by RT-PCR, which is in 
contrast to an approximately fourfold difference in expression of the VLGR1b isoform 
over the VLGR1a isoform previously observed in human fetal kidney, brain, and lung 
(McMillan et al. 2002). One explanation for this disparity could be the way the RT-PCR 
of the VLGR1a and VLGR1b isoforms was performed, as the study by McMillan et 
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al. (2002) amplified VLGR1a and VLGR1b in multiplex, whereas we chose to amplify 
them in separate reactions because of a significant difference in the TMs of the sense 
primers. 
Figure 1. Segregation of VLGR1 mutations Q2301X, M2931FS, I2906FS, and T6244X in families 
735, 964, and 1848 (with USH2C). (A) Paternal inheritance of Q2301X in family 1848 is shown 
by agarose-gel electrophoresis of exon 31 PCR product XmnI digests. Q2301X mutation is a 
6901 C>T transition, 33 bp on the 3’ end of the alternate exon 31 splice donor, affecting only 
the VLGR1b mRNA isoform (fig. 2a). Shown here are sequence electropherograms from the 
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heterozygous family 1848 proband (HET), an apparent Q2301X homozygote, and wild-type 
(WT) BAC clone RP11-29K14, with sequence and amino acid translation differences (arrows). 
The Q2301X homozygote was the result of a brother-sister incestuous union, whereas another 
singleton case was a Q2301X/occult heterozygote (data not shown; table 2). (B) Maternal 
inheritance of M2931FS in family 964 is shown by agarose-gel electrophoresis of exon 39 PCR 
product NcoI digests. Sequence electropherograms of the WT and the cloned M2931FS allele 
show 8790delC in exon 39 (arrows). This deletion causes a 10-codon frameshift. ending with a 
TAG stop encoded by the last 3 bases of exon 39, affecting VLGR1b. (C) Maternal inheritance 
of I2906FS in family 1848 by DHPLC of exon 38 PCR products. Sequence comparison of the 
cloned I2906FS mutation shows an 8716-17insAACA (arrows) causing a frameshift of 5 codons 
and ending with a TGA stop 1 bp short of the 3_ end of exon 38, affecting VLGR1b. (D) Paternal 
inheritance of Y6244X detected by DHPLC of exon 89 PCR products. A 19-bp deletion brings a 
TAG stop codon immediately in-frame. Y6244X removes 63 amino acids from the COOH end of 
VLGR1a and VLGR1b. The putative maternal and paternal mutations in family 735 and family 964 
have not been identified.
Table 2. Clinical summary of patients with USH2C harbouring VLGR1 mutations
Family 
no. 
Individual 
no.
Severity of
hearing loss
Age at RP 
diagnosis
(years)
Sex RP 
symptoms
VLGR mutation(s)
73a 1 Moderate-severe 27b Female Typical T62244X/occult
 Moderate-severe 2 Female NA T62244X/occult
6 Moderate-severe 20 Female NA T62244X/occult
7c Moderate-severe 19 Female NA T62244X/occult
964d 1 Moderate-severe 24 Female Typical M2931FS/occult
3 Moderate-severe 21 Female Typical M2931FS/occult
4 Moderate-severe 33 Female Mild M2931FS/occult
1127 1 Moderate-severe 42 Female Typical Q2301X/occult
1848a 1 Moderate-severe 32b Female NA Q2301X/I2906FS
2 NA 29 Female NA Q2301X/I2906FS
3 NA 29 Female NA Q2301X/I2906FS
4 NA 21 Female NA Q2301X/I2906FS
2684e 1 Moderate-severe 17 Female NA Q2301X/Q2301X
NA: p not available.
a United States, country of origin.
b The RP diagnosis in the oldest child led to the earlier age at RP diagnosis in the other siblings.
c Reported that loud sounds caused nausea and, occasionally, dizziness.
d Sweden, country of origin.
e Consanguineous.
The VLGR1b and VLGR1c isoforms differ by 83 bp as a result of the alternative 
exon 31 donor splicing (Skradski et al. 2001, McMillan et al. 2002). A mouse Vlgr1 
mutation in exon 31 (7009delG; 2250FS) is responsible for the monogenic audiogenic 
seizure susceptible (MASS) phenotype (Skradski et al. 2001). The Vlgr17009delG (Vlgr1Mass1) 
mouse allele mutates both mouse Vlgr1b and Vlgr1c splice isoforms, whereas the human 
exon 31 VLGR1 mutation (Q2301X), in addition to the other three USH2C mutations, 
affects VLGR1b (fig. 2 and 3). To determine if species-specific differences in the 
VLGR1b and VLGR1c isoforms might help to explain the VLGR1 mutant phenotypes, 
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RT-PCR of VLGR1 band VLGR1c isoforms from mouse and human fetal RNA was 
performed. For RT-PCR of the VLGR1b and VLGR1c isoforms, random-primed total 
mRNA from human and mouse fetal brain RNA (Clonetech) was reverse transcribed with 
Superscript III (Invitrogen), according to standard conditions, and PCR with AmpliTaq 
Gold (PE Biosystems) was as described for genomic PCR amplification, except that the 
amount of MgCl2 was 3.0 mM. Amplification primers for the mouse Vlgr1b and Vlgr1c 
isoforms were as follows: sense 5’-CGAACTGGAGGAACATTTGCAG-3’ and antisense 
5’-GCAGACACGTTCACCCAAGTTC-3’. Cloning and sequencing of VLGR1b and 
VLGR1c RT-PCR products from both human and mouse confirm the evolutionarily 
conservation of the alternative exon 31 splice donor sites in both species (data not 
shown). It is not surprising that, although the VLGR1b messages of human and mouse 
share 81% sequence identity overall, the last 113 bp of exon 31 are 100% conserved 
at the DNA level, indicating that the sequence context of the mRNA in this region is 
critically important, perhaps defining a critical cis element necessary for alternative 
mRNA processing. A comparison of RT-PCR products from fetal human and mouse 
brain revealed a difference in the relative abundance of VLGR1b and VLGR1c isoforms, 
indicating a species-specific difference in mRNA processing through the alternative 
exon 31 donor sites (fig. 3c). These results suggest that isoform-specific mutations in 
VLGR1, either alone or in combination with a specific difference in mRNA processing, 
may underlie the manifestation of phenotype in these species.
In situ hybridisation of mouse embryo sections had shown Vlgr1 expression 
concentrated in the ventricular zone where neural progenitor cells reside during 
embryonic neurogenesis, suggesting that the Vlgr1b and Vlgr1c isoforms play a role in 
the development of the murine CNS (McMillan et al. 2002). This idea is strengthened 
by the association of the MASS phenotype with the Vlgr1 mutant allele (Skradski et al. 
2001). The Vlgr1 mouse ortholog includes in its open reading frame three additional 
and distinct mRNAs previously characterized as isoforms of the mouse Mass1 gene 
(Mass1.1, Mass1.2, and Mass1.3) on mouse chromosome 13 (Skradski et al. 2001) (fig. 
2). The Frings mouse has not been reported to have deficient hearing or vision; however, 
no histological or electrophysiological data have been published that explicitly rule out 
such possibilities. In addition to Frings, the BUB/BnJ inbred mouse was also found to 
be a Vlgr1Mass1 homozygote, and it exhibits the MASS phenotype until a progressive 
age-related hearing loss phenotype manifests in this strain by 3 wk of age (Skradski et 
al. 2001). BUB/BnJ is one of several inbred mouse strains exhibiting AHL (Zheng et al. 
1999). The variable severity and progression of hearing loss in many AHL mouse strains, 
including BUB/BnJ, is influenced by a major modifier locus on mouse chromosome 10 
(ahl, also the modifier-of-deaf-waddler locus, mdfw). Both ahl and mdfw are caused 
by the Cdh23753G>A splicing mutation, a synonymous transition of the last nucleotide 
of exon 7 (Noben-Trauth et al. 2003). It remains to be determined if the early onset of 
hearing loss in BUB/BnJ is influenced by the Vlgr1Mass1 mutation, as has been shown 
for other AHL “accelerating alleles” in combination with Cdh23753A (Noben-Trauth et al. 
2003). It should be noted that BUB/BnJ is also homozygous for rd1, a mutation in the 
Pde6b gene that results in early photoreceptor-cell apoptosis because of a lack of cGMP 
phosphodiesterase activity. The fact that BUB/BnJ carries homozygous mutations in 
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Pde6b (rd1), Cdh23 (ahl, mdfw), and Vlgr1 (Mass1) suggests caution should be used in 
interpreting the phenotypic effects of these genes in this mouse strain.
Figure 2. Domain structure of VLGR1/MASS1 isoforms. Conceptual translation of VLGR1b 
mRNA reveals a protein with a large ectodomain with 35 Calx-b domains, 1 LamG/TspN/PTX 
homology domain (Beckmann et al. 1998), 7 EAR/EPTP repeats forming a putative b-propeller 
folding domain (Scheel et al. 2002, Staub et al. 2002), a GPS, a B-family 7TM domain, a putative 
intracellular tail with multiple potential serine phosphorylation sites, and a putative PDZ-binding 
COOH-terminal end (McMillan et al. 2002). The PTX domains of VLGR1 and the USH2A protein 
usherin are most similar to one another, with a BLASTP score of 2e-09. The locations of human 
USH2C (grey) and febrile-seizure (FS)-associated mutations are shown on VLGR1a, VLGR1b, 
and VLGR1c isoforms. The mouse audiogenic reflex seizure model Frings and the age-related 
hearing loss model BUB/BnJ are both homozygous for the V2250FS mutation and are noted on 
Mass1.1, Mass1.2, and Mass1.3 isoforms (Skradski et al. 2001).
 The VLGR1 protein belongs to a 33-member subgroup of the large N-terminal 
family B (LNB) seven transmembrane (7TM) receptors. Of the 33 LNB 7TM members, 
32 are orphan receptors and only a few have demonstrated specific G-protein signaling 
(Foord et al. 2002). All LNB 7TM members, including VLGR1, have a G-protein-coupled 
proteolysis site (GPS); cleavage at this site is thought to be a requirement for the proper 
expression of this class of 7TM receptors on the cell surface (Krasnoperov et al. 2002). 
VLGR1 may function, like other LNB 7TM members, as a natural protein chimera, with an 
extracellular cell-adhesion subunit and a canonical G-protein-coupled receptor subunit 
that are linked by noncovalent interactions (Krasnoperov et al. 2002). The possible 
function of VLGR1 might be best explored by trying to predict the functions of the two 
putative subunits separately.
The C-terminal residues of VLGR1 correspond to the consensus motif that is 
recognized as a ligand for the class I subfamily of PDZ domains (PDZ-binding interface 
[PBI] [Nikkila et al. 2000, Hung and Sheng 2002]). Interestingly, the C-termini of cadherin 
23, protocadherin 15, harmonin, and SANS, all proteins with mutations that cause 
the USH1 phenotype, have class I PBIs. An interaction through the 2nd PDZ domain 
of harmonin and the C-terminal PBI ligand of cadherin 23 has been independently 
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confirmed (Boëda et al. 2002, Siemens et al. 2002). Colocalisation of harmonin and 
SANS in transfected HeLa cells suggests that these proteins also interact, perhaps 
through a PDZ-PBI interaction (Weil et al. 2003). The fact that all USH1 protein mouse 
mutants, including the nonmuscle myosin VIIa, which also has a protein interaction 
with harmonin, phenotypically present with defects in hair cell stereocilia development 
suggests that these proteins function as a macromolecular complex necessary to shape 
and maintain the stereocilia as an organized cohesive unit (Boëda et al. 2002, Siemens 
et al. 2002, Weil et al. 2003). It remains to be determined whether one or more of the 
three PDZ domains of harmonin, or other PDZ domain-bearing protein, have a high-
affinity interaction with the PBI of VLGR1.
The very large extracellular portion of VLGR1b has a total of 35 CalX-β modules 
(fig. 2), named for the homology shared between the regulatory domains of Na+/Ca2+ 
exchanger proteins and the cytoplasmic portion of integrin-β4 (Schwarz and Benzer 
1997, McMillan et al. 2002). Portions of the extracellular domain of VLGR1a that 
include a subset of the CalX-β domains bind Ca2+ and other cations (Nikkila et al. 2000). 
Because of the extensive CalX-β modules, one might postulate that the molecule acts 
as an extracellular Ca2+ sink, as an extracellular Ca2+ monitor sensitive to the regulation 
of intra- and extracellular Ca2+ trafficking, or in Ca2+-dependent cell adhesion. Disruption 
of normal Ca2+ metabolism is known to affect both hearing and vision. For example, 
mutations in the plasma membrane Ca2+ ATPase pump Atp2b2 (PMCA2) cause the 
deaf waddler (dfw) phenotype in mice (Kozel et al. 1998, Street et al. 1998). It has been 
postulated that the murine ahl gene (mdfw, Cdh23753A) acts epistatically to cause an 
age-dependent hearing loss through an interaction between the Ca2+-extruding PMCA2 
channel and the calcium-dependent homotypic cell-adhesion properties of the cadherin 
23 protein (Noben-Trauth et al. 1997, 2003). Furthermore, a functional interaction has 
been postulated between PMCA2 and the sodium bicarbonate cotransporter, NBC3, at 
the photoreceptor synapse, as the loss of H+ buffering by NBC3 causes retinal dystrophy 
(and hearing loss) in NBC3 knock-out mice (Bok et al. 2003). The possibility that calcium 
homeostasis is involved in USH2C is especially intriguing in light of the observation that 
the Ca2+-channel-blocking drug, diltiazem, is protective against noise-induced hearing 
loss (Maurer et al. 1998, Heinrich et al. 1999). However, there is conflicting evidence 
about whether diltiazem is neuroprotective for the retina, since none of the animal 
models tested had RP resulting from a calcium metabolism defect (Frasson et al. 1999, 
Pasantes-Morales et al. 2002, Pawlyk et al. 2002). 
The large VLGR1b ectodomain has two recognized potential protein-interaction 
domains, LamG/TspN/PTX (Beckmann et al. 1998) and EAR/EPTP (Scheel et al. 2002, 
Staub et al. 2002) (fig. 2). It has been suggested that the multiple Ca2+-binding CalX-β 
modules may mediate the protein-protein interactions of these two domains (McMillan 
et al. 2002). The EAR/EPTP motif occurs as a repeated set of domains that together are 
postulated to form a seven-bladed-propeller structure that, in other proteins, acts as a 
highly specific receptor (Pons et al. 2003). Probable ligands for the  EAR/EPTP domain 
of VLGR1 would be extracellular or cell-adhesion proteins. Usherin, the product of the 
USH2A gene, is a known extracellular basement-membrane protein (Bhattacharya et 
al. 2002). When usherin is defective, the phenotype is remarkably similar to that seen 
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in patients with inactivated VLGR1. Immunolocalisation of usherin to the perinurium of 
the spiral ganglion cells of the cochlea (Bhattacharya et al. 2002) and the likely neuronal 
localization of the VLGR1 receptor indicates that VLGR1 and usherin may colocalise in 
specific subcellular compartments. Furthermore, the significant homology between the 
LamG/TspN/PTX motifs of VLGR1 (fig. 2) and usherin indicates that the two proteins 
may share an affinity for a common binding partner, reinforcing the hypothesis of an 
interaction between these proteins. Whether usherin is the extracellular ligand or 
another yet-to-be-identified USH2 protein remains to be established.
Figure 3. RT-PCR of VLGR1 mRNA splice forms from human and mouse fetal tissue. Human 
fetal tissues from left to right: eye (Ey), cochlea (Co), brain (Br), kidney (Ki), colon (Cl), stomach 
(St), lung (Lu), liver (Li), spinal cord (Cr), muscle (Mu), tongue (To), and adult placenta (Pl). 
(A) The relative locations of the human Q2301X and the Frings and BUB/BnJ mouse V2250FS 
mutations to the alternative donor site that differentiates the VLGR1b and VLGR1c splice isoforms. 
These isoforms differ by 83 bp because of the alternative use of a 5’ splicedonor site in exon 31 
(Skradski et al. 2001, McMillan et al. 2002). Expression from eye and cochlear tissue is less 
intense at 30 cycles of RT-PCR than from brain and spinal cord. At 40 cycles, all tissues but liver 
and placenta show VLGR1 expression of similar relative intensities for VLGR1c, compared with 
VLGR1b (fig. 2b; data not shown). (B) The location of the VLGR1a 5’ start site, relative to the exon 
65 3’ splice acceptor of VLGR1b. RT-PCR results at 30 cycles for VLGR1a and VLGR1b splice 
forms show a similar tissue distribution to that in figure 2a, as well as similar relative intensities. 
All RNAs were positive for D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (data not 
shown). (C) A comparison of VLGRb and VLGR1c concentration in human and mouse reveals a 
species-specific difference in the relative abundance of these isoforms, which were amplified from 
fetal brain mRNA, indicating a difference in the use of the alternate exon 31 donor sites between 
species.
Because VLGR1 is expressed as at least three different isoforms in the human, 
questions arise as to which of the isoforms is responsible for USH2C and, as a corollary, 
whether mutations involving other isoforms cause a different phenotype, especially a 
seizure disorder. The USH2C mutations we have observed all involve isoform VLGR1b, 
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but not isoform VLGR1c. The Frings mutation affects both VLGR1b and VLGR1c. We 
specifically asked all of the patients with USH2C in our study about seizures of any type 
and received uniformly negative responses. It is plausible to hypothesize that the Frings 
seizure disorder is primarily due to mutations affecting the VLGR1c isoform. Whether 
a functional protein is encoded by VLGR1c will be important in helping to determine 
whether the disparity in phenotype between human and mouse VLGR1 mutants are 
governed by species-specific differences in VLGR1 function, the inactivation of a subset 
of VLGR1 isoforms, or a combination of the two. The fact that the VLGR1 S2832X and 
S2764P mutations (isoform VLGR1b) segregate in families with both febrile and afebrile 
seizures (FEB4 [MIM 604352]) suggests a causal relationship between human seizures 
and VLGR1. But the relative low frequency of FEB4-associated mutations, the lack of 
a significant association between VLGR1 SNPs and FEB4, and the lack of any self-
reported seizure-related phenotype in our USH2C patients suggest that VLGR1b is not 
a significant contributor to any seizure disorder (Nakayama et al. 2002).
All 13 patients with USH2C and VLGR1 mutations are female, a highly significant 
deviation from expectation (P < .002, Fisher’s exact test). The biologic significance, 
if any, of this observation can only be speculated on. Although some selection bias 
could conceivably play a role, it is difficult to understand why the shift in sex ratio is 
so extreme. A likely explanation is that males are being excluded from the sample: the 
male phenotype might be more severe, possibly lethal; it could be associated with some 
other hearing-/vision-loss syndrome; or the phenotype could be very mild or nonexistent. 
Nonetheless, the possibility that an endocrine-based component could influence the 
Usher syndrome phenotype as a modifier of VLGR1 expression and/or protein function 
is intriguing. Mutations in VLGR1 do not seem to be responsible for a large proportion 
of the USH2 cases in our sample, despite the fact that the gene is large and one might 
have expected otherwise. The possibility of male lethality could explain the apparently 
low contribution of USH2C mutations to the total USH2 mutational load.
The discovery of USH2C-associated VLGR1 mutations poses several interesting 
and important questions regarding the etiology of USH2. Localization and functional 
studies, in addition to thorough genetic screening for additional VLGR1 mutations, will 
be needed to elucidate the role of VLGR1 in the development, maintenance, and function 
of vision and hearing. Furthermore, its capacity as a putative G-coupled receptor makes 
it a legitimate target in the search for possible therapeutics that may have a broad 
impact on all types of Usher syndrome.
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General Discussion
6.1 The value of a subtracted cochlea cDNA library
In chapter two the construction of a human fetal cochlea cDNA library with a subtraction 
suppressive hybridisation technique and the analysis of this cDNA library was described. 
In view of recent publications, some aspects of this study will be discussed. 
 Several cDNA libraries of the inner ear were constructed either with or without 
subtraction and/or enrichment. A comparison was made of the 46 most frequently 
represented known genes in the present library (table 2, chapter 2) with the known 
genes represented in the human foetal cochlea cDNA library analysed by Robertson et 
al. (1994) (http://hearing.bwh.harvard.edu/cochleacdnalibrary.htm), the organ of Corti 
cDNA library analysed by Pompeia et al. (2004) (http://neibank.nei.nih.gov), and the 
complete collection of inner ear derived ESTs in dbEST (http://neibank.nei.nih.gov). 
Thirty-five of these 46 genes were found to be represented in the Morton cDNA library, 
31 were found to be represented in the Pompeia organ of Corti cDNA library, 31 genes 
were found in the dbEST inner ear collection, and 21 genes were found to be represented 
in all of these libraries. Recently, the analysis of a cDNA library prepared with RNA from 
cartilage of 18 to 20 week old human foetuses was published (Krakow et al. 2003, 
Pogue et al. 2004). Of the 21 genes found in all cDNA collections described above five 
are also found in the cartilage cDNA library (Pogue et al. 2004). Only three genes from 
the cDNA library described in chapter 2, SNCA, PSEN1 and AS3, were not found in 
any of the above-mentioned cDNA collections. Whether the presence of these genes in 
our cDNA library has any functional significance is not clear. We can however conclude 
that the cochlea cDNA library that we constructed contains unique sequences that are 
not found in the other inner ear cDNA libraries. The frequency with which known genes 
were represented varies greatly between the different cDNA libraries which, among 
other reasons, is due to the different subtraction and/or enrichment procedures used to 
construct the libraries.
The RNA that we used for the construction of the cDNA library was extracted 
from 16 to 22 week old foetal cochleas. At this stage the cochlea is still developing (table 
1, chapter 1) and as expected, among the known genes represented there are several, 
e.g. DIO2, FGFR2, IGF1, and SOX9 that are involved in cochlear development as 
described in chapter one. Genes involved in nonsyndromic hearing loss that are found 
in the library include ACTG1, COCH, CRYM, MYO6, and POU3F4. In addition, genes 
were found that have not been implicated in hearing loss or inner ear development, but 
are good candidate genes because of their function and presence in the library (CDH11, 
EYA2, FGF13, OTOR, PCDH9, PCDH18 and SOX4). Not all known nonsyndromic 
deafness genes are found in our library, which is due to the method used to construct 
the library, subtraction suppressive hybridisation. Genes that are expressed in any of 
the tissues used to prepare the driver cDNA pool were selected against. However, some 
genes that are known to be specifically expressed in the cochlear hair cells, for example 
STRC, were not found either. This could be due to the developmental time window in 
which these genes are expressed, but more likely they were not identified in this study 
because they are expressed in a specific type of cells. The amount of for example hair 
cells is very low when compared to the whole cochlea, less than 1%. As a result, the 
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mass of mRNAs encoded by hair cell specific genes may be too low in the large pool of 
RNAs derived from the whole cochlea.
In chapter two SIX1 is suggested to be a good candidate gene for DFNA23. 
The involvement of SIX1 in the development in the inner ear, as part of the SIX-PAX-
EYA-DACH genetic network, was suggested. Ruf et al. (2004) have indeed found three 
different mutations in SIX1 in patients suffering from branchio-oto-renal (BOR) syndrome 
type 3. BOR syndrome is characterised by hearing loss and malformations of the kidney 
or urinary tract. It was demonstrated that the mutations in SIX1 disturb EYA1-SIX1 
interaction and DNA binding (Ruf et al. 2004).
As mentioned in chapter two many collagen genes were represented in our 
cDNA library. An explanation is that the cochleas used for preparing the RNA samples 
were embedded in cartilage, which cannot be completely removed by microdissection. 
Due to the absence of RNA derived from a bony tissue in the driver cDNA pool, genes 
expressed in cartilage were not selected against during the subtraction procedure. The 
publication of a human foetal cartilage cDNA library (Krakow et al. 2003, Pogue et al. 
2004) enabled a comparison and estimation to what extent our cDNA library contains 
cartilage-derived cDNAs. As expected, collagen cDNAs were highly represented in 
the cartilage library (COL2A1, COL9A1, COL9A2, COL11A1), but interestingly not all 
collagens, e.g. COL1A1, COL1A2, COL3A1, were found. Other genes that were found 
to be highly represented in the cartilage and cochlea cDNA libraries were; ACTG1 
(actin gamma 1), HSPA8 (heat shock 70kD protein), SPARC (osteonectin), and VIM 
(vimentin). In total, nine out of the 46 most highly represented genes in our cDNA library 
were found in the cartilage cDNA library. 
In the cochlea cDNA library a large number of clones were found to be located 
3’ to or in introns of known or predicted genes and generally lacked an open reading 
frame. It was assumed that they were derived from the 3’-untranslated regions of 
those genes or from alternatively spliced isoforms. However, recent publications by 
Cawley et al. (2004) and Numata et al. (2004) have provided an alternative explanation. 
Numata et al. (2004) show that a significant fraction of the RIKEN mouse full-length 
cDNA collection (>14%), consists of noncoding RNAs (ncRNAs). NcRNAs are encoded 
by highly regulated, in most cases multi-exon, transcriptional units, are processed like 
typical protein-coding mRNAs and are increasingly implicated in the regulation of many 
cellular functions in eukaryotes. NcRNAs have been identified in plants and animals and 
are expressed in a tissue-specific manner (Erdmann et al. 2001). In addition, Cawley 
et al. (2004) have found that the human genome contains many more transcription 
factor binding sites than can be expected based on predictions of open reading frames. 
Only 22% of the transcription binding site regions is located at the 5’-end of protein 
coding genes while 36% lie within or immediately 3’ to well characterised genes and are 
significantly correlated with ncRNAs. Many reports demonstrate that naturally occurring 
antisense transcription regulates prokaryotic gene expression (Wagner and Simons 
1994), and there has been an increasing appreciation that antisense transcription plays 
an important role in eukaryotic cells (Yelin et al. 2003). Examples of this include X-
chromosome inactivation (Brockdorff et al. 1992, Brown et al. 1992), small ncRNA-
mediated control of gene silencing in C.elegans (Ashrafi et al. 2003, Kamath et al. 2003) 
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and plants (Hamilton and Baulcombe 1999), gene imprinting (Sleutels and Barlow 2002), 
and more recently elucidated individual gene regulation (Solymar et al. 2002, Kramer et 
al. 2003). In view of this data, we believe that a number of the cDNAs from the cochlea 
cDNA library are ncRNAs and that they may be functional.
Four of the 38 genes known to cause nonsyndromic hearing loss have been 
found using inner ear specific cDNA libraries. Although the construction and analysis of 
tissue specific cDNA libraries is time consuming and expensive, these studies provide 
gene expression information, which can help to elucidate the developmental processes 
and homeostasis of the inner ear. It is also important that data generated with the 
analysis of cDNA libraries is deposited in publicly available databases so it can be 
used in comparative analysis as shown by Pompeia et al. (2004) and the website of the 
national eye institute (http://neibank.nei.nih.gov). Among the 46 most highly represented 
genes in our cDNA library, three genes were previously implicated in nonsyndromic 
hearing loss and seven were previously implicated in syndromic hearing loss. Thus far, 
our cDNA library did not yield novel nonsyndromic hearing loss genes. However, since 
the majority of nonsyndromic hearing loss genes remains to be identified, a systematic 
mutation analysis approach of the most promising candidate genes in the future, e.g. 
using capillary DGGE analysis, can lead to the identification of novel disease genes. 
6.2 Molecular mechanisms underlying DFNA5
DFNA5 was first identified in a large Dutch family (Van Laer et al. 1998). In chapter 
three a second Dutch family is described, and in 2003 Yu et al. described a novel 
Chinese DFNA5 family. The hearing loss in all three families is similar: nonsyndromic, 
progressive, sensorineural and starting in the high frequencies. The DFNA5-associated 
mutations are different in each family, a complex insertion-deletion mutation in intron 7 
in the first Dutch family (a 1,189 bp fragment is deleted from intron 7, 127 bp from intron 
8 are inserted into intron 7 in the opposite direction, followed by a GCCCA-stretch of 
unknown origin), a nucleotide substitution in the splice acceptor site of intron 7 in the 
second Dutch family described in chapter three (c.991-6C>G), and a three nucleotide 
deletion in the polypyrimidine tract of the 3’ splicing site of intron 7 (c.991-17_19del). 
Interestingly, at the mRNA level all three mutations have the same affect; skipping of 
exon 8. This leads to a frameshift starting after amino acid 330, which introduces an 
aberrant stretch of 41 amino acids followed by a stop codon that prematurely truncates 
the protein (p.Cys331_Glu395>LysfsX41). 
Morpholino antisense nucleotide knock-down of dfna5 function in zebrafish leads 
to disorganisation of the developing semicircular canals and reduction of the pharyngeal 
cartilage (Bunsch-Nentwich et al. 2003). This phenotype closely resembles previously 
isolated zebrafish craniofacial mutants including the mutant jekyll (Neuhauss et al. 1996). 
The jekyll zebrafish has a homozygous mutation in Ugdh (uridine 5’-diphosphate (UDP)-
glucose dehydrogenase), an enzyme that is required for the synthesis of proteoglycans 
including the extracellular matrix component hyaluronic acid (Walsh and Stainier 2001). 
In many areas of the developing human inner ear hyaluronic acid is highly abundant and 
it is suggested to serve as a friction reducing lubricant and molecular filter in the inner 
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ear (Anniko and Arnold 1995). In zebrafish treated with dfna5 morpholinos, expression 
of ugdh is absent in the developing ear and pharyngeal arches, and hyaluronic acid 
levels are strongly reduced in the outgrowing protrusions of the developing semicircular 
canals (Bunsch-Nentwich et al. 2003). If hyaluronic acid biosynthesis is reduced or lost 
in the human inner ear, it is possible that this disruption of extracellular matrix causes 
increased mechanical stress on hair cells and thus disfunction and/or degeneration of 
the hair cells. 
The striking similarity of the functional effect of the three different DFNA5 
mutations, i.e. the skipping of exon 8, strongly suggests that this is a “gain of function” 
mutation, resulting in a truncated protein with a deleterious new function. Gregan et 
al. (2003) showed the first evidence of this deleterious new function. They describe a 
CCCH domain as a domain that is shared between DFNA5 and the Mcm10 family of 
DNA replication proteins. Mcm10 is required for efficient initiation of DNA replication 
(Wohlschlegel et al. 2002). Interestingly, yeast cells with mutant mcm10 (Merchant et al. 
1997) have the same phenotype as yeast cells carrying DFNA5 containing the mutation 
described in humans by van Laer et al. (1998). Both are blocked in G1 or early S phase 
of the cell cycle. The truncated proteins both lack the CCCH domain and the expression 
of wild-type DFNA5 did not affect the yeast cells. In addition, van Laer et al. (2004) 
presented evidence for the involvement of the truncated DFNA5 protein in cell cycle 
dysregulation. The percentage of dead HEK293T cells was significantly higher when 
the cells were transfected with mutant DFNA5 compared to cells transfected with wild-
type DFNA5. The number of necrotic cells was also significantly higher when the cells 
were transfected with mutant DFNA5, while the number of apoptotic cells remained 
stable. Van Laer et al. (2004) also show that wild-type DFNA5 was distributed evenly 
in the cytoplasm, while mutant DFNA5 was localised in the cytoplasm in a granular 
manner. Mutant DFNA5 seemed to be associated with the plasma membrane especially 
in cells with an unhealthy appearance. The localisation of mutant DFNA5 at the plasma 
membrane might indicate that a predicted transmembrane region in the aberrant tail of 
the protein is functional or that mutant DFNA5 interacts with a membrane protein. 
Expression of DFNA5 was detected at low levels in every tissue investigated 
so far (Van Laer et al. 1998). If cell death would occur in every tissue that expresses 
DFNA5, a lethal phenotype would be expected in mutation carriers. However, affected 
individuals show progressive hearing loss as the only recognisable clinical characteristic. 
It is possible that cochlear cells are much more sensitive to the deleterious actions 
of mutant DFNA5 because DFNA5 might interact with cellular components that are 
expressed specifically in cochlear cells.
6.3 The DFNA11 phenotype is caused by mutations in different functional 
domains of myosin VIIa
In 1997 Liu et al. described a Japanese family with autosomal dominant hearing 
impairment caused by a mutation in MYO7A (DFNA11). Patients suffered from 
sensorineural hearing loss with gradual progression at all frequencies and minor 
vestibular problems. This phenotype was similar to the phenotype found in patients 
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from a Dutch family and, as described in chapter three, indeed a mutation was found 
in MYO7A. At the same time, mutations in MYO7A were found in an American and a 
German family with DFNA11 (Bolz et al. 2004, Street et al. 2004). The patients from 
the American family showed progressive sensorineural hearing loss at all frequencies 
with the greatest progression at the high frequencies, but the clinical phenotype varied 
between patients from different branches of the family. In the German family, patients 
were found to have slowly progressing hearing loss and mild vestibular dysfunction. 
The American family was the only family in which vestibular problems were not found. 
In none of the families there was evidence for retinitis pigmentosa. 
Different mutations in MYO7A segregate with the hearing loss in the four 
families; in the Japanese family a 9-bp deletion in exon 22 lead to a 3 amino acid 
deletion in the coiled-coil domain of the protein (c.2656_2664del [p.Ala886_Lys888del]), 
in the Dutch family a nucleotide change in exon 13 is predicted to result in an amino acid 
substitution in the motor head domain of the protein (c.1373A>T [p.Asn458Ile]), in the 
American family a nucleotide substitution in exon 17 is predicted to cause an amino acid 
substitution in the motor head domain of the protein (c.2164G>C [p.Gly722Arg]) and 
in the German family a missense mutation in exon 21 changes the fourth evolutionary 
conserved residue of the consensus sequence of the fifth IQ motif, a putative calmodulin 
binding domain (c.2557C>T [Arg853Cys]). Even though all four mutations are different 
and have a different predicted effect on protein function, the disease mechanism seems 
to be the same because in all cases a similar phenotype and mode of inheritance is 
found. To be able to understand how these different mutations lead to a similar phenotype 
in humans, the effect of these mutations on protein function can be studied in a model 
system. 
Recently, a mouse model for DFNA11 with low frequency autosomal dominant 
hearing loss was published by Rhodes et al. (2004). In an ENU screening the heterozygote 
headbanger mutant that displays classic behaviour indicative of vestibular dysfunction 
including hyperactivity and head bobbing was found. The mice show a Preyer reflex in 
response to sound but have raised cochlear thresholds especially at low frequencies. 
Scanning electron microscopy of the surface of the organ of Corti revealed abnormal 
stereocilia bundle development from an early age that was more severe in the apex than 
the base. Mutation screening of Myo7a revealed a nucleotide transversion (c.532A>T) 
that is predicted to cause an amino acid substitution in a conserved region of the motor 
head domain of the protein (p.Ile178Phe). Studying the mouse model further might 
reveal in which way the protein function is impaired in the headbanger mouse and how 
different mutations in myosin VIIa relate to the phenotype found in humans.
The use of another model system, Dictyostelium discoideum, was illustrated by 
Sato et al. (2004). A mutation in the myosin VI gene responsible for DFNA22 in humans 
(c.1325G>A [p.Cys442Tyr]) (Melchionda et al. 2001) was studied in Dictyostelium. Sato 
et al. (2004) found three major changes in mechanoenzymatic functions of the myosin 
VI protein that are altered by the DFNA22 mutation. First, the ADP dissociation rate 
is markedly increased by the mutation. Second, the mutation markedly increased the 
basal ATPase activity of myosin VI. Thirdly, the actin-activated ATPase activity of mutant 
myosin is Ca2+ sensitive.  These results indicate that Dictyostelium is a good model 
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system for studying the effect of mutations on the biochemical properties of myosin 
proteins.
6.4 VLGR1 involvement in Usher syndrome type II
In chapter five mutations in VLGR1 are described that are causative for Usher syndrome 
type IIc. Other mutations in VLGR1 are known to cause febrile and afebrile seizures in 
humans (Nakayama et al. 2002), and audiogenic seizures in mice (Skradski et al. 2001, 
McMillan and White 2003). Three VLGR1 isoforms are found in humans and these and 
three additional isoforms are found in mice. The function of full length VLGR1 or any 
of the isoforms is not clear. Therefore, it is also difficult to speculate on the phenotype 
of mutations in different isoforms. As described in chapter five, in some patients only in 
one allele a mutation was found. It is important that the mutation in the other allele is 
also found in these cases to exclude the involvement of other genes in these cases, but 
considering the size of the VLGR1 gene (>19 kb) and the multiple splice variants this will 
not be easy. Alternatively, the use of a model system is important to study the effect of 
the mutations on protein function. Two mouse models, with a natural mutation (Frings) 
(Skradiske et al. 2001) and an introduced deletion (McMillan and White 2003) have 
already been published. It would be interesting to study the effect of USHIIc mutations 
on the phenotype in mice.
 Putative protein-protein interaction domains found in VLGR1 seem to imply 
that VLGR1 is part of a protein complex that also includes cadherin 23, SANS and 
USH2A. Recent evidence indeed suggests the existence of a large macromolecular 
protein complex including both USH1 and USH2 proteins that is necessary to shape 
and maintain the stereocilia as an organised cohesive unit (Boëda et al. 2002, Siemens 
et al. 2002, Weil et al. 2003, and personal communications).
6.5 General conclusion
This thesis describes several strategies to identify the molecular defects underlying 
hereditary hearing loss. Results described in this thesis and table 6 of the introduction 
suggest that positional cloning is the most successful strategy to identify these genes. 
However, especially when studying small families and isolated patients where positional 
cloning cannot be used, other strategies are also needed to identify additional hearing 
loss genes. In general, a combination of different strategies is expected to be the most 
successful. 
6.6 References
Anniko M. and Arnold W., Hyaluronic acid as a 
molecular filter and friction-reducing lubricant in the 
human inner ear. ORL J Otorhinolaryngol Relat Spec 
199 7: 82-86.
Ashrafi K., Chang F.Y., Watts J.L., et al., Genome-
wide RNAi analysis of Caenorhabditis elegans fat 
regulatory genes. Nature 2003 421: 268-272.
Boëda B., El-Amraoui A., Bahloul, et al., Myosin 
VIIa, harmonin and cadherin 23, three Usher I gene 
products that cooperate to shape the sensory hair 
cell bundle. EMBO J 2002 21: 6689-6699.
Bolz H., Bolz S.S., Schade G., et al., Impaired 
calmodulin binding of myosin-7A causes autosomal 
dominant hearing loss (DFNA11). Hum Mut 2004 24: 
274-27
Brockdorff N., Ashworth A., Kay G.F., et al., The 
Chapter 6
141
product of the mouse Xist gene is a 15 kb inactive X-
specific transcript containing no conserved ORF and 
located in the nucleus. Cell 1992 71: 515-526.
Brown C.J., Hendrich B.D., Rupert J.L., et al., The 
human XIST gene: analysis of a 17 kb inactive X-
specific RNA that contains conserved repeats and is 
highly localized within the nucleus. Cell 71: 527-542.
Bunsch-Nentwich E., Söllner C., Roehl H., et al., The 
deafness gene dfna5 is crucial for ugdh expression 
and HA production in the developing ear in zebrafish. 
Development 2003 131: 943-951.
Cawley S., Bekiranov S., Ng H.H., et al., Unbiased 
mapping of transcription factor binding sites along 
human chromosomes 21 and 22 points to widespread 
regulation of noncoding RNAs. Cell 2004 116: 499-
09.
Erdmann V.A., Barciszewska M.Z., Hochberg A., et 
al., Regulatory RNAs. 2001 Cell Mol Life Sci 2001 
8: 960-977.
Gregan J., Van Laer L., Lieto L.D., et al., A yeast model 
for the study of human DFNA5, a gene mutated in 
nonsyndromic hearing impairment. Biochin Biophys 
Acta 2003 1638: 179-186.
Hamilton and Baulcombe, A species of small 
antisense RNA in posttranscriptional gene silencing 
in plants. Science 1999 286: 90-92.
Kamath R.S., Fraser A.G., Dong Y., et al., Systematic 
functional analysis of the Caenorhabditis elegans 
genome using RNAi. Nature 2003 421: 231-237.
Krakow D., Sebald E.T., Pogue R., et al., Analysis 
of clones from a human cartilage cDNA library 
provides insight into chondrocyte gene expression 
and identifies novel candidate genes for the 
osteochondrodysplasias. Mol Genet Metab 2003 79: 
34-42.
Kramer C., Loros J.J., Dunlap J.C., et al., Role for 
antisense RNA in regulating circadian clock function 
in Neurospora crassa. Nature 2003 421: 948-2.
Liu X.Z., Walsh J., Mburu P., et al., Mutations in the 
myosin VIIA gene cause non-syndromic recessive 
deafness. Nat Genet 1997 17: 268-269. 
McMillan D.R. and White P.C., Loss of the 
transmembrane and cytoplasmic domains of the 
very large G-protein-coupled receptor-1 (VLGR1 or 
Mass1) causes audiogenic seizures in mice. Mol Cell 
Neurosci 2003 26: 322-329.
Melchionda S., Ahituv N., Bisceglia L., et al., MYO6, 
the human homologue of the gene responsible for 
deafness in Snell’s waltzer mice, is mutated in 
autosomal dominant nonsyndromic hearing loss. Am 
J Hum Genet 2001 69: 635-640.
Merchant A.M., Kawasaki Y., Chen Y., et al., A lesion 
in the DNA replication initiation factor Mcm10 induces 
pausing of elongation forks through chromosomal 
replication origins in Saccharomyces cerevisiae. Mol 
Cell Biol 1997 17: 3261-3271.
Nakayama J., Fu Y.H., Clark A.M., et al., A nonsense 
mutation of the MASS1 gene in a family with febrile 
and afebrile seizures. 2002 Ann Neurol 52: 654-657.
Neuhauss S.C., Solnica-Krezel L., Schrier A.F., et 
al., Mutations affecting craniofacial development in 
zebrafish. Development 1996 123: 357-367.
Numata K., Kanai A., Saito R., et al., Identification of 
putative noncoding RNAs among the RIKEN mouse 
full- length cDNA collection. Genome Res 2004 13: 
1301-1306.
Pogue R., Sebald E., King L., et al., A transcriptional 
profile of human fetal cartilage. Matrix Biol 2004 23: 
299-307.
Pompeia C., Hurle B., Belyantseva I.A., et al., Gene 
expression profile of the mouse organ of Corti at the 
onset of hearing. Genomics 2004 83: 1000-1011.
Rhodes C.R., Hertzano R., Fuchs H., et al., A Myo7a 
mutation cosegregates with stereocilia defects and 
low-frequency hearing impairment. Mamm Genome 
2004 1: 686-697.
Robertson N.G., Khetarpal U., Gutierrez-Espeleta 
G.A., et al., Isolation of novel and known genes from 
a human fetal cochlear cDNA library using subtractive 
hybridization and differential screening. Genomics 
1994 23: 42-0.
Ruf R.G., Xu P.X., Silvius D., et al., SIX1 mutations 
cause branchio-oto-renal syndrome by disruption of 
EYA1-SIX1-DNA complexes. PNAS 2004 101: 8090-
809.
Sato O., White H.D., Inoue A., et al., Human deafness 
mutation of myosin VI (C442Y) accelerates the ADP 
dissociation rate. JBC 2004 279: 28844-28854.
Siemens J., Kazmierczak P., Reynolds A., et al., 
The Usher syndrome proteins cadherin 23 and 
harmonin form a complex by means of PDZ-domain 
interactions. PNAS 2002 99: 14946-14951.
Skradski S.L., Clark A.M., Jiang H., et al., A novel 
gene causing a mendelian audiogenic mouse 
epilepsy. Neuron 2001 31: 537-544.
Sleutels F. and Barlow D.P., The origins of genomic 
imprinting in mammals. Adv Genet 2002 46: 119-
164.
Solymar D.C., Argawal S., Bassing C.H., et al., 
A 3’ enhancer in the IL-4 gene regulates cytokine 
production by Th2 cells and mast cells. Immunity 
2002 17: 41-0.
Street V.A., Kallman J.C., and Kiemele K.L., Modifier 
controls severity of a novel dominant low-frequency 
MyosinVIIA (MYO7A) auditory mutation. J Med 
Genet 2004 41: e62.
Van Laer L., Huizing E.H., Verstreken M., et al., 
Nonsyndromic hearing impairment is associated with 
a mutation in DFNA5. Nat Genet 1998 20: 194-197.
Van Laer L., Vrijens K., Thys S, et al., DFNA5: hearing 
impairment eon instead of hearing impairment gene. 
J Med Genet 2004 41: 401-406
Wagner E.G. and Simons R.W., Antisense RNA 
control in bacteria, phages, and plasmids. Annu Rev 
Microbiol 1994 48: 713-742.
Walsh E.C. and Stainier D.Y., UDP-glucose 
dehydrogenase required for cardiac valve formation 
in zebrafish. Science 2001 293: 1670-1673.
General Discussion
142
Weil D., El-Amraoui A., Masmoudi S., et al., Usher 
syndrome type I G (USH1G) is caused by mutations 
in the gene encoding SANS, a protein that associates 
with the USH1C protein, harmonin. Hum Mol Genet 
2003 12: 463-471.
Wohlschlegel J.A., Dahr S.K., Prokhorova T.A., et al., 
Xenopus Mcm10 binds to origins of DNA replication 
after Mcm2-7 and stimulates origin binding of Cdc45. 
Mol Cell 2002 9: 233-240.
Yelin R., Dahary D., Sorek R., et al., Widespread 
occurrence of antisense transcription in the human 
genome. Nat Biotechnol 2003 21: 379-386.
Yu C., Meng X., Zhang S., et al., A 3-nucleotide 
deletion in the polypyrimidine tract of intron 7 of 
the DFNA5 gene causes nonsyndromic hearing 
impairment in a Chinese family. Genomics 2003 83: 
7-79.
Chapter 6
Summary
Chapter 7

14
Summary
7.1 Summary
Hearing loss is the most common sensory disorder in the human population. It affects 
0.1% of all young children and by the age of 70, 30% of the population suffers from hearing 
loss greater than 40 dB. When early onset hearing loss is inherited, 70% is classified as 
nonsyndromic and 30% as syndromic. Nonsyndromic hearing loss is further subdivided 
by its mode of inheritance; ~77% of the cases are autosomal recessive (DFNB), ~22% 
are autosomal dominant (DFNA) and ~1% are X-linked (DFN). Eighty nonsyndromic 
hearing loss loci have been described so far, but new loci are continuously found. For 
approximately half of the loci the genetic defect responsible for the hearing loss has 
been identified. Several strategies are being used to elucidate the genetic defect for the 
remaining loci. The method most commonly used employs linkage analysis in affected 
families followed by positional cloning of the gene involved. 
Although positional cloning has been very successful in identifying hereditary 
hearing loss genes in the past, several new strategies have been developed recently for 
identifying candidate genes. One of these strategies, the construction and analysis of a 
cDNA library, is described in chapter two. Using a suppression subtractive hybridisation 
technique a human fetal cochlea cDNA library was constructed. By using sequence 
and BLAST analysis 2640 clones were characterised. Approximately 150 cDNA clones 
were found to map in nonsyndromic hearing loss loci for which the causative gene 
had not been identified yet. The expression of these cDNA clones and some additional 
interesting clones was analysed by RT-PCR. None of the analysed cDNAs were 
exclusively expressed in the cochlea, however, the expression data showed that about 
25% of the novel cDNAs from the library were preferentially expressed in the cochlea. 
Although the characterisation of the cDNA library did not yield any new nonsyndromic 
hearing loss genes yet, it did generate a large number of candidate genes for hereditary 
hearing loss and inner ear development.
The use of clinical data (e.g ARTAs) can greatly facilitate the elucidation of 
the cause of hearing loss in specific families (chapter three and four) exemplifying the 
synergism that occurs upon a close collaboration between clinicians and researchers. 
The fifth dominant nonsyndromic locus that has been described, DFNA5, is 
characterised by high frequency hearing loss caused by a mutation in the DFNA5 gene. 
The second Dutch family with DFNA5 is described in chapter three. The hearing loss 
segregating in this family is sensorineural and symmetric. In the high frequencies, 
hearing impairment amounted to 30 dB at young age. Progression of hearing loss was 
most pronounced at 1 kHz. A nucleotide change in the splice acceptor site of intron 7, 
c.991-6C>G, leading to skipping of exon 8 in part of the transcripts, was found to be 
responsible for the hearing loss segregating in this family. The skipping of exon 8 leads 
to a prematurely truncated protein with an aberrant stretch of amino acids that likely 
results in a deleterious gain of function of the protein in the inner ear. 
Another form of dominantly inherited high frequency hearing loss is DFNA11. 
The hearing impairment is characterized by flat audiograms at young ages and mild 
progression most prominent at the high frequencies. DFNA11 is associated with a 
mutation in the MYO7A gene. In chapter 4 a Dutch family with DFNA11 is described. 
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The hearing loss in this family segregates with a c.1373A>T transversion in MYO7A 
that is heterozygously present in all affected family members. The nucleotide change 
is predicted to lead to an p.Asn458Ile amino acid change in the motor domain of the 
myosin VIIA protein. A molecular model of the protein was built based on the myosin 
II heavy chain of Dictyostelium discoideum. In the model, the amino acid substitution 
predicts conformational changes with severe effects on the function of the myosin VIIA 
protein. 
As mentioned above, 30% of prelingual inherited hearing loss is classified as 
syndromic. Usher syndrome is a form of syndromic hearing loss that is characterized by 
various degrees of congenital hearing loss and of loss of eyesight through progressive 
retinitis pigmentosa and is the most common form of deaf-blindness (50%). Its prevalence 
is currently estimated in developed countries at 3.8-4.4 per 100,000 live births. Usher 
syndrome is a genetically heterogeneous autosomal recessive disorder, for which at 
least twelve loci account for subtypes of the syndrome. For Usher syndrome type II there 
are at least three genetic subtypes (USH2A, USH2B, and USH2C). Chapter 5 describes 
the identification of mutations in VLGR1 in patients suffering from Usher syndrome type 
IIC. Three human VLGR1 mRNA isoforms are expressed (VLGR1a, VLGR1b, and 
VLGR1c) and four isoform-specific mutations were found in the patients. On the basis 
of its potential extracellular and intracellular protein-protein interaction domains and its 
wide mRNA expression profile, it is probable that VLGR1 serves diverse cellular and 
signalling processes.
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7.2 Samenvatting
Gehoorsverlies is de meest voorkomende sensorische aandoening in de humane 
populatie. Ongeveer 0.1% van alle jonge kinderen en 30% van alle volwassenen boven 
de 70 hebben een gehoorsverlies groter dan 40 dB. Gehoorsverlies wat optreedt 
op jonge leeftijd en mendeliaans overerft kan worden onderverdeeld in syndromaal 
gehoorsverlies (70% van alle gevallen) en niet-syndromaal gehoorsverlies (30% van 
de gevallen). Niet-syndromaal gehoorsverlies wordt geclassificeerd op basis van de 
vorm van overerving; in ~77% van de gevallen is de overerving autosomaal recessief 
(DFNB), in ~22% autosomaal dominant (DFNA), en in ~1% X-gebonden (DFN). Tot 
nu toe zijn 80 niet-syndromale doofheidloci beschreven, maar nieuwe loci worden 
nog steeds gevonden. Voor ongeveer de helft van alle doofheidloci is het oorzakelijke 
gendefect geïdentificeerd. 
Verschillende methoden worden gebruikt om nieuwe “doofheid-genen” te vinden, 
maar de meest gebruikte methode is koppelingsonderzoek in aangedane families 
gevolgd door het positioneel kloneren van het betrokken gen. In het verleden is deze 
methode erg succesvol gebleken, desondanks zijn recentelijk enkele nieuwe strategieën 
ontwikkeld. Een van deze strategieën, het construeren en analyseren van een cDNA-
bank, wordt beschreven in hoofdstuk twee. Een suppressie-subtractie-hybridisatie-
techniek werd gebruikt om een humane foetale cochlea cDNA-bank te construeren en 
met behulp van sequentie- en BLAST-analyse werden 2640 klonen gekarakteriseerd. 
Ongeveer 150 cDNA klonen werden gelokaliseerd in loci betrokken bij vormen van 
niet-syndromaal gehoorsverlies waar het oorzakelijke gen nog niet voor gevonden is. 
De expressie van deze en andere interessante klonen werd geanalyseerd met behulp 
van RT-PCR. Geen van de geanalyseerde klonen kwam uitsluitend tot expressie in 
de cochlea, maar op basis van de expressie data kan worden geconcludeerd dat 
ongeveer 25% van de nieuwe klonen preferentieel tot expressie komt in de cochlea. 
Ondanks dat de analyse van de cDNA-bank nog niet heeft geleidt tot de identificatie 
van nieuwe genen betrokken bij niet-syndromaal gehoorsverlies, heeft de analyse wel 
een groot aantal kandidaat genen voor vormen van erfelijk gehoorsverlies en binnenoor 
ontwikkeling opgeleverd.
Het gebruik van klinische data (b.v. ARTAs) kan het ophelderen van de oorzaken 
van erfelijk gehoorsverlies in specifieke families ten goede komen. De resultaten die in 
hoofdstuk 3 en 4 van dit proefschrift worden beschreven zijn het gevolg van een goede 
samenwerking tussen wetenschappers en clinici.
Het doofheidlocus dat als vijfde werd beschreven, DFNA5, wordt gekarakteriseerd 
door hoge tonen gehoorsverlies veroorzaakt door een mutatie in het DFNA5 gen. 
In hoofdstuk 3 wordt de tweede Nederlandse familie met DFNA5 beschreven. Het 
gehoorsverlies in deze familie is sensorineuraal en symmetrisch. Op jonge leeftijd kan 
het gehoorsverlies in de hoge tonen oplopen tot 30 dB en bij 1 kHz is de progressie van 
het gehoorsverlies het grootst. Een nucleotideverandering in de splice-acceptor-site 
van intron 7, c.991-6C>G, die het overslaan van exon 8 in een deel van de transcripten 
veroorzaakt, is verantwoordelijk voor het gehoorsverlies in deze familie. Het overslaan 
van exon 8 resulteert waarschijnlijk in een prematuur beëindigd eiwit met een aantal 
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afwijkende aminozuren. Deze verandering van de samenstelling van het eiwit leidt 
waarschijnlijk tot en verandering van de functie van het eiwit. Mogelijk is deze nieuwe 
functie nadelig voor het functioneren van het binnenoor.
 Een andere vorm van dominant overervend hoge tonen gehoorsverlies is 
DFNA11. DFNA11 wordt gekarakteriseerd door een vlak audiogram op jonge leeftijd 
en milde progressie die het grootst is in de hoge tonen. Deze vorm van gehoorsverlies 
is geassocieerd met een mutatie in het MYO7A gen. In hoofdstuk vier wordt een 
Nederlandse familie met DFNA11 beschreven. In deze familie erft het gehoorsverlies 
over met een c.1373A>T nucleotideverandering in MYO7A die heterozygoot aanwezig is 
in alle aangedane familieleden. De gevonden nucleotide verandering leidt waarschijnlijk 
tot een p.Asn458Ile aminozuur-verandering in het motor domein van het myosine 
VIIA eiwit. Een moleculair model van myosine VIIA werd geconstrueerd gebaseerd 
op de myosine II heavy chain van Dictyostelium discoideum. Het model voorspelt 
een conformatieverandering van het eiwit als gevolg de aminozuurverandering. 
De conformatie verandering van het eiwit zal de functie van het myosine VIIA eiwit 
waarschijnlijk verstoren.
Zoals hierboven al werd aangegeven, is 30% van het prelinguaal erfelijk 
gehoorsverlies syndromaal. Usher syndroom is een vorm van syndromaal gehoorsverlies 
die wordt gekenmerkt door een variërende mate van congenitaal gehoorsverlies in 
combinatie met gezichtsverlies door progressieve retina dystrofie (retinitis pigmentosa). 
Usher syndroom is de meest voorkomende vorm van doof-blindheid (50%) en volgens 
schattingen lijden er in westerse landen 3.8-4.4 per 100.000 levend geboren kinderen aan 
Usher syndroom. Usher syndroom is een genetisch heterogene autosomaal recessieve 
aandoening. Ten minste 12 loci zijn verantwoordelijk voor de drie verschillende typen 
van het syndroom (USH1, USH2 en USH3). Voor Usher syndroom type II zijn tot nu toe 
drie verschillende subtypen (USH2A, USH2B en USH2C) beschreven. In hoofdstuk vijf 
wordt de identificatie van mutaties in het VLGR1 gen in patiënten met Usher syndroom 
type IIC beschreven. Drie verschillende VLGR1 mRNA isovormen komen tot expressie 
(VLGR1a, VLGR1b, VLGR1c) in de mens. Vier isovorm-specifieke mutaties werden 
gevonden in de USH2C-patiënten. Op basis van de voorspelde extracellulaire en 
intracellulaire eiwit-eiwit interactie-domeinen van het VLGR1 eiwit, wordt aangenomen 
dat VLGR1 een rol speelt in diverse cellulaire en signaaltransductieprocessen.
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re
ce
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 b
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 C
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 m
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 c
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 m
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ra
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e 
su
rr
ou
nd
in
g 
m
es
en
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 m
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an
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an
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or
y 
ep
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iu
m
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in
 
th
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 d
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d 
su
bs
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in
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re
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 o
f 
kn
oc
k-
ou
t 
m
ic
e 
re
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 d
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re
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de
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at
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 b
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e c
oc
hl
ea
 
sh
ow
s 
pr
og
re
ss
iv
e 
m
o
r
p
h
o
lo
g
ic
a
l 
de
ge
ne
ra
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at
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 d
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r f
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l d
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ro
zy
go
us
 
de
le
tio
n 
of
 
G
AT
A
3 
(v
an
 
E
sc
h 
et
 a
l. 
20
00
)
G
B
X
2
G
bx
2 
(m
,c
)
in
 
ch
ic
k 
in
 
th
e 
m
ed
ia
l 
re
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 c
hi
ck
 in
 th
e 
m
ed
ia
l r
eg
io
n 
of
 
th
e 
ot
oc
ys
t 
(H
id
al
go
-S
an
ch
ez
 
et
 a
l. 
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m
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 m
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ra
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 c
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is
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 m
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 m
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m
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re
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m
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 c
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 c
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is
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 m
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 o
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at
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m
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at
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at
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 o
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m
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w
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 fa
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m
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I c
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re
ta
rd
at
io
n 
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)
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a 
de
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an
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a 
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ra
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ry
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E
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R
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D
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 t
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l o
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 m
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en
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e 
an
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th
e 
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ve
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pi
ng
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di
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ry
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(L
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o-
K
er
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t a
l. 
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)
in
 
nu
ll 
m
ut
an
t 
m
ic
e 
m
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ra
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n 
of
 b
ot
h 
au
di
to
ry
 
an
d v
es
tib
ul
ar
 ne
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s 
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m
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m
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, 
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e 
m
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e 
ar
e 
pr
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ou
nd
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 d
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du
e 
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 s
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e 
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 o
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ne
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ar
 s
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eu
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de
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t (
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)
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lix
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1
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)
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at
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g 
ne
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e 
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f c
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ry
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on
s 
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 d
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r c
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 m
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ra
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 m
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ra
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 p
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 r
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 m
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ra
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ra
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 d
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ra
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 m
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ra
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 o
tic
 v
es
ic
le
 (
M
or
sl
i 
et
 a
l. 
19
99
)
in
 m
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ra
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m
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 m
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m
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ro
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m
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at
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P
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 p
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er
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 m
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, m
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ot
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 m
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e 
se
ns
or
y 
ep
ith
el
ia
 
re
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er
al
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al
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20
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ur
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 a
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m
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 d
uc
t 
an
d 
co
m
m
on
 
cr
us
, 
co
ch
le
ar
 
ou
tg
ro
w
th
 in
 th
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 c
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at
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 c
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ra
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P
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re
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8.3 Appendix 2: Full colour figures
Chapter 4
Figure 3. Identification of the Asn458Ile mutation and the predicted functional effect in the myosin 
VIIA model. (A) Sequence analysis of exon 13 of MYO7A reveals a heterozygous c.1373A>T 
(Asn458Ile) substitution. (B) Sequence analysis of exon 13 of MYO7A of an unaffected individual. 
(C) Molecular modelling of myosin VIIA. If isoleucine replaces asparagine at position 458, its 
larger side-chain collides with the backbone oxygen of phenylalanine 439 in the switch II loop 
(arrow), pushing the loop towards the ATPase pocket. This is assumed to negatively influence the 
sensing of the active site state (involving Asp437) and the reorientation in the switch II loop hinge 
region (Ile438 and Gly440, not shown).
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Figure 1. Segregation of VLGR1 mutations Q2301X, M2931FS, I2906FS, and T6244X in families 
735, 964, and 1848 (with USH2C). (A) Paternal inheritance of Q2301X in family 1848 is shown 
by agarose-gel electrophoresis of exon 31 PCR product XmnI digests. Q2301X mutation is a 
6901 C>T transition, 33 bp on the 3’ end of the alternate exon 31 splice donor, affecting only 
the VLGR1b mRNA isoform (fig. 2a). Shown here are sequence electropherograms from the 
heterozygous family 1848 proband (HET), an apparent Q2301X homozygote, and wild-type 
(WT) BAC clone RP11-29K14, with sequence and amino acid translation differences (arrows). 
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The Q2301X homozygote was the result of a brother-sister incestuous union, whereas another 
singleton case was a Q2301X/occult heterozygote (data not shown; table 2). (B) Maternal 
inheritance of M2931FS in family 964 is shown by agarose-gel electrophoresis of exon 39 PCR 
product NcoI digests. Sequence electropherograms of the WT and the cloned M2931FS allele 
show 8790delC in exon 39 (arrows). This deletion causes a 10-codon frameshift. ending with a 
TAG stop encoded by the last 3 bases of exon 39, affecting VLGR1b. (C) Maternal inheritance 
of I2906FS in family 1848 by DHPLC of exon 38 PCR products. Sequence comparison of the 
cloned I2906FS mutation shows an 8716-17insAACA (arrows) causing a frameshift of 5 codons 
and ending with a TGA stop 1 bp short of the 3_ end of exon 38, affecting VLGR1b. (D) Paternal 
inheritance of Y6244X detected by DHPLC of exon 89 PCR products. A 19-bp deletion brings a 
TAG stop codon immediately in-frame. Y6244X removes 63 amino acids from the COOH end of 
VLGR1a and VLGR1b. The putative maternal and paternal mutations in family 735 and family 964 
have not been identified.
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Dankwoord
Eindelijk, mijn proefschrift is klaar. En aan het einde van een proefschrift is er gelukkig 
ruimte om de mensen te bedanken zonder wie er geen proefschrift was geweest.
Als eerste Frans, jij was het die dit project schreef en mij de kans gaf om in jou groep 
mijn promotie onderzoek te doen. Ik heb aan jou enorm veel te danken. Ondanks dat er 
momenten zijn geweest dat ik heb getwijfeld over het slagen van dit project was jij altijd 
vol vertrouwen. De snelheid waarmee jij altijd mijn manuscripten hebt nagekeken, jou 
enorme kennis en betrokkenheid bij je personeel zijn uniek. Ik ben dan ook trots dat je 
naast mijn begeleider ook mijn promotor bent geworden.
Toen ik begon aan mijn promotieonderzoek was ik de enige op ons lab die aan 
doofheid werkte. Maar nadat jij, Hannie, het doofheidonderzoek ging leiden groeide het 
“doofheidgroepje” gestaag. Jou inbreng in dit project is ontzettend belangrijk geweest 
en ook nadat ik uit Nijmegen weg was gegaan was jij het die steeds het contact hebt 
gehouden en mij hebt gemotiveerd om het allemaal af te maken. Ik weet zeker dat er 
met jou aan het hoofd van het dffheidonderzoek er nog vele successen in het verschiet 
liggen.
Han, bedankt dat ook jij me destijds de kans hebt gegeven om binnen de afdeling 
antropogenetica aan de slag te gaan. Jou aanwijzingen en verbeteringen hebben mijn 
publicaties zeker verbeterd.
Het al eerder genoemde “doofheidgroepje” wil ik bedanken voor de leerzame 
werkbesprekingen, de inhoudelijke discussies en de goede samenwerking binnen “ons” 
groepje. 
Graag wil ik iedereen waar ik mee heb samengewerkt op het lab van moleculaire 
genetica bedanken voor de gezelligheid tijdens lunch en koffie pauzes en de keren dat 
we gingen eten en dansen in de stad. Maar zeker ook bedankt voor alle hulp en het 
goede advies dat ik gedurende de tijd op het lab heb gekregen, en niet in de laatste 
plaats voor al die keren dat ik tegen jullie mocht klagen en zeuren, bedankt voor het 
aanhoren, zonder jullie was het allemaal een stuk minder leuk geweest. In het bijzonder 
geldt dit voor mijn kamergenootjes.
 
Speciaal wil ik Dorien, Gerard en Erwin bedanken voor hun bijdrage aan respectievelijk 
hoofdstuk twee, drie en vier van dit proefschrift. Zonder jullie had dit proefschrift er 
heel anders uitgezien. Erwin wil ik natuurlijk in het bijzonder bedanken, omdat hij mijn 
paranimf wil zijn.
De samenwerking met de afdeling KNO heeft een belangrijke rol gespeeld bij de 
totstandkoming van dit proefschrift. Ik wil iedereen van de afdeling KNO die heeft 
bijgedragen aan met name hoofdstuk drie en vier van dit proefschrift bedanken. Dit 
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proefschrift is mede het resultaat van deze goede samenwerking.
In Nijmegen heb ik niet alleen tijdens werktijd mensen leren kennen die een belangrijke 
rol hebben gespeeld voor mijn promotie. Ernie bedankt voor de broodnodige ontspanning 
in de vorm van sport- en eetafspraken, Yvette bedankt voor je hulp in mijn eerste tijd op 
het lab en de gezelligheid buiten het lab en natuurlijk de meisjes van de Sint Annastraat 
26, door jullie was het altijd prettig thuis komen.
Natuurlijk moet ik mijn ouders bedanken die het voor mij mogelijk hebben gemaakt om 
te gaan studeren en mij altijd hebben gesteund in de keuzes die ik heb gemaakt. Jullie 
onvoorwaardelijke vertrouwen in een goede afloop is altijd een enorme steun geweest.
Jolanda, je bent niet alleen mijn zus maar ook mijn beste vriendin en bovendien mijn 
paranimf, bedankt voor alles.
Alle familie, schoonfamilie en vrienden die altijd meegeleefd hebben, bedankt voor jullie 
interesse en bemoedigende woorden als het even niet zo mee zat.
Als laatste Tanno, zonder jou had ik dit niet kunnen doen. Je was enthousiast en 
geïnteresseerd als het goed ging, maar ook begripvol en een grote steun als het niet zo 
goed ging. Bovendien heb je jou stempel op dit proefschrift gedrukt door het tekenen 
van verschillende figuren en het ontwerpen van de kaft van dit proefschrift. Ik ben blij 
dat ik jou vrouw ben.
Zonder alle mensen die ik hierboven genoemd heb en nog veel meer mensen die ik niet 
genoemd heb, was dit proefschrift er nooit gekomen, dus bij deze allemaal bedankt!
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